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Abstract 
Fibroblast Growth Factor (FGF) and Transforming Growth Factor beta (TGFbeta) are key 
regulators of bone development. Constitutively activating mutations of FGF Receptors (FGFR) 
1-3 result in craniosynostosis, premature fusion of cranial sutures. The aim of this thesis was to 
determine how FGF signalling is impaired in osteoblasts with the mutation FGFR2-C278F, 
known to induce craniosnostosis and investigate possible interactions with TGFbeta signalling. 
 
To this purpose MC3T3-E1 osteoblasts (derived from newborn mouse calvaria) that had been 
stably transfected with human FGFR2 (wild type FGFR2-WT or mutated FGFR2-C278F) were 
used as an in-vitro model and these cell lines were named R2-WT and R2-C278F. These cell 
lines were characterised at the cellular and molecular level to define the craniosynostotic 
phenotype. Gene expression was assessed with real time PCR, proliferation using both 
fluorescence activated cell sorting (FACS) and the methylene blue assay and protein expression 
by FACS, immunocytochemistry and Western blotting. Cell proliferation was reduced and 
apoptosis increased in the R2-C278F mutant and differentiation increased, as shown by reduced 
expression of differentiation marker osteopontin and an increase in osteocalcin. The effect of 
FGF signalling on cell growth was demonstrated by using FGFR inhibitor SU5402. This study 
suggested that FGFR2-C278F decreases the level of FGFR signalling. 
 
FGFR2-C278F impairs TGFbeta signalling as shown by: i) reduced Tgfbeta1 and -3 expression 
in R2-C278F cells; ii) maximal reduction of cell growth only in R2-C278F cells following 
TGFbeta inhibition using SB431542 (1µM); iii) the inability of exogenous TGFbeta1 to induce 
proliferation in R2-C278F cells. This suggests that exogenous TGFbeta1 cannot rescue the 
impaired TGFbeta signalling caused by FGFR2-C278F mutation. Fgf and Tgfbeta signalling 
may converge to affect osteoblast proliferation via extracellular related kinase 1/2 (Erk1/2). 
Analysis of the Erk1/2 protein expression in R2-C278F cells showed that Erk1 isoform had 
increased relative to Erk2. This change has been associated with growth arrest in osteoblasts, 
fibroblasts and hepatocytes and therefore it is likely to underlie the defect in proliferative 
response to Fgf and Tgfbeta signalling in R2-C278F cells. 
 
In summary FGFR2-C278F in MC3T3 cells impairs Fgf and Tgfbeta signalling, resulting in a 
proliferation defect for which increased differentiation is implicated as a secondary effect. A 
key convergence between FGFR2-C278F and Tgfbeta appears to be via impaired Erk1/2 signal 
transduction. These findings provide a valuable basis for future investigations of other Erk1/2 
upstream pathways and their contribution to the craniosynostotic osteoblast phenotype.  
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Chapter 1  Introduction 
1.1 Anatomy  of  the  Cranium 
The human cranium (skull) is the essential supporting structure for organs of the head to 
function. It protects the brain, the brain stem, eyes, cranial nerves and assists muscle movement 
in stereo vision, facial expression, breathing and verbal communication. The size, morphology 
and composition of the skull may affect the function of any of these organs and also the social 
interactions of the individual with society. 
 
The entire skull consists of many bone plates that are grouped (with various nomenclature) into 
two main regions: 
 
1.  Cranial (Skull) Vault / Neurocranium – bones that encase the brain 
2.  Facial Skeleton / Viscerocranium / Orognathofacial Complex / Splanchnocranium 
- jaw and facial bones. 
 
These are coloured in Figure 1.1. The cranial vault can be subdivided into two further regions: 
 
1.  Calvarium / Desmocranium – the superior and lateral casing of the brain 
2.  Cranial Base / Chondrocranium – the inferior brain casing 
 
 
Figure 1.1 Side view illustration of an adult skull 
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1.1.1  The calvarium at birth 
The calvarium is dome-shaped and consists of the frontal, parietal, occipital and part of the 
temporal bone (see Figure 1.2, temporal bone not shown). Between the bones lie fibrous joints 
called sutures. In new born humans there are membranous areas that resemble suture tissue 
called fontanelles. The fontanelles will usually disappear by the 2





Figure 1.2 Human Newborn skull vault.  
Superior view of the bones and sutures of the skull. Annotations show the sutures. AF: Anterior 




















Sutures:   Chapter 1 Introduction 
 
   21 
 
1.2  Craniofacial bone and sutures 
Bone may be classified as endochondral and membranous, based upon its mode of formation.  
Membranous bone forms from direct ossification and is mainly protective in function. 
Endochondral bone varies in shape, grows from preformed cartilage, which differentiates into 
bone and allows weight bearing and skeletal movement. Craniofacial bones constitute the 
cranium and most are membranous except for the chondrocranium and the ossicles (bones of the 
ear), which are derived from Meckel’s cartilage during development. The mandible is largely 
membranous, but forms from the mesenchyme that surrounds Meckel’s cartilage (Sadler, 2004). 
 
1.2.1  Origins of Craniofacial bone 
Craniofacial bone is formed from mesenchymal tissue. The mesenchyme derives from two 
embryonic cell populations: cranial neural crest and head paraxial mesoderm (Jiang et al., 
2002). In the embryo, the neural plate folds to create the neural tube between the 3
rd and 8
th 
week of gestation. The neural crest is formed from neuroepithelial cells that undergo epithelial 
to mesenchymal transition (EMT) at the neural plate border, between surface ectoderm and the 
neural plate, along most of the vertebral axis (Trainor, 2005). Paraxial mesoderm first arises at 
the lateral edges of the primitive node and cranial end of the primitive streak (Sadler, 2004; 
Opperman, 2000). Both neural crest and paraxial mesoderm lie lateral to the neural tube (Figure 
1.3). In the avian and mammalian skull, neural crest-derived mesenchyme populates the facial 
skeleton and the frontal bone, whereas paraxial mesoderm-derived mesenchyme forms the 
parietal and occipital bone structures (Morriss-Kay and Wilkie, 2005). 
 
1.2.2  Development and growth of craniofacial bone and sutures 
The bones of the human skull vault form around the 8
th week of foetal development. Studies on 
the mandibular, maxillary and frontal bone development have shown that an epithelial-
mesenchyme interaction induces the neural crest-derived mesenchymal cells to commit to an 
osteogenic lineage (Dunlop and Hall, 1995; Tyler and McCobb, 1980; Tyler, 1983). A report by 
Opperman has suggested that tissue-tissue interactions with the underlying dura mater might 
also induce bone formation in the parietal and occipital regions, where paraxial mesoderm-
derived mesenchyme is found (Opperman, 2000). Interestingly, epithelial-mesenchymal 
interactions do not induce bone formation in mesenchyme that is normally non-osteogenic, such 
as trunk neural crest (Hall, 1981). This may suggest that differences in permissiveness to bone 
formation exist, depending on the type of neural crest cell.   Chapter 1 Introduction 
 




Figure 1.3 Cross-sections of the stages of neural tube formation  
The neural plate (A) folds onto itself to form the neural tube (B) between the 3
rd and 8
th week of gestation. 
Neural crest (blue) is found on the crest of the folding neural plate and undergoes epithelial-mesenchymal 
transition as it leaves the neuroepithelium (C). The paraxial mesoderm is found just lateral to the neural 
tube. 
 
Once osteogenic commitment is induced, no further signals are required to maintain the cell 
lineage. Immature osteogenic cells condense into clusters. This initiates differentiation into 
mature osteoblasts, which are responsible for bone matrix formation (Dunlop and Hall, 1995). 
As the bone matrix formation continues, it will form nodules, which will later fuse together to 
create a bone plate. The bone plate is covered by periosteum; a layer of osteogenic cells and an 
outer fibrous layer. The major sites of main bone formation occur at the edges of opposing bone 
plates known as bone fronts. 
 
The bone front consists of several layers of osteogenic cells at different stages of differentiation: 
These range from the most differentiated osteoblasts that form mature bone, which lie next to 
A 
Key: 
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the newly formed bone, to the least differentiated osteoprogenitor cells that have just 
differentiated from the mesenchyme. The growth of the bone fronts occurs mainly by 
osteoprogenitor proliferation with a small contribution of mesenchymal cells recruited into an 
osteogenic fate (Lana-Elola et al., 2007). 
 
1.2.3  Suture formation, stability and fate 
When two bone fronts approach each other, a presumptive suture is formed, comprising of 
undifferentiated mesenchymal tissue. During this process there remain a few wide regions of 
mesenchymal tissue known as fontanelles. Sutures may be overlapping or butt ended in 
morphology (Figure 1.4). The formation, growth and maintenance of the craniofacial bone and 
sutures depend upon many factors. These may be cell autonomous, local (within a particular 
tissue) and paracrine interactions between the tissue of the bone front, suture and dura. It is 
thought that the mechanism underlying suture formation is a gradient of growth factor signalling 




Figure 1.4 Cross section of a suture 
Overlapping sutures include the lambdoid and parietal sutures. The sagittal suture is a butt ended suture.  
 
Once the suture has begun to form, the dura is essential for its initial stability, otherwise the 
suture will fuse (Opperman et al., 1993). In the presumptive (forming) suture, the dura sends 
osteogenic signals causing the joint (suture and bone fronts) to thicken. As the suture tissue 
matures, it is thought that the suture sends osteo-inhibitory signals to the dura to cease 
osteogenic signalling, which leads to reduction in suture thickness (Opperman, 2000).  The dura 
may play a role in controlling suture fate. In rats, the frontal suture remains patent and the 
sagittal fuses when the frontal (metopic) and sagittal suture positions are switched, such that the 
frontal suture overlies dura that normally interacts with the sagittal suture and vice versa 
(Levine et al., 1998). Furthermore, blocking the interactions between the dura and the frontal 
suture delays the time of suture fusion (Roth et al., 1996). Collectively, these reports indicate 
that the dura promotes suture patency or fusion depending on the region of the dura. When a 
suture has matured at the postnatal stage, it no longer requires the dura for maintenance (Kim et 
al., 1998). 
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As mentioned, the fate of a suture is either to fuse (obliterate) or remain patent (non-fused). 
When a suture fuses, the mesenchyme is replaced by bone, forming a continuous layer of bone 
between the bone plates. The timing of fusion differs according to the suture. In humans, about 
90 % of metopic sutures fuse between the 2
nd and 5
th year after birth (Cohen, 1986). However 
coronal, sagittal and lambdoid sutures remain patent (open), allowing further growth of the 
cranial vault. The time for fusion of these sutures ranges from 20 to 60 years (Sahni et al., 2005; 
Perizonius, 1984). A similar pattern of suture fate occurs in rats: the posterior frontal suture 
(analogous to the metopic suture) fuses between 12 and 20 days postnatally, whereas coronal, 
sagittal and lambdoid sutures remain patent (Moss, 1958). In mice, only the posterior frontal 
cranial suture fuses, starting anteriorly between 25 and 29 days and fusing by 39 and 45 days 
postnatally (Bradley et al., 1996). 
 
1.2.4  Differentiation at the bone fronts 
As bone fronts approach each other, there is tight regulation of molecular signalling that causes 
cells in the suture to differentiate in a controlled manner. Within the suture, a mesenchymal cell 
will differentiate into an osteoprogenitor cell, then pre-osteoblast and later an osteoblast 
secreting bone matrix that mineralises and extends the bone front. Some osteoblasts may further 
differentiate into osteocytes when they are incorporated into the bone matrix. 
 
Runt-related transcription factor (Runx2) is a key gene required for maturation of 
osteoprogenitors into osteoblasts and is expressed when mesenchymal cells differentiate into 
osteoprogenitors (Otto et al., 1997; Prince et al., 2001). Its expression is essential for bone 
maturation and mineralisation, as Runx2 null mutants do not show ossification (Otto et al., 
1997). In patients, many loss of function mutations in Runx2 leads to an autosomal dominant 
condition known as cleidocranial dysplasia in which the clinical features include a lack of 
ossification and delayed suture fusion (Lou et al., 2008). Runx2 is a transcription factor that 
contains a runt domain, which binds to promoters of osteoblast differentiation marker genes 
such as Collagen type1 ( COL1),  Alkaline Phosphatase ( ALP),  Osteopontin ( OPN) and 
Osteocalcin (OC) (Ducy et al., 1997; Harada et al., 1999; Karsenty et al., 1999). These Runx2 
target molecules may be used to help classify the stage of differentiation of bone according to 
whether they are expressed and the level of their expression (Figure 1.5). Twist is another 
marker of osteoblast differentiation; its expression decreases during maturation of the suture 
(Johnson et al., 2000). The expression patterns and relative levels of expression of the bone 
markers are listed in Table 1.1. 
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Figure 1.5 Markers of differentiation in osteogenic cells 
Bone formation is mainly due to proliferation and differentiation of the bone front (green), with a small 
contribution from mesenchymal cells (pink) which differentiate into osteogenic cells (green). The stage at 
which each gene is first expressed may mark the stage of differentiation as indicated from left to right, 
though it is important to note that expressions of each gene tend to continue once started and overlap with 
one another. 
 
Table 1.1 Differentiation marker expressions in osteogenic cells 
Marker Osteoprogenitor Pre-osteoblast  Mature  osteoblast 
Runx2  Present  Present, amount unknown  Moderate 
Collagen1 Low  Moderate  Moderate 
Twist High  Moderate  Low 
Opn  None to low  None to low  None to High 
Bsp  None to low  None to high  None to High 
Oc  Undetectable  Undetectable  None to High 
Adapted from (Aubin, 2001; Lee et al., 1999) 
 
1.2.5  Signalling molecules in sutures and bones 
Many molecules are involved in both suture and bone formation and maintenance. Fibroblast 
growth factor (FGF), transforming growth factor beta (TGFbeta), bone morphogenic protein 
(BMP) and Wnt are some of the main cell signalling molecules known to regulate bone 
formation.   Chapter 1 Introduction 
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1.3  Fibroblast Growth Factor (FGF) 
The FGFs are a family of structurally related polypeptides, identified by a highly homologous 
central core of 140 amino acids and a strong affinity for heparin and heparin-like 
glycosaminoglycans (HLGAG) (Burgess and Maciag, 1989; Ornitz and Itoh, 2001). In addition 
to bone formation, FGFs are involved in development, repair, regeneration, tumourgenesis and 
degeneration (Powers et al., 2000; Jackson et al., 2006; Partanen, 2007; Grothe and Timmer, 
2007). There are currently 25 known FGFs, of which 22 have been found in human (FGF1-23 
except for FGF15 in mouse) (Katoh and Katoh, 2005; Reuss and Bohlen und, 2003). 
 
A typical FGF gene such as FGF1, -2, -4 or -9 has three exons and is transcribed from a 
methionine (AUG) codon (Ornitz and Itoh, 2001), but a number of Fgfs also contain alternative 
CUG starting codons in the 5’ sequence (upstream of AUG), which allow transcription of other 
higher molelcular weight isoforms (Arnaud et al., 1999; Kiefer et al., 1994). Examples include 
FGF2, which can vary from 17 to 34 kDa (Yu et al., 2007). Alternative isoforms can also be 
generated from splicing of exon 1, as shown with FGF8 (MacArthur et al., 1995). FGFs have 
been reported to initiate intracellular and extracellular signalling and their ability to do this is 
due in part to the existence of these isoforms. 
 
1.3.1  Extracellular FGF signalling 
Extracellular signalling occurs when extracellular FGFs, for example FGF1 and -2 complex 
with cell surface membrane FGFRs and heparan sulphate proteoglycans (HSPGs). FGF1 and -2 
lack the classical signal peptide; however they are still exocytosed via non-ER-Golgi 
mechanisms, such as heat shock protein (Mignatti et al., 1992; Jackson et al., 1992; Piotrowicz 
et al., 1997). 
 
There are four FGF receptors (FGFRs). Each has three immunoglobulin-like (Ig-like) 
extracellular domains and two intracellular tyrosine kinase (TK) domains (Figure 1.6). The Ig-
like domain II and III form the FGF binding sites. FGFR1-3 have splice variants in IgIII labeled 
“b” and “c”, which confer specificities to particular FGFs (Table 1.2). FGFs may bind in a 1:1 
ratio to FGFRs (Figure 1.7) and the ligand-receptor complex dimerises to initiate signalling, a 
process mediated by heparan or heparin induced FGF oligomerization (Harmer, 2006; Spivak-
Kroizman et al., 1994). FGFR dimerisation brings the TK domains close enough for 
autophosphorylation and activate downstream signalling. The order of FGF, FGFR and HSPG   Chapter 1 Introduction 
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binding before activation is still under debate, however some of the models suggest that the 
FGF to FGFR binding is stabilised by HSPG to allow dimerisation (Powers et al., 2000). 
 
 
Figure 1.6 The general structure for FGFR. 
FGFRs have three Ig-like domains, one transmembrane domain (TMD) and two tyrosine kinase domains 






Figure 1.7 Interactions between FGF and FGFR for signalling (Guimond and Turnbull, 1999) 
In order for FGFR signalling to occur, FGF binds to FGFR and this complex dimerises with another FGF-
FGFR complex. This process requires heparan, which is bound to the FGF-FGFR. FGFR signalling is 
then initiated. 
S S  SS S S
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1 2 3
TMD TK1  TK2 
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Table 1.2 Ligand specificities of  FGFR isoforms (Eswarakumar et al., 2005) 
Isoform Ligand  specificity 
FGFR1IIIb  FGF1, -2, -3 and -10 
FGFR1IIIc  FGF1, -2, -4, -5 and -6 
FGFR2IIIb  FGF1, -3, -7, -10, -22 
FGFR2IIIc  FGF1, -2, -4, -6, -8, -9, -17 and -18 
FGFR3IIIb  FGF1, and -9 
FGFR3IIIc  FGF1, -2, -4, -8, -9, -17, -18 and -23 
FGFR4  FGF1, -2, -4, -6, -8, -9, -16, -17, -18, -19 
Note: FGF8 also included in binding to FGFR2IIIc (Ornitz et al., 1996). 
 
Following FGFR signalling, the complexes are then endocytosed and either degraded or 
translocated to the cytosol and nucleus. The C-terminus of the FGFR may determine this fate, as 
shown in COS-1 cells (derived from African green monkey kidney), where FGF1 complexed 
with either FGFR1 or FGFR4 is translocated to the cytosol and nucleus, whereas FGFR2 or -3 
(that have a different C-terminus to FGFR1 and FGFR4) are degraded after complexing with 
FGF1 (Sorensen et al., 2006b). Both ligand and receptor may translocate to different parts of the 
nucleus, for example FGF2 and FGFR1, where it is thought that they play different roles to each 
other and extracellular FGF-FGFR signalling (Reilly et al., 2004). 
 
1.3.2  Intracellular FGF signalling 
The intracellular FGFs include FGF 11, 12 13, and 14; these are known respectively as FGF 
Homologous Factors (FHFs) 3, 1, 2, and 4 (Schoorlemmer and Goldfarb, 2001). Unlike other 
FGFs, FHFs do not interact with any of the FGFRs even when added exogenously, but bind to 
intracellular proteins such as mitogen activated protein kinase (MAPK) scaffold protein Islet 
Brain-2 (IB2) (Olsen et al., 2003). Intracellular FGFs also include FGF1, -2 and -3, which are 
found intracellular and extracellularly (Sorensen et al., 2006a). Although FGF3 intracellularly 
has a signal peptide for extracellular signalling, it competes with a nuclear localisation signal on 
the protein, resulting in a significant level of intracellular localisation and signalling (Kiefer et 
al., 1994). Binding targets for these non-FHF ligands such as FGF2 may include intracellular 
proteins such as FGF interacting Factor (FIF) (Van den et al., 2000).  
 
Some forms of FGFR exist intracellularly and do not reach the cell surface membrane. Evidence 
of nuclear localisation and transcriptional regulation by FGFR1 suggests that intracellular   Chapter 1 Introduction 
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signalling may be initiated by FGFRs, although it is not clear this is dependent on the FGF 




Figure 1.8 Sites where FGF signalling may be initiated and the likely complexes formed 
1: Cell surface FGF signalling is brought about by formation of the FGF-FGFR complex in association 
with HSPG. 2 & 3: Intracellular activation. Activation may occur by target proteins being bound to FGF, 
FGFR or with the FGF-FGFR complex. 
 
1.3.3  The roles of FGFRs in craniofacial bone 
All four FGFRs are present in craniofacial bone (Britto et al., 2001; Chan and Thorogood, 1999; 
Cool et al., 2002; Rice et al., 2003). Analysis of normal and mutated receptor expression 
patterns have helped to define some roles for FGFR1-3, which are the isoforms associated with 
developmental defects such as craniosynostosis. FGFR4’s role in bone is not clear as mutation 
studies in this receptor have not revealed any specific function in bone and osteoblast 
development (Gaudenz et al., 1998), which may suggest redundancy of its function or that it has 
other roles as yet unknown. 
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Fgfr1 is positively upregulated in differentiated mouse osteoblasts (Kitching et al., 2002), but 
downregulated as osteoblasts mature and express osteopontin (Iseki et al., 1999). This indicates 
a role for Fgfr1 in osteoblast differentiation. 
 
In human embryonic craniofacial bone, FGFR2IIIc is the predominant isoform of FGFR2 (Chan 
and Thorogood, 1999). In mouse calvaria, Fgfr2IIIc induces bone formation (Eswarakumar et 
al., 2002). On a cellular level, Fgfr2 may positively regulate proliferation in osteoprogenitors, 
because its gene expression is down regulated upon differentiation into osteoblasts (Iseki et al., 
1999). This view is supported by a study showing that expression of dominant-negative Fgfr2 
results in reduced osteoblast proliferation (Ratisoontorn et al., 2003). Conditional inactivation of 
Fgfr2 has revealed that differentiation markers were still present, suggesting that Fgfr2 may not 
be required for differentiation (Yu et al., 2003). Interestingly the expression patterns of Fgfr2 
and differentiation marker Opn are mutually exclusive (Iseki et al., 1997), indicating that 
osteoblast proliferation induced by Fgfr2 signalling precedes differentiation regulated by Opn. 
 
Fgfr3 is expressed predominantly in the cartilaginous regions of the skull such as the 
synchondrosis of the cranial base and the mandibular condyle (Rice et al., 2003).  Chondrocyte 
proliferation is negatively regulated by Fgfr3 (Sahni et al., 1999). It is also suggested to increase 
osteoblast differentiation (Funato et al., 2001). Fgfr3
-/- mutations increase osteoblast number and 
activity in mouse tibia and femur, indicating a negative role for Fgfr3 in osteoblast proliferation; 
In addition, as Fgfr3 plays a positive role in long bone mineralisation, its role may be similar in 
craniofacial bone (Valverde-Franco et al., 2004). 
 
In summary, of the four FGFR isoforms in osteoblasts, only FGFR2IIIc has been shown to be 
positively essential for osteoblast proliferation, whereas FGFR3 is a negative regulator. FGFR1 
and -3 positively regulate differentiation. FGFR4 is not essential for either proliferation or 
differentiation. 
 
1.3.4  Roles of FGFs in craniofacial bone 
Fgf1 is expressed in embryonic rat dura and is replaced at the postnatal stage by Fgf2 (Ogle et 
al., 2004). The addition of exogenous FGF1 increases proliferation in the immature mouse 
osteoblast (OB1) cell line (Mansukhani et al., 2000), whereas in the mature MG63 human 
osteoblast cell line it causes an increase in apoptosis (Chang et al., 2005). 
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FGF2 is of importance in craniofacial bone development, as indicated by up-regulation of its 
mRNA in normally fusing sutures and by exogenous Fgf2 treatment resulting in suture fusion 
(Gosain et al., 2004; Moursi et al., 2002; Moursi et al., 2002). FGF2 is known to have varied 
effects on osteoblast behaviour, such as increasing proliferation slightly in immature 
osteoblasts, and increase differentiation in mature osteoblasts (Debiais et al., 1998). The effect 
of FGF2 induced differentiation may be mediated by altering the expression patterns of Fgfr1 
and -2, as Fgfr1 up-regulation and Fgfr2 down-regulation is observed in mouse sutures treated 
with FGF2 beads  in vivo (Iseki et al., 1999). The effects of FGF2 are concentration dependent. 
Blocking FGF2 with a single bead soaked in neutralising antibody in chick cranial vault 
increased proliferation, however when several beads were used to block FGF2, both 
differentiation and proliferation were blocked (Moore et al., 2002). FGF2 interacts with other 
growth factors, such as BMP and TGFbeta, which are also involved in bone growth and 
development. FGF2 can significantly increase the transcription of Tgfbeta1 for 24 hours after 
treatment (Mathy et al., 2003). Bmp expression is also upregulated by FGF2 stimulation (Choi 
et al., 2005). Nuclear translocalisation of FGF2 is necessary for the proliferative response 
(Sorensen et al., 2006a). 
 
Fgf18 is found in mesenchyme and differentiating osteoblasts and it is required for osteoblast 
proliferation and differentiation (Ohbayashi et al., 2002). A lack of Fgf18 expression results in 
delayed ossification and delayed suture fusion (Liu et al., 2002; Ohbayashi et al., 2002). FGF18 
is most homologous to FGF8 and FGF17 (Itoh and Ornitz, 2004). 
 
Both FGF6 and FGF17 can bind FGFR2IIIc, but in terms of bone development there has been 
no clear role and only FGF17 has been associated with costal cartilage development (Xu et al., 
1999). FGF8 is known to stimulate osteogenesis in bone marrow cells (Valta et al., 2006), 
though its role in skull vault development has not been characterised. FGF9 has been reported to 
induce endochondral ossification in craniofacial bone and is therefore significant, though of 
lesser interest in intramembranous ossification (Govindarajan and Overbeek, 2006). In 
summary, the main FGFs that have been characterised for calvarial growth are FGF1, -2 and -
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1.3.5  Mediators of downstream FGFR signalling 
FGFR signalling in the cytosol activates downstream pathways that include mitogen activated 
protein kinase (MAPK), protein kinase C (PKC), phospholipase C-gamma (PLC-γ), 
phosphatidylinositol 3-kinase (PI3-K) and other pathways that are activated by less well 
characterised molecules such as Crk, Src and Shc (Dailey et al., 2005; Klint and Claesson-
Welsh, 1999; Spector et al., 2005). Signalling in pathways are initiated by phosphorylation of 
specific tyrosine residues in the Tyrosine Kinase (TK) domain of FGFR. The local 
conformational structure around these residues allows proteins that contain PTB or SH2 
domains to bind to them. Examples of these proteins are PLC-γ, PI3-K, Crk, Src and Shc, which 
are shown in Figure 1.9. 
 
MAPK pathway involves a cascade of four kinases. The range of MAPK pathways includes 
Extracellular Related Kinase 1/2 (ERK1/2), p38 and c-jun N-terminal Kinase (JNK), each of 
which has their own specific molecules along their cascades. The RAS/RAF/MEK/ERK 
signalling cascade was the first to be discovered. As implied, the RAS molecule of the MAPK 
pathway is not directly activated by the TK domain of FGFR, but activated by the guanine 
exchange factor Son of Sevenless (SOS), which is complexed to Grb2, Shc and FRS2α (Dailey 
et al., 2005). FRSα directly binds to FGFR and is involved in ERK stimulation as 
overexpression of FRS results in prolonged FGF induced ERK activation (Hadari et al., 2001). 
RAS is a g-protein that lies on the cytoplasmic surface of the cell membrane. SOS dissociates 
GDP from RAS, resulting in an association of GTP with RAS. The resulting conformational 
change allows RAS to bind to effector proteins such as RAF. RAF may also be activated by 
Protein Kinase C (PKC) pathways (Grammer and Blenis, 1997).  
 
In osteoblasts FGFR activates RAS/RAF/MEK/ERK pathway via SOS, but not via a PI3-K 
mechanism. However, if initiated by PDGF-BB, PI3-K may also activate RAS/RAF/MEK/ERK 
in this cell type (Chaudhary and Hruska, 2001). MEK1 may be activated independently of RAF 
(b-RAF) by autophosphorylation by PAK, which is associated with cell adhesion molecules 
such as Fibronectin (Park et al., 2007). This suggests that downstream pathways have complex 
interconnections that depend on the upstream signal. ERK MAPK signalling may be inhibited 
by the non-competitive MEK inhibitor U0126 (Suzuki et al., 2002a). 
 
ERK1/2 controls proliferation in osteoblasts (Chambard et al., 2007; Fremin et al., 2007; Suzuki 
et al., 1999). In addition it is important for differentiation (Lai et al., 2001; Spector et al., 2005). 
In MC3T3 cells the JNK pathway mediates FGF2 induced release of VEGF, which important   Chapter 1 Introduction 
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for stimulating vascular endothelial growth. The p38 MAPK is involved in differentiation, as it 
positively regulates ALP expression in osetoblasts (Suzuki et al., 2002a). It also positively 
regulates the expression of PKC-eta (Lampasso et al., 2006). However p38 is not associated 
with FGF2-induced osteoblast apoptosis (Debiais et al., 2004).  
 
PKC plays a role in cell proliferation (Kozawa et al., 1989; Sabatini et al., 1996; Uht et al., 
2006; Villa et al., 2003) and is associated in differentiation. There are many isoforms of PKC.  
PKC-δ mediates FGF2 induced Runx2 activation and expression (Kim et al., 2006; Kim et al., 
2003). It binds to and directly phosphorylates Runx2. It is also associated with FGFR and BMP 
induced osteoblast apoptosis (Fromigue et al., 2005; Lemonnier et al., 2001). PLC-γ is thought 
to activate PKC (Tang et al., 2007). 
 
PI3-K positively mediates osteoblast cell survival induced by FGF2 (Debiais et al., 2004). It 
may be activated directly by FGFR or via Grb2 complexed to FRS2 (Hatch et al., 2006). 
Downstream of PI3-K is Akt, which is required for osteoblast cell survival, as disruption of the 
Akt gene in MC3T3 cells leads to increased susceptibility to mitochondria-dependent apoptosis 
(Kawamura et al., 2007). However a number of studies indicate that FGFR activated PI3-K may 
lead to variation in Akt activation in osteoblasts. In subconfluent MC3T3 cells and immortalised 
human neonatal calvarial (INHC) osteoblasts cells, Akt is either not activated or activated at 
very low levels by PI3-K (Chaudhary and Hruska, 2001; Debiais et al., 2004). FGF1 treatment 
in immature mouse osteoblasts (OB1) leads to low levels of Akt activation, whereas in the more 
mature OB5 osteoblasts the level of Akt activation appears to increase slightly (Raucci et al., 
2008). Differentiation in OB1 and OB5 osteoblasts is enhanced by increasing the level of active 
Akt. Runx2 dependent osteoblast differentiation has been shown to require PI3-K-Akt 
signalling, in particular to allow Runx2-Akt interactions (Fujita et al., 2004). Together, this 
suggests a role for PI3-K and Akt in survival and differentiation in osteoblasts. 
 
Synthetic inhibitors have been generated for FGF signalling such as SU5402. SU5402 binds to 
the adenine pocket of the ATP binding site of the FGFR tyrosine kinase and the substituted 
groups at the R1 position bound to the hydrophobic pocket of the ATP binding site, thus 
inhibiting the TK activity (Li et al., 2006). 
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Figure 1.9 Downstream signals of the FGF-FGFR complex 
In the Tyrosine Kinase domains of FGFR there are tyrosine residues, which are binding sites for proteins 
that contain Phosphotyrosine-binding (PTB) or Src Homology 2 (SH2) domains (Pawson 1993). The 
circled molecules shown in this figure either bind directly, because they contain PTB or SH2 domains, or 
they are adapter proteins. There are a number of downstream pathways of FGF signalling, which include 
MAPK, PKC, PLC-γ and PI3-K. The effects of these signal pathways involve the nucleus to produce 
cellular responses. Activation of MAPK requires a complex formation. FRS2 (Fibroblast growth factor 
receptor substrate 2) contains PTB domains to bind to FGFR. It binds to Shp and Grb2 (Growth factor 
receptor-bound protein 2), which is complexed to the Ras activator SOS (Son of Sevenless). SOS is one 
of the main initiators of MAPK signalling, however MAPK signalling may also be initiated by PKC. PI3-
K may also be activated by Grb2 in addition to direct activation by FGFR. Adapted from Dailey et al, 
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1.4  Transforming growth factor beta (TGFbeta) 
TGFbetas are part of the TGFbeta superfamily, a large group of structurally related dimeric 
cytokines (Janssens et al., 2005). The superfamily includes bone morphogenic proteins (BMPs) 
(Ito and Miyazono, 2003). Aside from bone formation, TGFbetas play roles in cancer and in the 
development of body structures including the blood vessels, eyes, lungs, heart and spine (Chai 
et al., 2003; Dubrovska et al., 2005). To date, there are three isoforms of TGFbeta in mammals 
(Schmierer and Hill, 2007). TGFbetas are homodimeric existence and must be activated before 
they can signal, by latency-associated peptide bound to TGFbeta based on studies of TGFbeta1 
(Rawlins and Opperman, 2008; Shi and Massague, 2003). 
 
1.4.1  TGFbeta signalling  
The TGFbetas are ligands that bind to TGFbeta receptors I and –II (TβRs), which are 
serine/threonine kinase receptors. For signalling to initiate, TGFbeta binds to a homodimer of 
TβRII, which permits a TβRI homodimer to bind to the complex (Zuniga et al., 2005). This 
results in the formation of a heterotetrameric receptor complex of TGFbeta:TβRI:TβRII (ten 
Dijke and Hill, 2004). Unlike FGFRs, one of the receptors (TβRII) is constitutively active and 
phosphorylates TβRI on formation of the complex (Janssens et al., 2005). 
 
Figure 1.10 TGFbeta signal initiation  
TGFbeta binds to a dimer of TβRII, which enables binding of this complex to TβRI. This completes the 
complex and allows TβRII to phosphorylate and activate TβRI, which initiates signalling. 
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1.4.2  The roles of TGFbetas in bone  
In general, TGFbeta1, -2 and -3 are able to increase proliferation in osteoblasts, depending on 
experimental conditions and the stage of osteoblast maturation. These are mainly based on 
studies in mouse. Tgfbeta1, -2 and -3 mRNA are expressed at the bone fronts and in the dura 
(Opperman et al., 1997). Tgfbeta1 is also expressed in sutural mesenchyme, at higher levels in 
the rat posterior frontal suture and dura compared to the sagittal suture (Gosain et al., 2004). 
Tgfbeta1 and -3 are expressed in osteogenic bone fronts of presumptive sutures. Tgfbeta1 and -2 
expression is found in fusing sutures (Opperman, 2000). During posterior frontal suture fusion, 
TβRI is upregulated relative to the brain (Gosain et al., 2004). 
 
Of the many phenotypes that disrupted TGFbeta signalling may produce, a common feature is 
an osteopetrosis phenotype, where there is increased bone thickness. In-vivo mouse models have 
shown that inactivated TGFbeta1, dominant negative mutations of TβRII and TGF-beta binding 
protein (Ltbp)-3 null mutations in mice lead to increased bone mass with decreased osteoclast 
activity, but no change to the rate of bone deposition (Dabovic et al., 2005; Filvaroff et al., 
1999). This indicates that TGFbeta signalling is also important for osteoclast activity and 
therefore bone remodelling. In bone, truncated TβRII mutations lead to a decrease in the 
osteocyte density (Filvaroff et al., 1999), whereas in TGFbeta2 overexpression mutants there is 
an increase in the number of osteocytes in bone (Erlebacher and Derynck, 1996; Erlebacher et 
al., 1998). This suggests that TGFbeta signalling is required for differentiation of osteoblasts 
into osteocytes. 
 
Most of the current literature suggest that TGFbeta1 increases proliferation, particularly in less 
mature mouse osteoblasts (Bosetti et al., 2007; Centrella et al., 1994; Chung et al., 1999; 
Ghayor et al., 2005; Janssens et al., 2005; Reyes-Botella et al., 2002). In osteoblasts at 
postconfluence, TGFbeta1 does not affect proliferation (Chung et al., 1999). TGFbeta1 
decreases proliferation in rat osteosarcoma cells and in MC3T3 at high passage (>60), or in 
serum free medium (Cabiling et al., 2007; Centrella et al., 1994; Chung et al., 1999). Runx2 is 
activated in UMR rat osteoblasts following by TGFbeta1 treatment (Selvamurugan et al., 2004), 
indicating that it may push differentiation. However, TGFbeta1 treatment decreases expression 
of late differentiation marker Oc, an effect that is abrogated by cycloheximide, indicating an 
indirect transcriptional control of Oc by TGFbeta1 (Noda, 1989). TGFbeta1 also inhibits 
BMP2-induced bone mineralization (Spinella-Jaegle et al., 2001). TGFbeta1 has not been 
reported to alter apoptosis, as demonstrated in E18 mouse osteoblasts cultured in differentiating 
medium after 2 days of TGFbeta1 treatment (Cabiling et al., 2007). Overall, TGFbeta1 is   Chapter 1 Introduction 
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suggested to increase early proliferation and block late stage differentiation and mineralization 
in osteoblasts (Alliston et al., 2001; Centrella et al., 1994).  
 
TGFbeta2 generally increases proliferation in osteoblasts (Bosetti et al., 2007; Centrella et al., 
1994; Opperman et al., 2000); although in rat osteosarcoma cells TGFbeta2 treatment leads to 
decreased proliferation (Centrella et al., 1994). TGFbeta2 also increases apoptosis in calvarial 
explants (Opperman et al., 2000). However this effect may depend on experimental conditions 
as in tibial bone in-vivo, osteoblast apoptosis is blocked by TGFbeta2 treatment (Dufour et al., 
2008). Tgfbeta2 has a positive role in suture fusion, which involves induction of proliferation 
and signalling along the Erk1/2 pathway (Opperman et al., 2000; Opperman et al., 2006). In 
TGFbeta2-null mice at stage E18.5 there is a reduction in calvarial bone size and ossification 
with enlarged fontanelles (Sanford et al., 1997). In contrast, overexpression of TGFbeta2 in 
mice leads to lower bone mass through greater bone resorption (Erlebacher and Derynck, 1996). 
This suggests that TGFbeta2 is positively involved in osteoblast proliferation, differentiation 
and bone remodelling and plays a role in osteoblast apoptosis. 
 
TGFbeta3 treatment increases proliferation in primary fetal rat bone cells and in primary human 
osteoblasts grown without differentiation factors (Bosetti et al., 2007; Centrella et al., 1994). In 
rat osteosarcoma cells, 0% serum culture conditions and calvarial explants, proliferation is 
decreased by TGFbeta3 treatment (Cabiling et al., 2007; Centrella et al., 1994; Opperman et al., 
2000). TGFbeta3 may also increase apoptosis in osteoblasts (Cabiling et al., 2007; Opperman et 
al., 2000). TGFbeta3-induced apoptosis and inhibited proliferation is thought to contribute to 
suture patency and the delay of suture fusion (Opperman et al., 2000; Opperman et al., 2002a; 
Opperman et al., 2002b). Together this suggests that TGFbeta3 increases osteoblast 
proliferation in immature osteoblasts, but may decrease proliferation in more mature cells and in 
the absence of serum. Apoptosis is positively regulated by TGFbeta3. 
 
TβRII is involved in regulating CNC cell populations for form frontal bone and development of 
the caudal region of the skull (Hosokawa et al., 2007; Sasaki et al., 2006). TGFbeta has 
differential functions, not only on osteoblasts, but in other cell types such as fibroblasts. For 
example, dermal fibroblasts have a higher hyaluronan (HA) expression compared to oral 
mucosal fibroblasts, which results in increased proliferation in dermal fibroblasts in response to 
TGFbeta1, whereas oral fibroblasts respond to TGFbeta1 by a reduction in proliferation (Meran 
et al., 2008). Interestingly, this effect is dependent on the downstream molecule Smad3, 
described in the next section. 
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1.4.3  Mediators of TGFbeta signalling 
TGFbetas signal directly via Small Mothers Against Decapentaplegic homologue (SMAD) 
transcription factors (Sekelsky et al., 1995; Savage et al., 1996) and also via MAPKs such as 
ERK1/2 (Lee et al., 2006). PI3-K and PKC may also be activated by TGFbeta, however it is not 
clear if they are directly activated by the TGFbeta receptor complex. 
 
The are eight SMADs, of which SMAD6-7 are inhibitory (Clarke and Liu, 2008). TGFbetas are 
best known to signal via SMAD2 and -3 by binding to TβRI (ALK5), but they can also signal 
via SMAD1 and -5 via a different TβRI (ALK1). In contrast, BMPs signal via SMAD1, -5 and 8 
(Miyazawa et al., 2002). In addition, these SMADs associate with SMAD4 (the common 
mediator SMAD) in order to confer the downstream signalling. These TGFbeta-SMAD 
configurations are shown in Figure 1.11. The actions of these SMADs are blocked by inhibitory 
SMAD6 and -7. In mice, Smad2 and -3 play important roles in the normal development of the 
skull, as Smad2 may rescue cleft palate in TGFbeta3 null mice (Cui et al., 2005) and Smad3 
mediates TGFbeta induced of downregulation of Runx2 and Osteocalcin expression, thus 
inhibiting osteoblast differentiation (Alliston et al., 2001). There are also some direct 
interactions between Smad3 and Runx3, and Runx2 acts synergistically with Smad1 and -5 to 
regulate bone specific genes (Ito and Miyazono, 2003). 
 
TGFbeta signalling may also activate MAPK by directly activating ShcA, which has been 
shown to result in ERK1/2 activation (Lee et al., 2007). TGFbeta may also activate 
prostaglandins, which activate PKC, which in turn activate the ERK1/2 pathway, leading to 
proliferation  (Ghayor et al., 2005). Erk1/2 pathway signalling is required for processes such as 
TGFbeta2 induced suture fusion (Opperman et al., 2006). The p38 MAPK mediates a number of 
TGFbeta’s functions with respect to differentiation (Karsdal et al., 2001; Lee et al., 2002; 
Selvamurugan et al., 2004; Sowa et al., 2002). Examples include the convergence of Smad and 
p38 pathways to regulate Runx2 expression (Lee et al., 2002), and osteoblast elongation 
mediated by p38 following TGFbeta treatment (Karsdal et al., 2001). Interestingly, the effect of 
p38 may depend on the upstream signal. For example, p38 mediated TGFbeta signalling 
decreases osteocalcin expression, whereas p38 mediated BMP increases osteocalcin expression 
(Lai and Cheng, 2002). JNK and p38 have been shown not to be involved in TGFbeta mediated 
MC3T3 cell proliferation, whereas ERK1/2 has been shown to be essential (Ghayor et al., 
2005). JNK and ERK1/2 play a role in differentiation by mediating TGFbeta inhibition of ALP 
expression and mineralisation (Tokuda et al., 2003). 
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TGFbeta influences cell survival by TGFbeta-PI3-K and Smad3-Akt interactions (Conery et al., 
2004; Dufour et al., 2008; Song et al., 2006). TGFbeta can activate PI3-K, leading to increased 
osteoblast survival. Conversely, TGFbeta-Smad3 signalling can induce osteoblast apoptosis, 
which is inhibited by Smad3-Akt binding, as this sequesters Smad3 (Conery et al., 2004). 
Interestingly, TGFbeta induced Akt activation in mesenchymal cells is dependent on p38 
(Horowitz et al., 2004). 
 
 
Figure 1.11 Receptor-Ligand complexes in TGFbeta and BMPs and associated SMAD signals  
TβRII and BMPRII are common to TGFbeta and BMPs respectively, whereas the TβRI and BMPRI 
receptors (also known as ALK) determine which SMADs are activated. In TGFbeta signalling, ALK5 
induces SMAD2/3 activation, whereas ALK1 induces SMAD1/5 activation. BMPs activate SMAD1/5/8 
via ALK2, -3 or -6. All of these SMADs bind to the SMAD4 (a Co-SMAD), resulting in regulation of 
transcription. Adapted from Miyazawa, 2002. 
 
SB431542 is a synthetic inhibitor of TGFbeta signalling. It inhibits ALK4, -5 and -7, but not 
ALK-1, -2, -3, and -6; hence it does not affect BMP signalling (Laping et al., 2002; Inman et al., 
2002). 
 
1.5  In-vitro model of bone development with MC3T3-E1 
MC3T3-E1 is an osteogenic cell line derived from a clone derived from newborn mouse 
calvaria, established under 3-day transfer, inoculum 3 x 10
6 cells (3T3) culture conditions 
(Kodama et al., 1981). The 3T3 protocol was first described by Todaro and Green in 1963, 
where 3 x 10
6 cells were plated onto 50mm diameter (20cm
2) petri dishes, however in practice 
only the 3 day transfer is conserved, as differences in cells such as doubling time affect the 
number of cells needed to inoculate the culture plate (Todaro and Green, 1963). MC3T3-E1 
cells resemble osteoprogenitors (Sudo et al., 1983), based on their fibroblastic appearance and 
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low ALP activity in the early stages of culture. The doubling time of MC3T3 was reported to be 
approximately 18 hours (Sudo et al., 1983). 
 
MC3T3-E1 is a useful model for intramembranous bone formation as cultures have 
characteristics that are similar to developing bone in-vivo, such as the stages of differentiation 
from osteoprogenitors to osteoblasts and osteocytes. Although a number of bone cell lines exist, 
only few originate from calvaria, such as OB cells (Mansukhani et al., 2000). MC3T3 cultures 
are able to mineralise bone matrix if cultured with both ascorbic acid and beta-glycerophosphate 
to form periosteum and bone nodules (Petiot, 2001). The timing of these differentiation 
processes is associated with the initial cell density. Morphologically, fibroblastic-like cells are 
found at 2 days in culture (2 DIC), whereas cuboidal cells are found at 4 DIC, based on a 
seeding of 50,000 cells on a 35 mm culture plate (about 5200 cells per cm
2) (Sudo et al., 1983). 
The basic description of the osteoblast morphology is summarised in Table 1.3. 
 
Table 1.3 MC3T3 maturity and morphology. Adapted from (Sudo et al., 1983) 
Cell Appearance  Day  observed 
Osteoprogenitor Fibroblastic  2 
Osteoblast precursor*  Lysozome rich cells  2 
Osteoblast Cuboidal  cells  4 
Osteocyte  Cell surrounded by bone  21 
*Could be described as late osteoprogenitor or early osteoblast 
 
A comparison of early and late passage MC3T3-E1 (<20 and >65 respectively) revealed marked 
changes in cell morphology and a reduction in both proliferation and cellular responses to 
TGFbeta1 and BMP2 (Chung et al., 1999). A study of MC3T3-E1 cell morphology, 7 days after 
seeding at 5000 cells/cm
2 showed that most were cuboidal in early passaged cells, whereas at 
late passage (>65), cells were spindle shaped (Chung et al., 1999). Exogenous TGFbeta1 
treatment increased proliferation in early passage, but decreased proliferation in late passage 
cells. BMP2 did not have any significant effect on proliferation in either cell group. In another 
study of MC3T3, although cell population doubling had decreased slightly in passage 42 
compared to passage 25, no significant difference in cell number was found until a few days 
post confluence (Peterson et al., 2004). 
 
These studies indicate that cell morphology, passage number and response to TGFbeta1 should 
be monitored and that cells should be excluded from experimentation for passage numbers 
above 65 or when MC3T3 cells no longer respond to TGFbeta1. 
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1.6 Craniosynostosis 
Craniosynostosis is a disease characterised by the premature fusion of one or more sutures 
leading to skull dysmorphologies. The incidence is approximately 1 in 2500 live births 
(Hollway et al., 1995). Bone growth is reduced at the site of suture fusion, which reduces the 
intracranial volume, as shown in rabbits with craniosynostosis (Cooper et al., 2006). 
 
1.6.1  Clinical and genetic background 
The key clinical features of craniosynostosis are the deformities at the prematurely fused 
suture(s) and also the compensatory growth in other areas of the skull to give head shapes 
described in Table 1.4. An example of sagittal suture fusion is given in Figure 1.12. 
Craniosyostosis is classically diagnosed according to the skull morphology around 2-3 weeks 
postnatally, to allow for normal skulls to return to their natural shape after deformation that may 
occur through the birth canal (Table 1.4). A direct defect in ossification leading to premature 
suture fusion is known as a primary craniosynostosis. These include syndromic 
craniosynostoses, which are categorised according to other cranial and extracranial features and 
specific genetic mutations (Table 1.6-1.6). For example, in Crouzon’s syndrome, hypoplasia of 
the maxilla and hypertelorism (wide spacing) of the eyes are observed and this is associated 
with FGFR2 mutations. A secondary craniosynostosis occurs as a result of other primary defects 
and disorders (Table 1.7). 
 
Table 1.4 Clinical classifications of craniosynostosis based on suture 
Clinical Description  Suture involvement  Head shape 
Scaphocephaly 
Syndolichocephaly 
Sagittal  Elongated (anterior – posterior) 
Plagiocephaly Unicoronal  Asymmetric forehead flattening 
Trigonocephaly  Metopic  Pointed triangular forehead 
Posterior plagiocephaly  Lambdoid  Asymmetric occipital flattening 
Brachycephaly Bicoronal  Spherical 
Acrocephaly 
Synoxycephaly** 
Bicoronal/multiple Pointed,  tower 
** The term turricephaly is also sometimes used to describe the tower-shaped deformity 
Adapted from Clinical Management of Craniosynostosis (2004)   Chapter 1 Introduction 
 




Figure 1.12 Dysmorphology in sagittal suture 
A: Normal Skull at brith with all sutures patent. B: The premature fusion of the sagittal suture results in a 
lack of bone growth at this site. Bone growth is compensated at the remaining patent sutures, giving rise 
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Approximately 40% (1:6250) of craniosynostoses are syndromic; the common ones include 
Apert, Crouzon, Pfeiffer, Muenke, and Saethre-Chotzen syndrome (Lajeunie et al., 2006). They 
are diagnosed by the clinical features and confirmed by genetic testing and skull imaging, for 
example X-rays, computer aided tomography (CT) and / or magnetic resonance imaging (MRI). 
 
Crouzon syndrome is one of the most common syndromes, occuring in 1:25,000 births (Renier 
et al., 2000). In 1912, Crouzon described the syndrome’s features: synostosis, hypertelorism 
(widely spaced eyes), exophthalmos (protrusion of the eyes), parrot-beaked nose, short upper lip 
(maxillary hypoplasia) and relative mandibular prognathism (forward positioned mandible) 
(Carinci et al., 2005). A bicoronal synostosis is often present, but other sutures may be involved 
or a unicoronal suture may exist (Hoefkens et al., 2004; Sher et al., 2008). Sutures are not 
always fused at birth, but progress to fusion within a few years of birth, delaying clinical 
diagnosis in some cases. Crouzon syndrome does not have clinically abnormal extracranial 
features, unlike other syndromes, which is useful in excluding Apert or Pfeiffer syndrome in the 
differential diagnosis (Renier et al., 2000). 
 
Pfeiffer syndrome occurs in 1:100,000 births and features described by Pfeiffer in 1964 
included coronal synostosis (with or without sagittal involvement) with turribrachycephaly, 
maxillary hypoplasia, hypertelorism, proptosis, low nasal bridge, choanal stenosis or atresia, 
partial syndactyly (Vogels and Fryns, 2006; Pfeiffer, 1964). Furthermore, Pfeiffer syndrome has 
extracranial features of broad thumbs and toes, that are useful in differentiating it from Apert 
syndrome (Cohen, Jr., 1993; Pfeiffer, 1964; Renier et al., 2000; Vogels and Fryns, 2006). 
Interestingly, a number of point mutations for Pfeiffer syndrome are also shared with Crouzon 
syndrome, such as FGFR2-C278F and FGFR2-C342Y (Ornitz and Marie, 2002). Pfeiffer 
syndrome is also clinically divided into 3 types, which exhibit additional features and 
prognoses. Type 1 is associated with normal neurological function and development with a 
good prognosis (Vogels and Fryns, 2006). Type 2 displays a trilobated skull deformity 
(cloverleaf skull), more extreme proptosis, elbow ankylosis or stenosis, respiratory difficulties, 
developmental delay and neurological complications, which carries a poorer prognosis for early 
survival. Type 3 is similar to type 2, but without the cloverleaf skull. 
 
Craniosynostosis is associated with an increased risk of raised intracranial pressure (ICP); single 
suture synostosis carries a 15-20% risk, whereas syndromic cranioynostoses 30-40% 
(Tamburrini et al., 2005). Contributing factors for ICP include smaller skull volume following 
craniosynostosis, raised ICP results in compression of the brain in the cranial vault and 
underlying nerves such as the optic nerve. This may impair or result in loss of visual, cognitive   Chapter 1 Introduction 
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and motor function and development, therefore monitoring ICP and treatment to reduce raised 
ICP is of primary concern (Bannink et al., 2008). The development of ICP can be a slow 
insidious process, therefore regular ophthalmological monitoring is advised (Marucci et al., 
2008; Renier et al., 2000; Tuite et al., 1996). It is currently debated whether primary defects in 
brain development independent ICP causing mental impairment exist (Raybaud and Di Rocco, 
2007). 
 
Management of craniosynostosis is surgical in order to correct skull dysmorphologies and to 
relieve high ICP, as damage to visual and mental development may occur if untreated. The 
surgical techniques are dependent on severity, the suture(s) and other cranial features present. 
 
Table 1.5 Example surgical treatments for craniosynostosis 





Plagiocephaly Forehead  reconstruction 
Trigonocephaly Forehead  reconstruction 
Brachycephaly  Floating forehead advancement 
Adapted from Renier et al, 2000    
   
Table 1.6 Genetic and phenotypic classification of syndromic craniosynostosis 
Syndrome  Cranial defects  Non-cranial defects Locus  Gene  Mechanism  Reference 
Adelaide  Frontal bossing, Mid-
face hypoplasia 
Phalangeal hypoplasia, coned 





Not established. Shares 
only cranial features with 
Jackson-Weiss 
(Hollway et al., 
1995) 
Apert  Coronal, wide midline 
defect, acrocephaly, 
midface hypoplasia 
Bony and cutaneous 
syndactyly hands and feet 
10q26  FGFR2  Loss of ligand specificity  (Wilkie et al., 1995) 
Beare-Stevenson  Cloverleaf  skull  Furrowed skin disorder of 
cutis gyrata 
10p26  FGFR2  Constitutive activation  (Przylepa  et  al., 
1996) 
Boston type  Cloverleaf  skull, 
forehead retrusion 
Short first metatarsals  5q34  MSX2  Gain of function  (Jabs et al., 1993) 
Carpenter Metopic,  sagittal, 
cloverleaf skull 
Hand brachydactyly, obesity, 
feet polysyndactyly  
6p12.1-
q12 
RAB23  Predicted loss of function  (Jenkins et al., 2007) 
Crouzon Coronal,  proptosis, 
hypertelorism 






hypoplasia,  proptosis 
acanthosis nigricans  4p16.3  FGFR3  Constitutive activation  (Meyers et al., 1995) 
Craniofrontonasal Coronal,  hypertelorism, 
grooved nasal tip,  
Partial cutaneous syndactyly  Xq12, 
Xq22 
EFNB1  Predicted loss of function  (Twigg  et  al.,  2006; 
Wieland et al., 2004)    
   
  
Genetic and phenotypic classification of syndromic craniosynostosis (continued) 
Syndrome  Cranial defects  Non-cranial defects Locus  Gene  Mechanism Reference 
Jackson-Weiss Frontal  bossing, 
Midface hypoplasia 
hypertelorism, 
Tarsal/metatarsal fusion, broad 
great toes 
10q26  FGFR2  Constitutive activation  (Jabs et al., 1994) 
Loeys-Dietz type 1  hypertelorism,  cleft 
palate, blue sclera,  






Predicted gain of 
function 
(Johnson et al., 2007; 
Loeys et al., 2005) 
Muenke Macrocephaly, 
midface hypoplasia 
Carpel/tarsal fusion, short 
hands/feet, coned epiphyses 
4p16.3  FGFR3  Constitutive activation  (Muenke et al., 1997) 
Pfeiffer Cloverleaf  skull, 
midface hypoplasia 






Constitutive  activation  (Muenke et al., 1997; 
Webster and Donoghue, 
1997) 
Saethre-Chotzen Coronal  Syndactyly,  hallucial 
duplication, brachydactyly 
7p21  TWIST  Haploinsufficiency  (de Heer et al., 2005) 
Shprintzen-
Goldberg 
Sagittal & lambdoid 
Exopthalmos, 
arachnodactyly 15q21.1  FBN1  Structural disruption  (Sood et al., 1996) 
Thanatophoric 
dysplasia 
Cloverleaf  skull  Straight femur, short stature, 
shortened limbs, short ribs 
4p16.3  FGFR3  Constitutive activation  (Tavormina et al., 1995) 
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Table 1.7 Secondary Craniosynostoses 
Primary condition  Examples 
Chromosomal disorders  Del (1q), dup (3q), del (7p), dup(7p), triploidy, tetrasomy 
14q 
Metabolic Disorders  Hyperthyroidism, Rickets 
Mucopolysaccharidoses  Hurler syndrome, Morquio syndrome 
Haematological Disorders  Thalassaemias, Sickle Cell Anaemia, Congenital 
Haemolytic Icterus, Polycythaemia Vera 
Teratogens  Aminopterin, Diphenylhydantoin, Retinoic acid, Valproic 
acid 
Malformations  Microcephaly, Encephalocoele, Holoprosencephaly, 
Hydrocephalus 
Adapted from (Cohen, Jr., 1993) 
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1.7 FGFR  mutations 
FGF signalling plays an important role in bone differentiation and proliferation. As shown 
previously in Table 1.6, many of the syndromes are caused by single point mutations in 
fibroblast growth factor receptors (FGFR) 1-3. FGFR2 is the most commonly reported mutated 
receptor in 90% of craniosynostosis patients with Apert, Crouzon, Pfeiffer and Jackson-Weiss  
syndromes (Passos-Bueno et al., 2008). FGFR2IIIc is of particular importance because it is the 
main isoform in craniofacial bone and is expressed in the paraxial and lateral mesoderm (Orr-
Urtreger et al., 1993) that later forms the mesenchyme (Sadler, 2004), and is a positive regulator 
of bone formation. FGFR2IIIb is expressed in ectoderm and endothelial organ lining (Orr-
Urtreger et al., 1993). FGFR3 is also important for long bone development as mutations lead to 
dwarfism conditions: thanatophoric dysplasia, achrondroplasia and hypochondroplasia (Meyers 
et al., 1995). The position of the mutation along the gene may be important as 99% of 
achondroplasia mutations are found in the transmembrane domain. Not all mutations in FGFR 
lead to craniosynostosis, indicating that specific mechanisms are involved in this disease 
process. For example, certain mutations of FGFR1 causes Kallmann’s syndrome (Albuisson et 
al., 2005), where there is failure of gonadotrophin releasing hormone (GnRH) releasing neurons 
to migrate from the olfactory epithelium to the hypothalamus, resulting in hypogonadism and 
anosia. These FGFR1 mutations result in the KAL2 form of Kallmann’s syndrome, which is 
autosomal dominant and thought to equate to a deficiency of FGFR1 signalling, leading to a 
failure of olfactory bulb development (Eswarakumar et al., 2005). 
 
Two main mechanisms associated of FGFR associated craniosynostosis have been reported and 
are considered as gain-of-function (increased signaling), with an autosomal dominant 
inheritance (Carinci et al., 2005). One is a loss of ligand specificity, where the FGFR is 
activated by FGF ligands that do not normally bind that receptor. The other is the constitutive 
activation of the FGFR, which is independent of FGF induced FGFR activation. Many of the 
mutations occur in the third Ig domain of the receptor such as FGFR2-C278F (Figure 1.13). 
Interestingly the chance of inheritance is increased from a father with gain-of-function FGFR2 
mutations such as Apert, as the FGFR signalling enhances sperm motility (Goriely et al., 2003; 
Wilkie, 2005). 
 
The mechanisms underlying premature suture fusion are still poorly understood. Though 
FGFR2 regulates proliferation (Iseki et al., 1999; Yu et al., 2003), the key characteristic 
observed in craniosynostosis is premature bone differentiation. There are a number of   Chapter 1 Introduction 
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conflicting reports concerning the effects of FGFR gain of function mutations on proliferation 




Figure 1.13 Point mutations reported in craniosynostosis (Ornitz and Marie, 2002) 
AS: Apert syndrome. CS: Crouzon syndrome. PS: Pfeiffer syndrome. JWS: Jackson Weiss syndrome. 
C278F mutation (black arrow) is one of the most common mutations. For the latest comprehensive details 
see also the review by Passos-Bueno (Passos-Bueno et al., 2008).   Chapter 1 Introduction 
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1.7.1  Loss of ligand specificity of FGFR 
These mutations increase receptor binding affinity for other FGF ligands to which they would 
not normally bind (Yu et al., 2000). Examples include the S252W and P253R mutations, which 
allow other FGF to bind as shown in Table 1.8 below: 
 
Table 1.8 Change of ligand binding due to FGFR2 mutation (Yu et al., 2000) 
Mutation Receptor  Ligand  binding  Abnormal Ligand binding 
S252W (Apert)  FGFR2IIIc  FGF1, -2, -4, -5, -6  FGF7, FGF10 
S252W (Apert)  FGFR2IIIb  FGF1, -3, -7, 10, -11  FGF2, FGF6 and FGF9 
 
Fgf10, an activator of FGFR2IIIb was shown be involved in inducing craniosynostosis, because 
genetic abrogation of the ligand rescued craniosynostosis in an Apert syndrome mouse model 
(Hajihosseini et al., 2008). 
 
1.7.2  Constitutive activation of FGFR 
FGF ligands bind to their FGFR, then these complexes dimerise in association with Heparin 
Sulphate proteoglycan (HSPG) (Harmer, 2006). Constitutive activation is usually considered as 
a gain-of-function mutation, where FGF signalling is expected to be over stimulated. There are 
at least three mechanisms for constitutive activation of the FGFR receptor all described in 
Figure 1.14. These include covalent bonding between receptor monomers via cysteine, 
hydrogen bonding between receptors in the transmembrane region and autophosphorylation of a 
monomer via mutation of the tyrosine kinase domain (Webster and Donoghue, 1997). 
 
A study of cysteine residues in FGFR2 has indicated that disruption of a disulphide bond at 
position 278 or 342 by mutations C278F, W290G, T341P and C342A in NIH3T3 leaves free 
cysteines in the IgIII domain that lead to receptor dimerisation and increased activation 
(Robertson et al., 1998). Increased activation was also found in C107A mutants, but not at 
positions 62, 179 and 231. Analysis of FGFR2-C278F in MC3T3 cells has shown that ligand 
independent dimerisation is intracellular and that the dimerisation may also occur if 
glycosylation of wild type FGFR is inhibited (Hatch et al., 2006). Thus it is likely that the 
presence of a free cysteine in the IgIII domain of an FGFR2 monomer may prevent complete 
glycosylation of FGFR2 and that complete glycosylation is necessary to prevent ligand 
independent FGFR2 dimerisation. 
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Figure 1.14 Changes in FGFR from FGFR mutations (Webster and Donoghue, 1997) 
FGF signalling is normally initated by the formation of the FGF-FGFR complex (a) in association with 
Heparin or HSPG. Constitutive activation may occur where receptors are dimerised, for example at the 
extracellular domain (b) or in the transmembrane domain (c). Kinase activation loop mutations (d), where 
one ligand is constitutively active also exist. 
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1.8  The FGFR2-C278F mutation 
The FGFR2-C278F mutation is one of the most common constitutively active FGFR mutation. 
It is thought to dimerise FGFR2 by disulphide bond formation between the extracellular 
domains. The FGFR2-C278F mutation is a nucleotide point mutation at position 883 from 
guanine to thymidine, resulting in an aminoacid change from cysteine to phenylalanine at 
position 278 in exon IIIa of the protein (Passos-Bueno et al., 1998). This breaks the normal 
disulphide bond between cysteine residues in the third Ig domain at position 278 and 342 
(Figure 1.13 black arrow). The free cysteine at position 342 becomes involved in the disulphide 
bond dimerisation of FGFR2, leading to constitutive activation (Robertson et al., 1998).  
 
A few studies have shown changes to osteoblast proliferation and signalling after transfection 
with FGFR2-C278F. In embryonic chick calvarial osteoblasts, proliferation is increased and 
differentiation decreased within 17 days of transfecting with FGFR2-C278F (Ratisoontorn et al., 
2003). One report has shown that in MC3T3-E1(C4) cells, the FGFR2-C278F receptor was not 
expressed on the cell surface, but co-localised with the endoplasmic reticulum (ER) in a peri-
nuclear pattern and was incompletely glycosylated (Hatch et al., 2006). This incomplete 
glycosylation was shown to increase dimerisation, subcellular trafficking, ubiquitination and 
degradation of FGFR2-C278F. Whereas FGFR2-C278F mRNA levels were significant; there 
were low protein levels, suggesting that significant protein degradation may have occured. In 
terms of signalling, there was increased receptor autophosphorylation shown by 
phosphorylation of FGFR2-C278F tyrosine. Furthermore, binding and activation of both 
phospholipase C γ (PLC-γ) and Frs2 to FGFR2-C278F was increased. This also implicated that 
Phospho-inositol-3 Kinase (PI3K) and MAPK pathways were also activated as they are 
downstream of Frs2. Metabolism may have increased as shown by the reduction of MTT 
(thiazolyl blue tetrazolium bromide), which was dependent on both PLC-γ and Frs2 signaling. 
There was also an increased basal level of anaerobic glycolysis, indicating an anaerobic 
metabolism occuring. The downstream signalling of PLC-γ, PI3-K and MAPK relative to the 
controls was not studied, therefore it is unknown whether the signalling is changed in these 
pathways. 
 
In summary, FGFR2-C278F increases embryonic chick osteoblast proliferation and in MC3T3 
cells is suggested to increase the level of downstream signalling via Frs and PL-C gamma, while 
increasing metabolism. Given Frs involvement, it is likely that MAPK and PI3-K signalling 
have been affected (section 1.4.3). 
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1.8.1  FGFR2-WT and FGFR2-C278F transfection of MC3T3 
The Ferretti lab at the Institute of Child Health (London, UK) created a number of stably 
transfected cell lines, each with one specific FGFR gene. Two of these in MC3T3 contained 
either a human wild type FGFR2 (FGFR2-WT) or a human FGFR2 with a point mutation of 
cysteine to 278 phenylalanine (FGFR2-C278F), which is associated with a Crouzon’s or Pfeiffer 
syndrome phenotype as shown in Figure 1.13 (Ornitz and Marie, 2002). Cell lines were initially 
labelled MC3T3, R2WT2 and R2M7, though subsequently were labelled MC3T3, R2-WT and 
R2-C278F for convenience. 
 
1.8.2  Studies by the Ferretti lab on FGFR2-C278F 
It has been shown that pre-migratory neural crest (NC) cells transfected with either FGFR1-
K656F or FGFR2-C278F induced chondrogenesis (Petiot et al., 2002). As FGF2 treatment of 
pre-migratory NC cells also induced chondrogenesis, this indicated that FGFR2-C278F may 
elicit FGF signaling in a way similar to the effects of exogenous FGF2 signaling. Using the 
knowledge that Crouzon syndrome is inherited in an autosomal dominant manner (Shotelersuk 
et al., 2003), it was thought that stable transfection of FGFR2-C278F into MC3T3 cells may be 
able to simulate the effects of a naturally occurring mutation. Initial characterisation of 
differentiation (Santos-Ruiz et al., 2007), proliferation and apoptosis in MC3T3, FGFR2-WT 
and C278F cells were made by the Ferretti lab (unpublished). 
 
Immunocytochemisty analysis revealed that Collagen1 (Col1) was present in most C278F cells 
at 2 days in culture (DIC) compared to MC3T3 and R2-WT cells, where it was confined to a 
few cells within very dense cell clusters. RT-PCR analysis of Runx2 at preconfluence and 
confluence showed that Runx2 expression was higher, when normalised to Glyceraldehyde-3-
Phosphate Dehydrogenase (Gapdh) expression. Proliferation was compared using 
Immunocytochemistry with phosphorylated histone 3 (pH3), which showed that R2-C278F cells 
had the lowest percentage of pH3 staining. Apoptotic studies were performed with Terminal 
deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) and revealed that at 1 
and 2 DIC, R2-C278F cells had a higher percentage of apoptotic cells (2 to 3%) compared to 
MC3T3 (0.5 to 1%). 
 
Together these data suggested that in C278F cells, proliferation had decreased, differentiation 
had increased and apoptosis had increased.   Chapter 1 Introduction 
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1.8.3  Comparison of cell behaviour in osteoblasts with FGFR2-C278F 
and other FGFR gain-of function mutants 
 
A number of groups have tried to model FGFR2 mutations that lead to craniosynostosis. R2-
C278F cell characteristics are similar to some of the human models, showing decreased 
proliferation, increased differentiation and apoptosis (Fragale et al., 1999; Marie et al., 2005). 
Among these was a study by Fragale et al on a human patient. In contrast, a number of mouse 
models studied displayed different characteristics: increased proliferation and decreased 
differentiation in osteoblasts. Details of the FGFR2 mutations concerning position 278 and 342 
and the animal models are shown in the table below. 
 
Table 1.9 Models FGFR2 gene mutations in osteoblasts known to cause craniosynostosis 
  FGFR2 Mutation  Model  In-vitro / in-vivo
Eswarakumar et al,  2006  C342Y  Mouse  In-vivo 
Fragale et al, 1999  C342R  Human patient  In-vitro 
Mansukhani et al, 2000  C342Y  Mouse OB1 cells  In-vitro 
Ratisoontorn et al, 2003  C278F  Chick  In-vitro 
 
 
The diffferences in osteoblast phenotype between mouse, chick and human models demonstrate 
the complexity of FGF signalling even among similar FGFR2 mutations, however the results 
are also informative about any potential effects that mutant receptor may have on osteoblast 
behaviour (Marie et al., 2005; Ratisoontorn et al., 2003). These potential effects fro the receptor 
may have been influences by factors such as the animal used, whether the study was in-vitro or 
in-vivo and the exact experimental conditions (for example the serum for culturing). 
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1.9  Summary and aims 
Craniofacial bone and suture development in humans and mice is finely regulated autonomously 
by the bone tissue and neighbouring structures such as the underlying dura. The key feature of 
all craniosynostoses is suture obliteration between two bone fronts, where there is a continuous 
layer of mineralised bone matrix secreted by differentiated osteoblasts. 
 
As a number of genes have been implicated in human syndromic craniosynostosis, it is sensible 
to focus on one of the most commonly mutated genes, FGFR2 (Passos-Bueno et al., 2008). 
Most of the point mutations occur at position 342 or 278 position (Passos-Bueno et al., 1998), 
but the one at the 278 position (FGFR2-C278F) has been less extensively studied. It is therefore 
of interest to gain further understanding of this mutation and to compare the similarities and 
differences between other “gain-of function” mutations at positions 278 and 342. FGFR2 and 
TGFbetas play a main role in osteoblast proliferation, which is altered by FGFR2-C278F. The 
in-vitro model using MC3T3, R2-WT and R2-C278F cells can be used to investigate the 
behaviour of FGFR2-C278F transfected osteoblasts, which may be difficult to study in-vivo. 
Currently there are several models for FGFR2 “gain of function” craniosynostoses, which differ 
in osteoblast phenotypes, particularly in proliferation for which FGFR2 has a major role. 
 
My hypothesis is that there is a pattern to the relationship between constitutively activated 
FGFR and osteoblast proliferation, differentiation and apoptosis. Furthermore, disturbed FGF 
signalling in MC3T3 cells expressing FGFR2-C278F will affect TGFbeta signalling. 
 
The aims of this thesis are as follows: 
 
1.  Characterise R2-C278F cell behaviour with respect to MC3T3 and the effects of 
FGFR2-WT expression in R2-WT cells and compare the level of proliferation, 
differentiation and apoptosis with reports of other FGFR2 “gain-of-function” 
craniosynostosis models to in order to explain the similarities and differences. 
2.  Determine what are the alterations to FGF signalling in R2-C278F cells and its 
downstream pathways that are involved in proliferation. 
3.  Investigate whether TGFbeta signalling is altered by the FGFR2-C278F mutation and 
also if and where TGFbeta interacts with FGF signalling in R2-C278F cells with respect 
to proliferation and differentiation. 
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Chapter 2  Materials 
Materials were stored at room temperature unless specified otherwise. Most of the reagents were 
obtained from Sigma. Any pH adjustments were made with HCl or NaOH, unless specified. 
PBS mentioned in this chapter is at 1X unless stated otherwise. 
2.1  General Materials and Reagents 
Table 2.1 General Reagent Preparations 
Description Preparation  and  Storage 
Borate Buffer 0.1 M (pH9)  Boric Acid in 800 mL dH2O, adjusted to pH 9.0, filled to 1L and 
autoclaved. 
HCl 2 M  600 ml: Dilute 100 ml of concentrated HCl  (37.25%) into 500 ml 
of dH2O 
Paraformaldehyde (PFA) / Sigma  4%: 40g PFA dissolved in 1 L PBS at 70 °C and aliquoted. Diluted 
in PBS as required. Stored at -20 °C 
Phosphate Buffered Saline (PBS) 
/ Oxoid, Basingstoke, UK 
10x Stock: 100 tablets dissolved in 1 L dH2O, autoclaved. Diluted 
in dH2O to 1x and autoclaved as required. 
Diethylpyrocarbonate (DepC) 
water 
1x: 10 tablets dissolved in 1 L dH2O, incubated at 37 °C overnight 
with the lid loose to allow for effervescene, then autoclaved. 
 
The following reagents used for treating cells were all stored at -20 ºC: 
 
Table 2.2 Reagents for treating cells 
Description  Stock Preparation  Supplier / Product Code 
Phorbol 12-myristate 
13-acetate (PMA/TPA) 
1 mg/ml in DMSO  Sigma / P8139 
SU5402  5 mM in DMSO  Calbiochem / 572630 
rhTGFbeta1 1  µg/ml with 1 mg/ml BSA 
in 4mM HCl  
R&D systems / 240-B-010 
SB431542  10 mM in DMSO  Sigma / S4317 
U0126  10-20 mM in DMSO  Cell Signaling Technology Inc. / 9903 
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2.2 Antibodies 
Primary and secondary antibodies were ready to use on purchase. The dilutions for experiments 
were method specific and provided either in this chapter or methods. Although not stated in the 
Phospho-Histone 3 (pH3) datasheet, I have confirmed that this antibody cross reacts with mouse 
pH3 (Appendix Figure 8.1). Primary antibody details are provided in Table 2.3. Secondary 
antibody details are in Table 2.4. 
 
The α-Tubulin, Opn and Runx2 were stored at 4 ºC, while the rest of the primary antibodies 
were kept at -20 ºC, according to the manufacturers’ instructions. 
 
Table 2.3 Primary Antibodies 





Mouse mAb / Human α-
Tubulin, Aa 149-448 
sc-5286 
BrdU  AbD serotec  Rat mAb Clone BU1/75  OBT0030 
ERK 
p44/42 MAPK 
Cell signaling / 
New England biolabs 




Cell signaling / 
New England biolabs 





Cell signaling / 
New England biolabs 
Rabbit mAb  2118 
Phospho-Histone H3 
(Ser10) 
Upstate cell signaling 
solutions 
Rabbit pAb / Human H3, aa 7-
20 
06-570 
Opn DSHB  Mouse  mAb  MPIIIB10 
Runx2 Santa  Cruz 
Biotechnology, inc 
Rabbit polyclonal / Mouse 
Runx2, aa 294-363 
sc-10758 
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HRP and Biotin conjugated secondary antibodies were stored at 4 ºC (Table 2.4). The Alexa 
fluorochrome conjugated antibodies were kept at 4 ºC and single use aliquots were kept at -20 
°C for longer term storage. 
 
Table 2.4 Secondary Antibodies 
Description Supplier  Dilution  Product  code 
Goat Anti-Mouse Alexa 488  Invitrogen  FACS 1:350  A11001 
Goat Anti-Mouse HRP  Dakocytomation  ICC 1:100 
WB 1:1000 
P0447 
Rabbit Anti-Mouse HRP  Dakocytomation  ICC 1:100 
WB 1:1000 
P0260 
Chicken Anti-Rabbit Alexa 647  Invitrogen  FACS 1:350  A21443 
Goat Anti-Rabbit Alexa 488  Invitrogen  ICC 1:350  A11034 
Goat Anti-Rabbit Biotin  Dakocytomation  ICC 1:100  P0432 
Rabbit Anti-Rat HRP  Dakocytomation  BrdU ELISA 1:100  P0162 
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2.3 Cell  Culturing 
Cell culture medium for maintaining cultures had 10 % v/v of FBS and 1% v/v of 10,000 U/ml 
Streptomycin as described in Table 2.5. Most experiments used 10% of FBS, except a few 
where the percentage was stated (1% or 0%). All culturing materials were prepared under the 
sterile conditions of an Aura B4 (Bio Air Instruments s.r.l.) tissue culture hood. 
 
Table 2.5 Culture reagents 
Description / Supplier & code  Preparation & Storage 
MEM-α Medium 1X / Invitrogen, 32571  None. Stored at 4 °C 
Fetal Bovine Serum (FBS) / Invitrogen  Aliquotted to 2, 20 and 50 mls. Stored at -20 °C 
Streptomycin Penecillin (10,000 U/ml) / 
Invitrogen, 15140122 
Aliquotted into 5 mls. Stored at -20 ºC 
Trypsin EDTA 1x / 
Gibco Invitrogen, 25300054 
Transferred to 5 ml aliquots. Stored at -20 ºC 
Trypan Blue 1x (0.4 %) / Sigma, T8154  Aliquotted into 5 mls. 




Table 2.6 Reagents for FACs 
Description Preparation  &  Storage 
7AAD  Stock 0.1mg/ml: 1 mg powder dissolved in 100 µl DMSO, then 
diluted in 9.1 ml PBS. Stored at -20 ºC 
Permeabilisation solution  0.1 % v/v Triton X-100, 0.1 % v/v Sodium citrate in dH2O. Stored at 
4 °C 
1%  PFA   4% PFA diluted to 1% with PBS at 37 °C. Stored at -20 ºC 
Methanol Fixative  90% Methanol in PBS. Stored at -20 ºC 
Incubation buffer  0.5g BSA in 100ml PBS. Stored at 4 ºC 




PBS See  section  2.1.1 
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2.5 Immunocytochemistry 
 
Table 2.7 Immunocytochemistry reagents 
Description Preparation  &  Storage 
PFA 2%  4% PFA diluted to 2% with PBS at 37 °C 
Hydrogen Peroxide solution (H2O2, 30%) H2O2 diluted to 3 % in dH2O shortly before use 
Sigma FAST  
3,3- Diaminobenzidine (DAB) 
One gold, one silver tablet dissolved in 2 ml dH2O 
Antibody buffer  0.1% BSA, 0.5% Triton X-100 in PBS. Stored at -20 °C 
Hoescht 33258 / Molecular Probes, 
Invitrogen 
Diluted to 1.2 mg/ml in dH2O. Stored at -20 °C 
Butanol / Fisher  None 
Histoclear / National Diagnosis  None 
Citifluor / Citifluor Ltd.  None 
  
2.6 Methylene  Blue 
 
Table 2.8 Methylene Blue reagents 
Description Preparation  /  Storage 
1% PFA Saline (0.15M)  8.77 g Sodium Chloride and 10g paraformaldehyde dissolved in 1 L dH2O. 
B o r a t e  B u f f e r  0 . 0 1  M  
(pH8.5) 
Dilute 100 ml of 0.1M Borate buffer (see section 2.1.1) with 900 ml dH2O 
1:10 readjust pH to 8.5. 
Methylene Blue solution  10g of Methylene blue powder (Gurr®) diluted in 0.01 M Borate Buffer 
(pH8.5) to 1% w/v. 
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2.7  Protein extraction, gel electrophoresis and western blotting 
 
Table 2.9 Reagents for protein extraction, gel electrophoresis and western blotting 
Description Preparation  /  Storage 
Lysis (RIPA) Buffer  5 % of 3 M NaCl, 1 % Nonidet P-40, 1 % of 10 % SDS, 5 % of 1 M Tris pH 
8.0 in dH2O. Stored at 4 °C 
Proteinase inhibitor / 
Complete, Roche 
25x Stock: 1 tablet dissolved in 1 ml dH2O. Stored at -20 °C 
Sodium Orthovanadate 
(Na3VO4) / Sigma 
100 ml of 200 mM Stock: 18.39 g of Na3VO4 in 80 ml dH2O. The pH was 
adjusted to 10.0 with NaOH, boiled until colourless and cooled to room 
temperature. The pH adjustment, boiling and cooling were repeated until the 
solution remained colourless at room temperature. Stored at -20 °C 
Loading Buffer  10 % 1 M Tris pH 6.8, 20 % Glycerol, 1 % 2-mercaptoethanol, 10 % SDS 
and a few crystals of Bromophenol blue in dH2O. Stored at 4 °C 
Running Buffer  10x Stock: 30 g/L Tris base, 144 g/L glycine and 10 g/L SDS in 1L dH2O. 
Diluted 1:10 before use. 
Transfer Buffer  0.5x Running buffer and 20 % methanol 
Tris Buffered Saline 
(TBS) 
10x Stock: 80 g NaCl, 2 g KCl and 30 g Trizma base dissolved in 800 mls 
dH2O. The pH adjusted to 8.0 with concentrated HCl and filled to 1 L. 
0.1% TBST  TBS with 0.1% Tween 20 
Blocking Buffer  5 % milk protein in PBS with 0.1% Tween 
 
2.8  RNA extraction, Reverse Transcription and PCR 
RNA extraction and reverse transcription were carried out in two steps, allowing analysis of 
multiple genes from a single source of RNA. 
 
Table 2.10 RNA extraction reagents 
Description Preparation  &  Storage 
TRI
®-Reagent (Sigma)  None. Stored at 4 °C 
Chloroform (Sigma)  None. Stored at 4 °C 
2-propanol (Sigma)  None. 
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Table 2.11 Reverse Transcription 
Description / Supplier  Preparation & Storage 
pN6 (Hexamer) 10pM / Roche  Diluted to 10pM in DepC water. Stored at -20 °C 
10 mM dNTPs / Promega  2.5 µl of 100mM of each dNTP (ATP, GTP,TTP and UTP) in 
90  µl of DepC water. Stored at -20 °C 
RNAsin / Promega, N211B  None. Stored at -20 °C 
MMLV / Promega , M170B  None. Stored at -20 °C 
5x RT Buffer / Promega, M531A  None. Stored at -20 °C 
 
2.8.1  PCR and Real time PCR reagents 
Two types of taq polymerases were used in the course of this thesis, due to introduction of the 
GoTaq® range from Promega and the company’s termination of sale of the old polymerase 
(Table 2.12). 
 
Table 2.12 PCR reagents 
Description / Supplier  Preparation & Storage 
10x Mg free Buffer / Promega  None. Stored at -20 °C 
25 mM MgCl2 / Promega  None. Stored at -20 °C 
Taq Polymerase / Promega  None. Stored at -20 °C 
5x GoTaq®Flexi Buffer / Promega, M891A  None. Stored at -20 °C 
5x GoTaq®DNA Polymerase / Promega, M830B  None. Stored at -20 °C 
 
 
Two methods were used for real time PCR, either with Taqman Gene Expession Assays and a 
TaqMan Master Mix or PCR primers with a SYBR green master mix (Table 2.13). 
 
Table 2.13 Real time PCR reagents 
Reagent / Supplier  Storage 
TaqMan® Fast Universal Master Mix (2X) with No AmpErase® UNG / 
Applied Biosystems 
-20 °C 
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2.8.2 PCR  and  Real  time PCR Primers 
 





Sequences (forward, reverse) 
(5’-3’) 
Product (bp) 





X00686  GTC TGT GAT GCC CTT AGA TG 




M32599  TTC CAG TAT GAC TCC ACT CAC G 
GGA TGC AGG GAT GAT GTT CT 




NM_010197  ACC GAG AGG TTC AAC CTG CC 
GCC ATA GTG AGT CCG AGG ACC 
387 / 35  55 
FGF2 
F=20, R=24 
NM_008006  GCC AGC GGC ATC ACC TCG CT 
TAT GGC CTT CTG TCC AGG TCC CGT 





AAG ACA TTC AAG TCC TGG G 
AGC CCA CAT ACC AAC CAG AG 
244 / 35  60 
FGFR2IIIc 
F=24, R=24 
M86441  CCC ATC CTC CAA GCT GGA CTG CCT 
CAG AAC TGT CAA CCA TGC AGA GTG 




Z71929  ATG GTG CGG AAG ATT TTG TC 
TAG AAT TAC CCG CCA AGC AC 
630 / 35  62 
Osteocalcin 
F=20, R=20 
NM_031368  TGA GGA CCC TCT CTC TGC TC 
GCG TCT GTA GGC GGT CTT TA 
266 60 
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2.8.3  Taqman Real time PCR gene Expression Assays 
Gene expression assays were purchased from Applied Biosystems (Table 2.15). 
 
Table 2.15 Gene Expression Assays 
Gene Expression Assay  Part no / ID 
Eukaryotic 18S rRNA   Part no: 4352930E 
Fgf1  Mm00438906_m1 
Fgf2  Mm00433287_m1 
Fgf18  Mm00433286_m1 
GAPDH  Part no: 4352932E 
TGFbeta1  Mm00441724_m1 
TGFbeta2  Mm004366952_m1 
TGFbeta3  Mm00436960_m1 
Runx2  Mm01269515_mH 
Spp (Osteopontin)  Mm01611440_mH 
Twist1  Mm00442036_m1 
Akt1  Mm00437443_m1 
Smad1  Mm00484721_m1 
Smad2  Mm00487530_m1 
Dlx5  Mm00438430_m1 
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2.9 Agarose  Gel  Electrophoresis 
 
Table 2.16 Agarose Gel Electrophoresis 
Description Preparation  &  Storage 
Gensieve LE agarose / 
Flowgen 
None 
0.0025 % Ethidium 
Bromide (EB) 
None 
0.5 M EDTA (pH8)  Stir 58.44g of EDTA powder into 300ml dH2O. Raise the pH with NaOH until 
pH 8. Add dH2O to 400ml. 
TAE buffer  Mix 242g of Tris base powder into 100ml of 0.5M EDTA (pH8) and 57.1ml 
glacial acetic acid under a fume hood. Add water to 800ml level and stir until 
all the powder is dissolved. Fill to 1 L with dH2O. 
5x Orange G  Mix DepC water, 0.5 g/ml sucrose, 2.5 mg/ml Orange G and 0.25 mg/ ml 
Sodium azide. Stored at -20 °C 
1kb DNA ladder 
Hyperladder IV / Bioline 
None. Stored at 4 °C or -20 °C for long term storage 
Formamide (BDH)  None. Store in a cabinet   Chapter 3 Methods 
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Chapter 3  Methods 
Details such as blocking and washing solutions are tabulised in the Materials chapter. 
3.1  Cell Culture and harvesting 
The cell lines MC3T3, R2WT2 and R2-C278F were grown and maintained in T75 culture flasks 
(TPP) with 10 to 12 ml of culture medium containing Minimum Essential Medium Alpha 
(MEM-α) medium with Glutamax (Gibco, Invitrogen), 10% fetal bovine serum (FBS) and 1% 
of penicillin and streptomycin (100 U/ml). Cultures were seeded at a density of 20,000 cells per 
cm
2 and were maintained by replating every three days. Cells were observed for cuboidal 
morphology at confluence and were not used for analysis beyond 65 passages, because at this 
stage MC3T3-E1 has been reported to behave like aged osteoblasts, which have an altered 
response to TGFbeta1 (Chung et al., 1999). 
 
Replating was performed as follows: Cultures in T75 flasks were washed prior to trypsinisation 
by replacing the culture medium with 8 ml PBS and then removing the PBS. Cells were 
trypsinized with 1 ml trypsin-EDTA (Invitrogen) for 5 minutes, then neutralised by 
resuspending with 5 ml of culture medium. This was transferred into falcon tubes and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, leaving the cell pellet 
which could be used for experiments. The cell pellet was resuspended in 5 ml culture medium 
before counting or directly seeding new cultures. When counting, 1.5 million cells from each of 
the cell lines were transferred into new T75 flasks containing 10 ml of culture medium. 
Otherwise, this was approximated to 1/12, 1/10 and 1/5 of MC3T3, FGFR2-WT and C278F cell 
suspensions respectively. For experimental cultures, the volumes of PBS, Trypsin-EDTA and 
culture medium were adjusted according to the size of culture plate or flask. 
 
Counting was performed at three days in culture, using a dilution factor of 10 (50 µl of cell 
suspension into 200 µl Trypan Blue and 250 µl PBS) and counting on a haemocytometer 
(Bright Line®, Reichert) and averaging the totals counted from the 8 large corner squares. 
Where numbers were too high (above 50 per large square), the dilution factor was increased to 
20. The cell number calculation was as follows: 
 
ml cells Factor Dilution
counted Cells
ml per Cells / 10 1
8
4 × × × =  
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Unless stated otherwise, cells for all experiments in this thesis were seeded at 20,000 per cm
2 
for which the approximate numbers are given in Table 3.1. 
 
Table 3.1 Number of cells to seed at 20,000 cells per cm
2 
Plate  Diameter (cm)  Surface Area (cm
2)  Number of cells 
T75 N/A  75  1.5  million 
T25 N/A  25  0.5  million 
6 well  3.4  9  182,000 
12 well  2.1  3.5  70,000 
24 well  1.5  1.8  35,000 
96 well  0.8  0.5  10,000 
 
3.1.1 Experimental  cultures  and medium compositions 
Cells were seeded in the cell culture medium defined at the beginning of Section 3.1 for three 
hours before replacing with the experimental culture medium. Unless otherwise stated, the 
experimental culture mediums contained Minimum Essential Medium Alpha (MEM-α) medium 
with Glutamax (Gibco, Invitrogen), 10% fetal bovine serum (FBS) and 1% of penicillin and 
streptomycin (100 U/ml). In experiments where 0% or 1% serum used, the remaining volume of 
FBS was replaced with MEM-α medium with Glutamax. 
 
In TGFbeta1 treatment experiments, the control mediums contained 1 mg/ml BSA in 4mM HCl. 
The control mediums for PMA, SU5402, and U0126 treatment contained DMSO. The DMSO 
concentration in both control and experimental mediums never exceeded 0.2% v/v, as this was 
reported to induce differentiation and PKC signalling in MC3T3-E1 cells (Cheung et al., 2006). 
 
3.1.2  RT-PCR and Real time PCR 
Cells were seeded into T25 flasks. For harvesting, cells were washed in 4 ml PBS, trypsinized 
with 500 µl Trypsin-EDTA for 5 minutes at 37 ºC and neutralised in 4.5 ml of culture medium. 
Samples were centrifuged for 5 minutes at 1000 rpm and the supernatant aspirated before 
placing the pellet on ice and stored at -80 °C. Pellets were then used for RNA extraction. 
 
3.1.3  FACS (Live cell analysis) 
Cultures were seeded on a 12 well plate. For harvesting, the cultures were washed in 1 ml PBS, 
trypsinized in 100 µl of trypsin-EDTA for 5 minutes at 37 ºC and neutralised with 2 ml culture   Chapter 3 Methods 
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medium. Samples were transferred to 5 ml FACS tubes and centrifuged (5 minutes at 1000rpm). 
The supernatant aspirated and the tubes placed on ice for analysis. 
 
Samples intended for cell cycle analysis were resuspended in permeabilizing solution (300 µl) 
and kept on ice for up to 2 hours before analysis. Samples for cell counting and apoptotic 
studies were resuspended in PBS (300 µl) and kept on ice. Just before FACS analysis a 20 µl 
aliquot of 7 aminoactomycin D (7AAD) was added to all samples. 
 
3.1.4  FACS (Fixed cells) 
Cells were cultured on a 12 well plate in 2 mls of medium. Cells were trypsinised, neutralised, 
transferred to 5 ml falcon tubes and centrifuged at 1000 rpm for 5 minutes. The pellet was 
loosened by tapping before resuspending in 500 µl of 1% PFA in PBS to avoid clumping. 
Fixation was for 10 minutes at 37 ºC. The fixed samples were cooled on ice for 1 minute and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated and the pellet resuspended 
and permeabilised in 90% methanol in PBS for 30 minutes on ice. Samples were stored for up 
to 7 days at -20 ºC before FACs immunostaining. 
 
3.1.5 Immunocytochemistry 
A 24 well plate was used to grow cells on sterilised 13 mm diameter coverslips. To prepare 
samples, the coverslips were washed with PBS and then fixed with 2% PFA in PBS at room 
temperature for 30 minutes or 4 °C overnight. 
 
3.1.6  Methylene blue cultures 
Cells were suspended in 200 µl of cell culture medium and seeded onto 96 well plates. Care was 
taken not to swirl the plates to avoid collecting cells at the centre of the wells. The medium 
replaced with 100 µl of the experimental medium. The experimental medium was replaced 
every 24 hours for 1, 2 or 3 days. In the experiments using TGFbeta1 or PMA with inhibitors 
such as SU5402 or U0126, the normal culture medium was replaced with 50 µl cell culture 
medium with inhibitor for 30 minutes, prior to adding 50 µl of cell culture medium with 
inhibitor and a 2x concentration of the TGFbeta or PMA. 
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3.1.7  Western blot cultures 
Cells were seeded in a T25s and cultured for 2 or 4 days before harvesting. See section 3.10.1 
for details for protein extraction. 
 
3.1.8 Freezing 
A medium for freezing cells composed of 8% DMSO, 20% FBS and MEM-Alpha medium was 
made and placed on ice, along with labelled cryotubes. After counting (see section 3.1 Cell 
Culture and harvesting), 6 million cells were transferred to falcon tubes tubes to be centrifuged 
(1000 rpm for 5 minutes). Supernatants were removed and each pellet resuspended with 3 ml of 
the medium for freezing and 1 ml aliquots were transferred to cryovials which were placed on 
dry ice. The cryovials (containing around 2 million cells) were frozen at -80 ºC overnight and 
placed in liquid nitrogen for long term storage. 
 
3.1.9 Thawing 
Cells were warmed rapidly in a 37 °C incubator and diluted in 10 ml of ice chilled fresh culture 
medium (MEM-Alpha medium, 10 % FBS and 1 % of penicillin and streptomycin) to slow the 
cell metabolism. The cells were then centrifuged at 1000 rpm for 5 minutes and the DMSO 
containing supernatant was removed by aspiration. The pellet was resuspended in 10 ml of fresh 
culture medium and plated to a T25 until 70% confluent, when they were transferred to a T75. 
 
3.2  Cell imaging and categorisation 
Cells were viewed in phase with an inverted light microscope (Axiovert 135M, Zeiss). A 
computerised system (Orbit, Improvision) was used to focus on the cells. Photographs at 5, 
10, 20 and 40x magnification were taken with either a Hamamatsu digital camera (C4742-95, 
Hamamatsu) controlled by the Openlab software (Improvision) or a Hamamatsu ORCA-ER 
camera and with the Volocity software (Improvision). These were exported as tiff files for 
publication and imported into Macromedia Fireworks MX in a 1024 x 768 pixel canvas for 
resizing, cropping and adjusting for brightness and contrast. Images were selected (where 
possible) such that cell population densities were similar between the cell lines to compare 
morphologies. 
 
For the cell categorisation experiment, a main grid of 250 x 250 pixel squares was overlayed 
onto the images with a smaller grid of 50 x 50 pixels. The same method for counting on a   Chapter 3 Methods 
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Haemocytometer was used in order to count and categorise cells more accurately and to avoid 
double counting of cells. 
 
3.3 FACS 
7-Aminoactinomycin D (7AAD, Sigma) intercalates double stranded DNA between cysteine 
and guanine bases. Unlike Propidium Iodide (PI), the absorbance / emission range allows 
detection of other fluorochromes, giving the flexibility of adding other fluorescent markers for 
simultaneous measurements. 
3.3.1  Cell counting and apoptosis 
The cell pellet preparations in the 5 ml falcon tubes were knocked, in order to resuspend the 
cells and placed on ice. Prior to FACS analysis, 25 µl of fluorospheres (1000 beads per µl, 
Flow-check™, Beckman Coulter) were added to the samples. To assess cell viability, 20 µl 
7AAD was added to each of the samples. 
 
Samples were well mixed then analysed using a Beckman Coulter Epics XL Flow cytometer. A 
488 nm laser was used to excite the 7AAD and the emission was detected at 675 nm with a band 
pass filter. Approximately 30,000 events were collected and 7AAD was used to label apoptotic 





sample in cells Total × =  
 
3.3.2 Cell  cycle 
The cell pellet was resuspended in permeabilizing solution (300 µl sodium citrate (0.1%) and 
Triton X-100 (0.1%) in dH2O) and kept on ice for up to 2 hours before analysis. The DNA was 
intercalated with 20 µl of 7AAD and the tubes tapped lightly just prior to flow cytometry 
analysis (Epics XL, Beckman Coulter). Absorption of the 488 nm argon laser by 7AAD, 
resulted in emission in FL3 (peaked at 647 nm), which was detected at 675 nm with a band pass 
filter and the data recorded, using the EXPO32 software (Beckman Coulter). 
 
The magnitude of a peak reading for individual cells and clumps of cells may be similar and 
could be hard to distinguish (Figure 3.1 A). Therefore a plot of peak vs area (FL3 fluorescence) 
was made in order to visualise regions of cell fragments, single cells and clumps of two or more 
cells (Figure 3.1 B). From G0 to M phase, the DNA becomes progressively more condensed as   Chapter 3 Methods 
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shown by an increasing Peak value. The area also increases as more DNA is present, covering a 
larger area. A two cell clump would give relatively similar peak values, as the DNA is as 
condensed as other single cells, however a broad area would be detected. Doublet 
discrimination was performed by selecting the region of single cells (gating). 
 
The selected region was plotted as a frequency vs area (Figure 3.1 C). The resulting curve was 
comprised of G0/G1, S and G2/M phase curves, which were mathematically analysed using 
MultiCycle for Windows (Phoenix flow systems, San Diego). The S phase was determined 
using the Dean and Jett method (Dean and Jett, 1974). This data was expressed as a graph that 
could be expressed as three smaller histograms (Figure 3.1 D). 
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3.3.3 FACS  immunocytochemistry 
Methanol fixed samples were washed by adding 2 ml of incubation buffer (0.5% BSA in PBS) 
and centrifuging for 5 minutes at 1000 rpm before removing the supernatant by flicking out into 
a sink. The same wash step was repeated, except that on the second wash, vacuum pipetting was 
used in order to keep sample volumes similar for antibody incubations. The pellet was 
resuspended in 100 µl of incubation buffer for 10 minutes for blocking. 50 µl of primary 
antibody was added to the samples, then mixed and allowed to incubate for 1-2 hours. Samples 
were washed twice described previously. 50 µl of secondary antibody was added and incubated 
for 30 minutes. A final two washes were performed as described and then resuspended in 500 µl 
of PBS before analysis on the CyAn Flowcytometer (Dako). 
 
3.3.4  Antibodies and conditions 
Primary antibodies were added as 50 µl to the 100 µl of blocking solution; therefore the 
dilutions given below do not reflect the final antibody concentration in Table 3.2: 
 
Table 3.2 Antibodies and conditions for FACS immunocytochemistry 
1ry Ab  1ry Dilution  Origin  2ry Ab  2ry Dilution 
Opn  1:10  Mouse  Goat Anti-Mouse Alexa 488  1:350 
PCNA  1:100  Mouse  Goat Anti-Mouse Alexa 488  1:350 
H3  1:100  Rabbit  Chicken Anti-Rabbit Alexa 647  1:350 
Runx2  1:10  Rabbit  Chicken Anti-Rabbit Alexa 647  1:350 
 
Higher concentrations of primary and secondary antibodies were often higher than in standard 
immunocytochemistry, partly to compensate for the diluting effects of residual solution in 
FACS tubes after washing. 
 
3.3.5  Analysis of pH3 immunostaining 
To analyse cells for pH3 staining, viable cells were first gated, to exclude cell fragments and 
other debris (Figure 3.2 A). The pH3 was stained with anti-pH3 antibody and an alexa 647 
conjugated secondary. Cells were plotted on FITC and alexa 647 wavelengths confirm a low 
level of the background stain in the negative control samples (Figure 3.2 B). The pH3 positive 
stains were also visualised on this plot to observe the quality of the stain, a good staining 
showing a space between the cells of high and low intensity staining (Figure 3.2 D). This was   Chapter 3 Methods 
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then visualised along an Alexa 647 vs frequency axis and a gate (R29) was placed on this axis 
to exclude low background stains, to be used for the positive staining (Figure 3.2 E). This gate 
was adjusted to the negative control with the highest background. Any percentage of artefacts 
within the gate from the negative samples was subtracted from the positive samples for each cell 
line. A good pH3 stain would display two groups of cell populations (one above the other) along 
the alexa 647 axis with a space between them. Finally the percentage of pH3 positive cells were 
measured by taking the gated pH3 positive as a percentage of the total cells analysed. 
 
 
Figure 3.2 Gating cells for FACS analysis and for positive pH3 FACS stains 
A 
B  C
D  E 
Side scatter 
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3.4 Immunocytochemistry 
3.4.1  Enzymatic and Chromatographic stainings 
Fixative was removed from the samples with three 10 minute PBS washes. Endogenous 
peroxidases were quenched with hydrogen peroxide (H2O2) solution (see section 3.5.2) for 20 
minutes. After washing twice with PBS for 5 minutes, samples were blocked for 1 hour in 50 µl 
of either 5 or 10% Goat serum in PBS. The block was replaced with primary antibody in a 
humidified chamber overnight at 4 ºC. Following three 10 minute PBS washes, secondary HRP 
antibodies were incubated with the samples for 1 hour at room temperature, before another three 
10 minute PBS washes. DAB was prepared and incubated with the samples, which were 
observed under light microscope until the brown product colour appeared whereby dH2O was 
added to quench the reaction. Two 5 minute butanol washes and then two 5 minute histoclear 
washes were performed to dehydrate samples, before mounting on slides with a drop of DPX 
per coverslip to preserve the sample. 
 
Where staining was weak, the secondary antibody used was biotin conjugated instead of an 
HRP conjugated antibody. ABC complex was made (A:B:PBS as 1:1:100 respectively). 
Samples were incubated with ABC in the dark for 30 minutes. ABC was removed with three 10 
minute PBS washes before the DAB incubation. 
 
3.4.2  Summary of Antibodies and conditions 
Conditions for antibody use are given in Table 3.3: 
 
Table 3.3 Antibodies and conditions for Immunocytochemistry (enzymatic) 
1ry Ab  Block  Dilution  H2O2 solution 
ERK  5 % Goat serum in PBS  1:100 in block  3% H2O2 in dH2O 
Gapdh  5 % Goat serum in PBS  1:800 in block  3% H2O2 in dH2O 
H3  10 % Goat serum in antibody buffer  1:300 in antibody buffer  3% H2O2 in dH2O 
Opn  10 % Goat serum in antibody buffer  1:500 in antibody buffer  6%  H2O2 & 10% 
Methanol in PBS 
Runx2  10 % Goat serum in antibody buffer  1:300 in antibody buffer  6%  H2O2 & 10% 
Methanol in PBS 
 
Goat anti-rabbit HRP secondary antibodies were used (1:300) on primary antibodies with rabbit 
origin. For primaries sourced from mouse, rabbit anti-mouse HRP antibodies (1:300) were used.   Chapter 3 Methods 
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3.4.3 Immunofluorescent  stainings 
Fixative was removed with three 10 minute PBS washes and samples were blocked for 1 hour in 
50 µl of 10% Goat serum in PBS. The block was replaced with primary antibody in a 
humidified chamber overnight at 4 ºC, followed by three 10 minute PBS washes. Hoescht dye 
and flurochrome conjugated secondary antibodies were incubated with the samples for 1 hour in 
the dark at room temperature, before another three 10 minute PBS washes in the dark. The 
coverslips were mounted onto slides with a drop of Citifluor
TM per coverslip. The edges were 
dried off with a clean tissue, sealed with nail varnish and and kept in the dark at 4 °C.  
 
3.4.4  Summary of Antibodies and conditions 
Antibodies were diluted into antibody buffer (see section 2.6 Immunocytochemistry) and used 
as in Table 3.4: 
 
Table 3.4 Antibodies and conditions for Immunofluorescent staining 
1ry Ab  1ry Dilution  Origin  2ry Ab  2ry Dilution 
Gapdh  1:800  Mouse  Goat Anti-Mouse Alexa 488  1:350 
Opn  1:500  Mouse  Goat Anti-Mouse Alexa 488  1:350 
PCNA  1:100  Mouse  Goat Anti-Mouse Alexa 488  1:350 
ERK  1:100  Rabbit  Goat Anti Rabbit Alexa 488  1:350 
H3  1:300  Rabbit  Goat Anti Rabbit Alexa 488  1:100 
Runx2  1:300  Rabbit  Goat Anti Rabbit Alexa 488  1:350 
 
3.5  Methylene Blue Assay 
The methylene blue assay protocol was adapted from that described in Oliver (1989). After 
culturing in 96 well plates, cell mediums were drained using a multichannel pipette and each 
well fixed with 100 µl of 4% PFA in 0.15 M saline for 30 minutes. Fixative was removed by a 
pronating flick of the wrist into a sink and the surface of the plate inverted and patted dry with 
at towel. 100 µl of methylene blue solution was added to each of the previously fixed wells for 
30 minutes. The dye was removed by a pronating flick of the wrist as described before. The 
plate was placed upside down on a paper towel to remove the methylene blue. Excess methylene 
blue in each well was washed with 200 µl of 0.01 M borate buffer, by filling from left to right 
with a multichannel pipette, before flicking into the sink as described previously. The second 
wash was performed by filling from right to left, to ensure that the washing time per well was   Chapter 3 Methods 
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the same on average. The first and second washes were repeated. The plate was then immersed 
in a tank of 0.01 M borate buffer and contents flicked out as before. The methylene blue that 
had stained the cells was extracted by adding a 100 µl mixture of 50% Ethanol and 50% 0.1 M 
HCl to each well. 
 
Wells were shaken gently and absorbance at 650 nm (A650) measured in each well with a 
microplate reader (Revelation v4.21, Dynex Technologies, inc) and the backround from empty 
wells subtracted. Samples were left for 1 to 2 hours at room temperature or overnight at 4 °C 
before measurement to allow most of the dye to exit the cells. 
 
3.6  RNA extraction and Reverse transcription 
The RNA extraction and reverse transcription protocols were the same for both RT-PCR and 
Real time PCR analysis. All reagents used were RNAse and DNase free. 
 
3.6.1 RNA  extraction 
RNA extraction was based on the Sigma TRI-reagent protocol. Sample pellets from culturing 
were resuspended in 1 ml TRI
®-Reagent, transferred to 1.5 ml tubes and pipetted until the pellet 
was no longer visible. The samples were left at room temperature for 5 minutes before adding 
200 µl of chloroform and shaken for 15 seconds and left to stand for 15 minutes. A centrifuge 
was pre-cooled and the samples spun at 12000 rpm for 15 minutes at 4 °C. Three phases were 
formed from top to bottom; a clear phase, a white solid phase and a pink phase. The clear phase 
was transferred to new 1.5 ml tubes with complete avoidance of the visible solid phase 
(containing gDNA). 0.5 ml of isopropanol was added and the solution was mixed and left for 5 
minutes at room temperature. The samples were then centrifuged at 12000 rpm for 10 minutes 
at 4 °C and the supernatant was removed. A solution of 75% ethanol in DepC water was added 
to the remaining pellet. This was centrifuged at 7500 rpm for 5 minutes at 4 °C. The supernatant 
was removed by pipetting, leaving the RNA pellet to partially dry within 2 minutes. The RNA 
pellet was resuspended in 40 – 50 µl of DepC water. A 1.5 µl aliquot of RNA was assessed for 
concentration and ratio (260/280), using the Nanodrop (ND-1000) and the ND-1000 software 
(v3.1.0). Ratios of 1.8-2.0 were used for qPCR. Agarose gel electrophoresis of the RNA was 
used to check the quality of the sample when suspect (ratios of 1.7 to 1.8).   Chapter 3 Methods 
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3.6.2  Reverse Transcription (RT) 
The RNA was diluted to 1 ng/µl in a 10 µl volume containing 2 µl of the random hexamer pN6 
(10 pM) and DepC water. This was vortexed and heated to 70 °C for 10 minutes in a PTC-100 
thermal cycler (MJ research inc.), before cooling for 5 minutes. The annealed RNA solution was 
mixed with 4 µl of RT buffer, 2 µl of 10 mM dNTPs, 1 µl RNAsin, 1 µl MMLV (reverse 
transcriptase) and DepC water. The final solution was heated in a thermal cycler (PTC-100) to 
42 °C for 1 hour for reverse transcription and 95 °C for 10 minutes for denaturing the MMLV. 
Summaries of the components are given in Table 3.5 and Table 3.6. 
 
Table 3.5 Components for annealing 
Component Volume 
RNA  (1 ng / µl) 
pN6 (Hexamer) 10pM  2 




Table 3.6 Components for reverse transcription 
Component Volume  (µl) 
Annealed solution  10 
RT Buffer  4 
10 mM dNTPs  2 
DEPC water  2 
RNAsin 1 




PCR was performed in 25 µl volumes. PCR master mix was made in order to reduce variability 
of the PCR reactions and stored at -20 °C. The full PCR solution was made in Table 3.7 or 
Table 3.8. Gapdh PCRs were run as a control gene expression against which the target genes 
were normalised. Control samples of E13.5 mouse head were used for positive and negative 
controls for the primers. 
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Table 3.7 PCR Master mix 
  PCR Master mix  Full solution 
Component  Volume (µl)  Volume (µl) 
DepC water  14.9  14.9 
10x mg free Buffer  2.5  2.5 
10 mM dNTPs  2  2 
25 mM mgCl2 1.5  1.5 
cDNA   2 
10 µM Primer (Forward)    1 
10 µM Primer (Reverse)    1 
Taq Polymerase    0.1 
Total Volume  20.9 25 
 
 
Table 3.8 PCR Master mix with Gotaq® reagents 
  PCR Master mix  Full solution 
Component  Volume (µl)  Volume (µl) 
DepC water  12.4  12.4 
5x GoTaq®Flexi Buffer  5  2.5 
10 mM dNTPs  2  2 
25 mM mgCl2 1.5  1.5 
cDNA   2 
10 µM Primer (Forward)    1 
10 µM Primer (Reverse)    1 
GoTaq®DNA Polymerase    0.1 
Total Volume  20.9 25 
 
The PCR was performed on a PTC-100 (MJ Research Inc.) with the following command list: 
 
1.  95 °C  for 3 minutes 
2.  95 °C  for 30 seconds 
3.  (Annealing temperature) for 30 seconds 
4.  72 °C  for 1 minute 
5.  Goto step 2 for the maximum number of cycles required (see Table 2.14) 
6.  4 °C  for 10 minutes 
7.  END 
 
The PCR products were then either kept at -20 °C or run on agarose gel.   Chapter 3 Methods 
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3.8 Agarose  Gel  electrophoresis 
RNA and PCR products were visualised using agarose gel electrophoresis. Gels were made on a 
basis of of 1.5 % agarose and 0.1 µl/ml of 0.0025 % ethidium bromide (EB) in TAE buffer 
depending on the volume requirements (see Table 3.9). The gel tray and combs were arranged 
and levelled with a circular spirit level. Agarose powder was weighed and transferred to a 
conical flask. TAE buffer was added to complete the gel volume. The solution was heated in a 
900W microwave until all the powder had dissolved and then cooled to a hand hot temperature 
(~60 ºC). Ethidium bromide was added at a ratio of 1:10,000 and mixed into the solution before 
pouring into the gel tray for DNA intercalation. The gel was set for at least 30 minutes, then 
lowered into an electrophoresis tank (Horizon
®, Life technology) and completely submerged 
with TAE buffer. 6 µl of 5x Orange G loading buffer was added and mixed into each 25 µl PCR 
product. 10 µl was loaded into each sample well and 5 µl of 1kb DNA ladder was loaded to 
reference the product size. The gel was run at 100 mV at 80-100 mA for at least 45 minutes to 
give separation of the bands of the ladder. 
 
Table 3.9 Gel electrophoresis details 
Gel Vol. 
(ml) 






Gel run time 
50  0.75  2  5  58  45 min + 
100 1.5  3  10  11.14  1  hr  + 
250  3.75  5  25  20.25  1 hr 30 min + 
 
3.8.1 Densitometry 
Gels were then imaged using UV light with a camera capture system (Uvidoc system, Uvitec). 
Image files were saved and analysed by densitometry using Labimage (v2.7.1, Kapelan). Bands 
were cropped and measured for area. The data for the genes of interest were normalised with the 
endogenous control (Gapdh) for each sample. At least 3 PCR runs were performed for the same 
samples to account for variability in the technique.   Chapter 3 Methods 
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3.8.2 RNA  gel 
The gels were prepared as describe previously. 8 µl formamide (BDH), 1 µl of RNA and 2 µl of 
5x Orange G loading buffer were mixed in a fume hood (due to the toxicity of formamide). 
Hyperladder VI was used for relative size monitoring. The gel was run for 1 hour at 100 V, 80 
mA. Two bands of 28S and 18S rRNA for an intact RNA would be present, or a smear below 
the 18S rRNA if there was significant degradation of the RNA (Figure 3.3). A complete loss of 




Figure 3.3 RNA gel run showing 28S and 18S bands 
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3.9  Real time PCR 
Most of the real time PCR analysis in this thesis was carried out using Taqman
® Gene 
Expression assays, unless stated that SYBR green was used. The Taqman
® Gene Expression 
assays consist of forward and reverse primers with a FAM
TM dye-labelled Taqman
® MGB probe 
conjugated to a quencher molecule to bind both forward and reverse sequences. During 
transcription, the 5’ nuclease activity of Taq DNA polymerase acts on the probe, releasing the 
FAM
TM-labeled MGB from its quencher molecule (Figure 3.4). This results in fluorescence 
proportional to the number of probes cleaved by the polymerase. The cDNA for PCR was 
prepared as described in section 3.7. Gene expression was relatively quantified using the CT 




Figure 3.4 Taqman Real time PCR: the probe binding system 
A: The Taqman probe is a primer with a fluorescent reporter dye (R), near a quencher fluorophore (Q), 
which reduces the fluorescence of the dye. B: The primer part of the probe binds to the cDNA. C: As the 
Taq polymerase synthesises the complemetary strand, the exonuclease activity on the probe releases the 
reporter dye from the proximity of the quencher, whereby it (R) becomes strongly fluorescent and is then 
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A titration test was performed on the following genes (ordered from left to right); 18S rRNA, 
Tgfbeta1, Tgfbeta2, Tgfbeta3, Runt related transcription factor 2 (Runx2), Osteopontin (Opn), 
Twist1, Akt1, Smad1, Smad2 as detailed in the Materials Chapter (see Section 2.8.3). The cDNA 
from mouse head was diluted 2 fold, 4 fold, 8 fold and 16 fold. The 4 fold dilution was found to 
be optimal for analysis. Mouse head cDNA was diluted with DepC water to 1/8 of the original 
concentration and used as a calibrator sample. TaqMan® Fast Universal Master Mix (2X) with 
No AmpErase® UNG was used. All necessary components were added to the wells (Table 3.10) 
and cycled for 40 or 50 repetitions of step 2 on the ABI 7500 FAST machine with a programme 
outlined in Table 3.11. 
 
Table 3.10 Real time reation and PCR master mix composition 
Component   µl/sample  Master mix for 10 samples 
Master mix (2x)  12.5  125 
Gene expression assay (20x)  1.25  12.5 
cDNA 2.5  - 
H2O 8.75  87.5 
Total 25  225 
 
Table 3.11 Real time PCR cycling programme 









Measurements were taken at the end of step 4. 
 
3.9.1  Relative Quantification (RQ) of Real time PCR data 
The amount of the gene target was normalised to endogenous reference and relative to the 
mouse head calibrator sample. The analysis was performed with the comparative CT method for 
relative quantification, using calculations completed by the ABI software. Sample data were 
entered into Microsoft Excel for graph plotting and into SPSS for statistical analysis.   Chapter 3 Methods 
  
  84 
 
3.9.2  Validation of Real Time PCR data 
The 18S rRNA gene was used as a control gene for relative quantification. The gene expression 
assay (GEX) for 18S (Part no: 4352930E) is not intron spanning, unlike previous target gene 
expression assays. Therefore the 18S GEX would not distinguish between cDNA and gDNA. 
RNA extraction (section 3.7) was performed without visible contamination from gDNA. 
Contamination was further analysed by reverse transcription of DepC water, and mRNA 
(substituting the Reverse Transcriptase with DepC water). The sample material was diluted 4 
fold as described earlier and compared to the positive controls. CTs of mRNA (31 cycles) and 
dH2O (34 cycles) were similarly low and 3 cycles apart. The CT difference between the cDNA 
(8 cycles) and mRNA was 23 cycles, an amount equivalent to less than 0.0001 % of the 18S 
rRNA reverse transcribed. This indicates that the error in the measurement of 18S by real time 
PCR analysis does not significantly affect the semi-quantification in this thesis. 
 
 
Figure 3.5 Real Time PCR amplification plots of 18S cDNA and 18S mRNA compared to water 
Sample cDNA 
Sample mRNA 
dH2O   Chapter 3 Methods 
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3.9.3  SYBR Green Real Time PCR 
The SYBR green PCR system uses a DNA intercalating fluorochome dye to bind to PCR 
product. Amplification of the PCR product results in many double stranded cDNA sequences 
for the target gene and hence a fluorescent level proportional to the amplification. Longer PCR 
products allow more of the SYBR green dye to intercalate, producing a greater fluorescence is 
greater per unit of PCR product, however a longer time is required for the transcription. The size 
of the PCR product was kept to less than 350 bp. 
 
The SYBR green master mix (2X) was mixed with cDNA and loaded into the wells. The 
forward and reverse primers were mixed into distilled water and added to the wells. The 
resulting reaction mix (Table 3.12) was centrifuged for 3000 rpm a few seconds with a plate 
centrifuge, before analysing by real time PCR on an ABI 7500 FAST machine, using the 
program detailed in Table 3.13. Step 2 was repeated for 40 or 50 cycles as required. 
 
Table 3.12 Real time SYBR Green master mix 
Component   µl/sample 
SYBR Green (2X)  6.25 
Forward Primer  0.625 






Table 3.13 Real time SYBR Green PCR Programme 
Step  Temperature ( °C )  Time ( mm:ss) 










   Chapter 3 Methods 
  
  86 
3.10 Protein extraction and quantification 
3.10.1 Protein extraction 
The protein extraction was performed on ice to minimise enzyme and metabolic activity from 
the point of cell harvesting. A rapid dephosphorylation appeared to occur within seconds of 
removing the culture medium, thus the following washing and lysis step was completed within 
approximately 20 seconds for each sample. An ice cold lysis buffer containing 1:25 proteinase 
inhibitor and 1:200 of sodium orthovanadate (1 mM Na3VO4) was prepared in order to inhibit 
phosphatase activity during protein lysis. Culture medium was poured out of the T25 culture 
flasks and ice cold PBS poured in to reduce protease and phosphatase activity. The PBS was 
poured out and replaced with 50 - 200 µl of the prepared ice cold lysis buffer. Lysis occurred 
rapidly and the cell lysate was transferred to 1.5 ml tubes. Samples were sonicated for a few 
seconds where solids were visible until the lysate solutions were cloudy. The lysate was 
centrifuged at 13,000 rpm in 4 °C for 30 minutes. This pelleted the cell membranes and DNA, 
which were removed where possible by pipette and then the supernatant transferred to 0.5 ml 
tubes and stored at -20 °C. 
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3.10.2 BCA™ protein Assay 
A small aliquot of the protein sample was diluted 1:10 and the protein concentration determined 
with the BCA™ Protein Assay Kit (Pierce Rockford, IL). Reagents A (sodium carbonate, BCA 
and sodium tartrate in 0.1M sodium hydroxide), and B (4 % cupric sulphate) were mixed at a 
ratio of 50:1 respectively and loaded at 200 µl per well on a 96 well plate. To this was added 25 
µl of either standard protein (see Table 3.14) or sample protein. Standard protein concentrations 
were made by mixing BSA stock with distilled water as outlined in Table 3.14 for tubes A, B 
and C. Tube D was composed by mixing 175 µl distilled water (shown in the table) and 175 µl 
of tube B and mixed thoroughly. Similar compositions were made for tubes E to H using 
distilled water and the tubes as directed on Table 3.14 and mixed thoroughly. Duplicate wells 
for standard proteins (A-I) and triplicate wells for target proteins were used to reduce loading 
errors. The plate was placed onto a shaker for 30 seconds and then incubated at 37 °C for 30 
minutes. The plate was cooled to room temperature before measuring absorbance at 560 nm 
with a microplate reader. The background absorbance (I) was subtracted from the samples. The 
protein standards were plotted against the optical density with a best fit curve. Sample protein 
concentrations were approximated from the standard curve. 
 
 
  Table 3.14 Composition of protein standards  for protein concentration assay 
Tube  Distilled water (µl)  BSA Stock* (µl)  Final conc ( µl/ml) 
A 0  300  2000 
B 125  375  1500 
C 325  325  1000 
D 175  175B  750 
E 325  325C  500 
F 325  325E  250 
G 325  325F  125 
H 400  100G  25 
I 400  0  0 
*BSA Stock: 2mg/ml BSA in PBS 
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3.11  Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
A clean gel apparatus (A large and small plate with two brackets, a comb and a backing, Biorad) 
were assembled and filled with water to test for leaks. The water was removed and combs were 
inserted and a level was marked about 2 mm below the comb teeth. Polyacrylamide gel 
solutions were composed as shown in Table 3.15 and mixed well.  Ammonium Persulphate and 
TEMED were used to initiate and acceleratre polymerisation respectively. The gel was poured 
into the apparatus immediately to the marked level. To reduce evaporation and flatten the 
meniscus for even resolution, a layer of isopropanol was added. To confirm whether gels had 
set, the remaining gel solution was kept, while proteins were prepared. Protein samples (20-40 
µg) were mixed with loading buffer in a 1:1 ratio and boiled at 100 °C for 10 minutes and 
cooled on ice. Meanwhile the isopropanol was washed out with distilled water and the stacking 
gel completed and poured into the gel apparatus. The comb was slowly lowered into the gel to 
avoid splash back and bubbles. Excess gel on the apparatus was removed with a paper towel. 
Remaining bubbles were removed by tapping the apparatus and the remaining gel kept to 
confirm that the stacking gel had set. The gel apparatus was transferred to a running tank filled 
with running buffer. Protein samples and 10 µl of protein standard (Precision Plus Protein™ 
Dual Color standards, Biorad) were centrifuged briefly, vortexed and loaded onto the gel. The 
protein load was made similar in each sample well by measuring protein concentration and 
using control protein α-Tubulin for relative quantification. The run was operated at 140 V and 
140 mA for 1 - 2 hours and on ice to prevent the gel from overheating. Observations were made 
every 30 minutes to monitor the distance moved by the bands. Blotting was performed using 
either the wet or semi-dry method. 
 
Table 3.15 Components for protein gels 
Component  12 % resolving gel (ml)  5 % stacking gel (ml) 
Distilled H20 3.3 1.4 
30 % Acrylamide 4.0  0.33 
1.5M Tris pH 8.8 2.5  NONE 
1.0M Tris pH 6.8 NONE  0.25 
10 % SDS 0.1  0.02 
10 % Ammonium persulphate (AP)* 0.1  0.02 
TEMED* 0.004 0.004 
*Mixed just before pouring gel solution. AP powder was freshly diluted in dH2O.   Chapter 3 Methods 
  
  89 
 
3.12 Western blotting 
Western blotting was performed with either wet or semi-dry transfer methods. The protein load 
was made similar in each sample well by measuring protein concentration and using control 
protein α-Tubulin for relative quantification. 
3.12.1 Wet Transfer Method 
Four sheets of 3MM chromatography paper (Whatman
®) and one nitrocellulose sheet of 
Hybond™-C Extra (Amersham Life Science) were cut to a size slightly larger than the gel and 
soaked in transfer buffer. Two flat sponges were also soaked in transfer buffer. The gel was 
detached from the apparatus and placed in the transfer buffer to keep wet. The sponges were 
placed one on each electrode plate and two pieces of filter paper were placed on the side of the 
black electrode. The gel was gently separated from the plates and added on top of the filter 
paper. Nitrocellulose (Hybond) paper was added on top carefully to avoid bubbles between the 
gel and the paper. Two more filter papers were added on top and the red flat electrode put on top 
to sandwich the gel. This was placed in a transfer tank with transfer buffer to fill to the top. 
Electrodes were plugged in such that the gel was on the negative side and the H-bond membrane 
on the positive side. The transfer buffer was fun for 2 hours at 200 mV and 200 mA at 4 °C. 
Afterwards, the sandwich was opened up with the positive side (red) on the bottom. The papers 
were removed and the top right corner cut to mark that the membrane was face up. The gel was 
removed and the membrane kept in transfer buffer to stay moist. 
3.12.2 Semi-dry Transfer Method 
Six sheets of 3MM chromatography paper (Whatman
®) and one nitrocellulose membrane of 
Hybond™-C Extra (Amersham Life Science) were cut to a size slightly larger than the gel and 
soaked in transfer buffer. Three pieces of the paper were placed on the surface of the bottom 
plate (anode), before placing the nitrocellulose membrane on top. The gel was placed on top and 
covered with three sheets of filter paper. Bubbles between the sheets were removed with a 
centrifuge tube at each stage of layering and the transfer performed at 400 mA and 20 V for one 
hour. Afterwards, the filter paper and gel were removed and the top right corner of the 
membrane was cut off in order to mark the top surface. Remaining gel was washed off the 
membrane with transfer buffer. 
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3.12.3 Ponceau S staining 
It was necessary to confirm that the protein had transferred before proceding. The membrane 
was incubated in Ponceau S solution, rocking gently for 10 minutes. The Ponceau S solution 
was washed once in TBS and excess solution dried off with a paper towel. The membrane was 
placed in a plastic sheath and scanned on a Hewlett Packard Scanjet 5100C. A successful 
protein transfer was indicated when pink bands in the sample lanes with similar intensities 
between lanes were observed, as in Figure 3.6. Ponceau S solution was washed off with TBS. 
 
 
Figure 3.6 Ponceau S solution staining of proteins on a nitrocellulose membrane 
 
3.12.4 Immunodetection 
To prevent non-specific binding, the membrane was incubated with blocking buffer for 45 
minutes at room temperature. Excess blocking buffer was drained with a paper towel before 
sealing the membrane in a plastic bag of primary antibody solution and incubating overnight at 
4 ºC on a gentle shaker. The primary antibody was removed by washing in 0.1% TBST six 
times for 8-10 minutes. The membrane was placed in a plastic bag filled with secondary 
antibody solution, sealed and gently rocked for 1 hour at room temperature. Excess antibody 
was removed with six sets of 10 minute washes with 0.1% TBST. 
 
Enhanced chemiluminescence reaction (ECL) was used to visualise the antibody bound to the 
target protein. 1ml of each ECL component was placed in a 50 ml tube. The membrane was 
placed inside and washed in ECL for 1-2 minutes. The membrane was lifted out and excess 
ECL drained on a paper towel to reduce back ground. The membranes were placed face up 
between two plastic sheets in a photographic plate and brought to a dark room. In the dark,   Chapter 3 Methods 
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Chemiluminesence Film (Kodak Biomax Light Film, Sigma-Aldrich) was cut on the top right 
corner and moved to the top right part of the plate and closed. This was timed for 1 minute, 
before the film was taken out and placed in the film processor, and labelled with the time. This 
was repeated for 4 and 16 minutes and other times to find the appropriate time of exposure, such 
that the intensity of the bands was not completely saturated. The bands for the protein ladder 
were traced on top of the film. Bands on the films were orientated along a horizontal axis and 
scanned for densitometry (Hewlett Packard scanjet 5100C). 
 
3.12.5 Densitometry 
Labimage (v2.7.1, Kapelan) was used to analyse scanned blots. Brightness and contrast were 
optimised before proceeding with the analysis. Area information for each target band was 
obtained and analysed in Excel. 
 
3.12.6 Summary of Antibodies and conditions 
Antibodies were diluted in blocking buffer to the levels shown in Table 3.16: 
 
Table 3.16 Antibodies and dilutions for western blot 
Antibody Dilution 
Primary  
Alpha Tubulin 1:1000 
ERK p44/42 1:1000 
Phospho-ERK p44/42 1:2000 
Gapdh 1:1000 
Secondary  
Goat anti-rabbit HRP 1:1000 
Rabbit anti-mouse HRP 1:1000 
Goat anti-mouse HRP 1:1000 
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The sample cDNA and PCR product of Human FGFR2 was prepared using methods described 
in section 3.7 and 3.8. The human FGFR2-C278F was sequenced in R2-C278F cells to confirm 
the presence of the codon change from cysteine to phenylalanine (Figure 3.7). 
 
 
Figure 3.7 Sequence of FGFR2 in R2-C278F cells. 
A: A short sequence of the region surrounding position 278 of the human FGFR2-C278F. The numbering 
of the nucleotides are arbitary. B: The chromatogram of the sequence of the highlighted in red in A. 





B   Chapter 3 Methods 
  
  93 
 
3.14 Statistical analysis 
SPSS (14, SPSS Inc. Chicago, IL, USA) was used for all statistical computations. The “n” 
provided in the results figures refer to the number of experiments for that study. 
 
3.14.1 Tests of normality and distribution adjustments 
The Shapiro-Wilks test was applied, using the “Explore function” in order to determine whether 
data was normally distributed before parametric tests were applied. Cases were excluded 
pairwise, as not all genes were analysed in all samples. Where data was not normally distributed 
(0.05 or below), data was logged and the test performed again. 
 
Parametric data were compared with the two samples T-test, whereas non-parametric data were 
compared using Mann-Whitney U test. Statistical differences were stated for p-value < 0.05. 
Unless stated otherwise, the P values were given from a T-test. Levene’s test was used to 
determine the equality of variances. Where the result was significant (0.05 or below), equal 
variances were not assumed in the T-Test. 
 
For gene expression profiling, ANOVA was not applied for 3 groups as the number of replicates 
was less than the recommended numbers (n < 20) as suggested in the GOSH Statistics and 
Research Methodology course book (p142, 2005 edition). ANOVA was used for comparison 
between more than 3 groups to avoid further increase of type 1 errors. The bonferroni post hoc 
test was applied to conservatively assess any significant differences observed by ANOVA. Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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Chapter 4  Characterising MC3T3, R2-WT and R2-C278F cells 
4.1 Introduction 
Mutations of Fibroblast Growth Factor Receptor (FGFR) 1-3 that cause ligand independent 
receptor dimerisation, such as FGFR2-C278F or FGFR2-C342Y are associated with 
craniosynostosis (Mangasarian et al., 1997; Robertson et al., 1998). These types of mutation 
result in a ligand-independent constitutively activated (LICA) FGFR, which affects osteoblast 
cell behaviour. 
 
It is implied that mutations that result in LICA FGFR2 have equivalent mechanisms of FGFR 
activation, although different results are observed in human and animal models. For example in 
cultured human osteoblasts carrying FGFR-C342R, proliferation is decreased and 
differentiation increased, whereas in both murine osteoblast cell lines (C342Y) and chick 
primary osteoblast cultures (C278F) proliferation is increased and differentiation decreased 
(Mansukhani et al., 2000; Marie et al., 2005; Ratisoontorn et al., 2003). Some hypotheses have 
been given for these discrepancies, such as different cell responses to FGF linked to osteoblast 
maturity and differences in human and murine genetic backgrounds, however they have neither 
been defined specifically or tested (Marie et al., 2005). 
 
FGFR2-C278F is a common mutation resulting in Crouzon or Pfeiffer syndromes. The effect of 
this mutation on proliferation and differentiation has been studied in embryonic chick 
osteoblasts, but not at postnatal stages (Ratisoontorn et al., 2003). In the Ferretti lab, murine cell 
lines were established by transfecting osteoblastic MC3T3-E1 cells with either human wild type 
FGFR2 or FGFR2-C278F and the lines named R2-WT and R2-C278F respectively, to create a 
murine in-vitro model for craniosynostotic osteoblasts (Petiot, 2001). The initial work on this 
newborn postnatal cell line suggested that stable expression of FGFR2-C278F may reduce 
proliferation, increase differentiation and increase apoptosis in R2-C278F cells. 
 
The first aim in this chapter is to confirm and extend published work by the Ferretti lab, 
focussing mainly on the stages of culture at pre-confluence and confluence (2 and 4 days in 
culture). The second aim is to extend the investigation into osteoblast behaviour by studying cell 
morphology, distribution and metabolism. The third aim is to define a working hypothesis to 
explain the similarities and discrepancies of craniosynostotic osteoblast phenotype reported in 
the literature. Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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4.2 Results 
4.2.1 The effect of FGFR2-C278F on osteoblast morphology and 
distribution 
Differences were found between the MC3T3, R2-WT and R2-C278F cell lines by two days in 
culture, using light microscopy (Figure 4.1A, C and E). MC3T3 cells were arranged in 
monolayered clusters of cuboidal cells surrounded by fibroblastic cells with processes that 
spanned the spaces between the clusters (Figure 4.1A). In contrast, R2-WT cells appeared to be 
more evenly distributed, arranged in smaller clusters of cuboidal cells and the cultures seemed 
to have more fibroblastic cells (Figure 4.1C). These monolayered clusters of cuboidal cells were 
also found in R2-C278F cultures, but with few fibroblastic cells spanning between clusters, 
compared to the MC3T3 cultures (Figure 4.1E). At 4 days in culture, almost all cells in the three 
cultures were cuboidal (Figure 4.1B, D and F). Both MC3T3 and R2-WT cell cultures had 
reached confluence and could not be distinguished from each other (Figure 4.1B and D). The 
R2-C278F cultures were not fully confluent; gaps between cells could be observed that made 
them easy to distinguish from both MC3T3 and R2-WT cultures (Figure 4.1F). 
 
On closer observation of cell morphology, certain shapes could be clearly identified and were 
classified as follows: “fibroblastic”, “bright and round”, “small” (10 µm diameter 
approximately), “cuboidal” and finally “fried egg” (100 µm diameter approximately). The 
relative percentage of cuboidal cells was difficult to categorise, as the morphology of some of 
the small cells was also cuboidal or round, but not bright. To simplify, cells were therefore 
divided into four categories: bright round, small/cuboidal, fibroblastic and “fried egg” (Figure 
4.2 A). The relative amount of these categories did not change between the MC3T3 and R2-WT, 
however in R2-C278F there was an increase in the percentage of the “bright round” and a 
decrease in the “fibroblastic” morphologies (Figure 4.2 B). 
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Figure 4.1 Phase contrast microscopy of MC3T3, R2-WT and R2-C278F at 2 and 4 days in culture 
Fibroblastic cells (arrow heads) and cuboidal cells (white arrows) are present in MC3T3 cells at 2 days 
(A). In R2-WT cells (C) most appear fibroblastic and in R2-C278F cells (E) most appear cuboidal with 
more bright round cells (wide arrow). MC3T3 and R2-WT cultures are confluent at 4 days (B, D), but R2-
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Figure 4.2 Classification of MC3T3, R2-WT and R2-C278F cell morphology at 2 days in culture 
A: Examples of cell morphologies were used for quantification. B: The small and cuboidal cells 
constitute the largest percentage of the cells present in all three cell cultures. The percentage of bright 
round cells is significantly higher in R2-C278F cells, compared to MC3T3 and R2-WT controls. The 
percentage of fibroblastic cells is lower in R2-C278F cells. No significant differences are found between 

















































Bright round  Small  Cuboidal 
Fibroblastic  Fried Egg 
B 
A Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
 
  98 
4.2.2  The effect of FGFR2-C278F expression on proliferation 
To measure cell growth, cells were counted at 4 days in culture by FACS analysis. This was 
done by suspending the cultured cells in a known volume of PBS and adding a fixed number of 
beads. From this, the forward and sideways scatter plot was used to identify cells from beads 
and allow calculation of the percentage of beads to cells in MC3T3, R2-WT and R2-C278F 
cells (Figure 4.3 A, B and C). A higher percentage of beads to cells indicates a lower cell 
number. From this percentage, the original number of cells was assessed. MC3T3 cultures had 
the greatest number of cells, followed by R2-WT and then R2-C278F cells (Figure 4.3). 
 
The DNA intercalating agent 7AAD was used to determine the proportion of cells at each stage 
of the cell cycle. A basic plot indicated that cells varied from haploid (low DNA content) to 
diploid (high DNA content). This plot was further analysed for the number of cells at each stage 
of the cell cycle, based on the Dean and Jett method (Dean and Jett, 1974). This produced three 
histograms underneath the original curve corresponding to G1, S and G2/M phase in MC3T3, 
R2-WT and R2-C278F cells (Figure 4.4 A, B and C). The curves were analysed, and the 
number of cells at each stage of the cell cycle were expressed as a percentage of the whole cell 
cycle (Figure 4.4 D). No significant differences were found between MC3T3 and R2-WT cells, 
however in R2-C278F cells there was a significant decrease in the proportion of cells in S and 
G2/M phase compared to that of both MC3T3 and R2-WT cells (Figure 4.4 D). The percentage 
of cells in G1 phase was also higher in R2-C278F cells than in the other cell lines. 
 
To assess the amount of cells in M phase, the pH3 antibody stain was used and the cells 
analysed by FACS. The cell count was plotted against the log fluorescence intensity of the pH3 
signal in each cell and a gate was placed to separate cells of low and high intensity, based on the 
negative control with the highest background (Figure 4.5 A, B and C). M phase was analysed by 
calculating the percentage of cells with high intensity stain. This showed that the percentage of 
M phase cells in R2-C278F (1.6%) were significantly lower than in MC3T3 (1.92%) and R2-
WT (1.85%) cells (Figure 4.5 D). 
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Figure 4.3 FACS analysis of cell number after 4 days in culture 
Cell samples were mixed with a fixed number of fluorosphere beads and counting approximately 45,000 
MC3T3 (A), R2-WT (B) and R2-C278F (C) cells. The percentage of beads (green) was used to calculate 
the total number of cells in the culture. A-C: The forward scatter (FS) was plotted against side scatter 
(SS) and the beads were gated and the percentage of beads to cells calculated for MC3T3, R2-WT and 
R2-C278F cells respectively given by percentage “A” on each plot. D: At 4 days in culture, the cell 
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Figure 4.4 FACS cell cycle analysis of MC3T3, R2-WT and R2-C278F at 2 days in culture 
7AAD was used to identify the phases of cell cycle as described in methods (3.3 FACS). Plots of cell 
number against DNA content for MC3T3 (A), R2-WT (B) and R2-C278F (C) cells. Three smaller plots 
corresponding to G1, S and G2/M phases of the cell cycle were made under the main curve, as explained 
in section 3.3.2 Methods. D: Data from the three plots analysed to assess the percentage of cells at 
different phases of the cell cycle. The percentage of cells in G1 phase is higher in R2-C278F cells than in 
MC3T3. The highest percentage of cells in MC3T3 and R2-WT are in S-phase. The percentage of cells in 
S-phase is significantly lower in R2-C278F. There is a significantly higher percentage of R2-C278F cells 
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Figure 4.5 FACS M-phase analysis of MC3T3, R2-WT and R2-C278F at 2 days in culture 
The cell count was plotted against the log intensity of phosphorylated histone antibody (pH3) in MC3T3 
(A), R2-WT (B) and R2-C278F (C) cells. A-C: A gate (R29) was placed to only include cells with high 
intensity, corresponding to pH3 positive cells in M-Phase. D: The pH3 positive cells were expressed as a 
percentage of the total number of cells. This percentage is decreased significantly in R2-C278F cells (n = 
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4.2.3  FGFR2-C278F increases apoptosis and cell death 
Apoptosis as measured by 7AAD was performed at 2 and 4 days in culture. The level of 
apoptosis was low at 2 days, between 0.2 and 0.3 % in MC3T3 and R2-WT cells (Figure 4.6 A). 
In R2-C278F cells in the percentage of apoptotic cells was also small, but significantly higher 
(0.6 %), compared to both controls (Figure 4.6 A). Also at 4 days, the level of apoptosis was 
low in MC3T3 and R2-WT (between 0.5 to 0.9 %) with no significant difference between the 
two cell lines. The level of apoptosis in R2-C278F cells was 2 to 3 fold higher (1.7 %) than in 
MC3T3 and R2-WT cells respectively (Figure 4.6 B). 
 
To further assess the extent of cell death in the different cell lines, cells were also cultured for 7 
days without any change in medium, and both adherent and non-adherent cells were counted. 
Adherent cells were analysed for apoptosis and the non-adherent cells were considered as dead. 
The number of live and both dead and apoptotic cells were counted (Figure 4.7 A). Similar to 
the cell number at 4 days, the number of live cells was highest in the MC3T3, lower in R2-WT 
and lowest in R2-C278F cells. The number of dead / apoptotic cells was highest in the R2-
C278F cells, followed by R2-WT and then MC3T3. The percentages of dead / apoptotic cells 
were 1.5, 6.6 and 25.7 % for MC3T3, R2-WT and R2-C278F cells respectively. 
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Figure 4.6 Analysis of apoptosis in MC3T3, R2-WT and R2-C278F cells by FACS using 7AAD 
Apoptotic cells were detected by their increased uptake of the DNA intercalating agent, 7AAD. A: At 2 
days in culture, there is no difference in apoptosis between MC3T3 and R2-WT cells, whereas in R2-
C278F is increased significantly (n = 3).  B: At 4 days in culture the level of apoptosis between MC3T3 
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Figure 4.7 FACs cell count and cell death at 7 DIC without medium change 
Adherent and non-adherent cells were counted after 7 DIC (A). The number of live cells was significantly 
smaller in R2-WT, compared to MC3T3, and even lower in R2-C278F cultures. The total number of dead 
cells (adherent and non-adherent) was significantly higher in R2-WT and R2-C278F cells compared to 
MC3T3 (** p < 0.05 versus MC3T3). No significant differences were found in the number of dead cells 
between R2-WT and R2-C278F cells. B: The number of dead / apopototic cells in (A) expressed as a 
percentage of the total cells counted. There is a significant increase in apoptosis in R2-C278F cells 
compared to both MC3T3 and R2-WT cells. R2-WT cells also show a higher level of apoptosis, 
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4.2.4  Metabolism is altered in R2-C278F cells 
The behaviour of the three cell lines in the absence of serum was assessed by seeding cells for 
24 hours in cell culture medium containing 10% FBS and then replacing this with a 0 % serum 
cell culture medium. Cell morphology and distribution were assessed. After 18 hours in 0 % 
serum, there were no obvious changes in cell distribution (Figure 4.8). There was an increased 
number of floating cells in the centre of the culture wells in all three cell lines, however the 
largest number of these cells was observed in R2-C278F cells. As osteoblasts are adherent cells 
unless sheared from their culture suface or trypsinized, this suggested that the amount of 
floating cells was associated the the amount of dead cells. Increased dependency on serum for 
survival in R2-C278F cells may have highlighted a potential metabolic abnormality. 
 
To investigate potential metabolic defects in R2-C278F cells on a molecular basis, Akt1 and 
Gapdh gene expression were analysed, because of their roles in cell survival and glucose 
metabolism respectively (Song et al., 2006). Gapdh expression in R2-C278F cells was 
significantly lower, compared to MC3T3 and R2-WT cells at both 2 and 4 days in culture 
(Figure 4.9A). Interestingly, at both timepoints the level of Gapdh expression in R2-WT cells 
was higher than in MC3T3 cells. Akt1 expression was not significantly different between R2-
WT cells and MC3T3, but in R2-C278F cells Akt1 expression was significantly lower compared 
to MC3T3 (Figure 4.9B). No significant differences were observed in Akt1 expression between 
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Figure 4.8 Phase contrast microscopy of serum starved cells after 18 hours 
Cells were seeded at 20,000 cells per cm
2 on a 12 well plate for 24 hours in 10 % FBS containing cell 
medium (A, C and E), before culturing with 0 % FBS cell medium for 18 hours and swirling the wells 
gently to collect floating cells together for imaging (B, D and F). Bright floating cells found in MC3T3 
and R2-WT cells (B and D). More of these floating cells were observed in the R2-C278F cell cultures (n 
= 4). 
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Figure 4.9 Real time PCR analysis of Gapdh and Akt1 in MC3T3, R2-WT and R2-C278F cells 
Relative Quantification (RQ) of gene expression against a calibrator (embryonic mouse head E13.5). A: 
For the analysis of Gapdh expression only, the RQ value was further normalised to the MC3T3 to 
compare several experiments, to determining whether Gapdh was higher in R2-WT cells than in MC3T3. 
Compared to MC3T3, at both 2 and 4 days in culture, Gapdh expression is significantly higher in R2-WT 
cells, and significantly lower in R2-C278F cells (n = 5). B: At 2 days in culture, the level of Akt1 
expression is not significantly different between MC3T3 and R2-WT cells, however it is significantly 
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4.2.5  The effects of FGFR2-C278F on differentiation 
Differentiation had initially been shown to increase in R2-C278F cells compared to MC3T3 
(Santos-Ruiz et al., 2007). To confirm this, MC3T3, R2-WT and R2-C278F were plated on a 24 
well plate and grown for 2 days. The cells were then fixed and stained for the early 
differentiation marker, Runx2 using immunocytochemistry (Figure 4.10). The Runx2 protein 
was present in all three cell lines and generally nuclear in localisation. There were no obvious 
differences in the level of Runx2 between R2-C278F cells and the two control cell lines. To 
quantify Runx2 expression, cells were plated on a 12 well plate and cultured for 2 days before 
analysing Runx2 using FACs immunocytochemistry. This analysis of Runx2 protein expression 
showed that levels were very similar between all three cell lines at 2 days in culture (Figure 
4.11). 
 
Gene expression was analysed in all three cell lines at 2 or 4 days in culture. Culture medium 
was changed at 2 days for cells that were analysed at 4 days. Real time PCR was used to 
measure the expression of differentiation markers Runx2, Twist1 and Osteopontin (Opn). Bsp 
and Osteocalcin (Oc) were analysed by SYBR Green real time PCR. There were no significant 
differences in Runx2 expression between the cell lines at 2 or 4 days in culture (Figure 4.12 A). 
All three cell lines expressed Twist1 at 2 and 4 days without any significant differences between 
them (Figure 4.12 B). Opn expression was similar in all three cell lines at 2 days in culture, 
however at 4 days its expression level was significantly lower in R2-C278F cells, compared to 
MC3T3 or R2-WT (Figure 4.12 C). Bsp expression was not found in any of the three cell lines 
(Appendix Figure 8.5). Osteocalcin (Oc) expression was observed in all three cell lines at 4 
days in culture. The level of Oc was higher in the R2-C278F cells than in the control MC3T3 
cells and in R2-WT cells it was significantly higher than in both R2-C278F and MC3T3 (Figure 
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Figure 4.10 Runx2 expression in MC3T3, R2-WT and R2-C278F cells at 2 days in culture 
Runx2 immunocytochemistry performed with DAB. A, C and E: Background control stainings where 
primary antibody was omitted. B, D and F:  Runx2 staining is mainly nuclear (black arrow heads), and 
more intense in the nuclei of smaller cells (white arrow heads). The cell staining is more ubiquitous in 
some of the fibroblastic cells (black arrows) (n = 3, black bar = 50 µm). 
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Figure 4.11 FACS analysis of Runx2 protein at 2 days in culture. 
Cells were plated to a 12 well plate at 20,000 per cm
2, trypsinised after two days, stained with Runx2 
antibody and a fluorescent secondary antibody (Alexa 647). Runx2 expression was normalised to the 
MC3T3 controls. No significant difference in Runx2 in protein expression level is observed. Note: The 
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Figure 4.12 Real time PCR analysis of Runx2, Twist and Opn at 2 and 4 days in culture 
The relative gene expression was quantified and normalised compared to that of mouse E13.5 at 2 and 4 
days. A: No significant differences in Runx2 between cell lines at 2 and 4 days in culture is observed (n = 
4). B: Twist1 expression is not significantly different between cell lines (n = 3). C: At 4 days Opn is 
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Figure 4.13 Oc Gene expression analysed by SYBR Green Real Time PCR analysis at 4 days 
Osteocalcin expression was significantly higher in R2-C287F cells compared to MC3T3. In R2-WT cells 
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4.3 Discussion 
4.3.1 R2-C278F cells are more differentiated in morphology than 
MC3T3 
Reports have shown that fibroblastic pre-osteoblast cells found at preconfluence, whereas at 
confluence nearly all cells are cuboidal osetoblasts (Chung et al., 1999; Migliaccio et al., 1993; 
Sudo et al., 1983). This suggests that osteoblast maturation is associated with a change from 
fibroblastic to cuboidal morphology. These distinct differences in morphology have been used 
to classify maturity of cells at preconfluence: Isolation of clones from newborn mouse 
osteoblasts (OB) revealed that cultures with cells mostly of spindle shaped (fibroblastic) 
morphology (OB1) contained immature cells, whereas in cultures with a mainly cuboidal 
morphology (OB4), there are more mature osteoblasts (Mansukhani et al., 2000). 
 
At preconfluence (2 days in culture), about 30% of the MC3T3 cell population are fibroblastic 
and at confluence (4 days in culture) all acquire cuboidal cell morphology, indicating that cells 
change morphology as they mature; consistent with the above reports. MC3T3 cells at 
preconfluence therefore appear to be more mature than OB1 cells according to morphological 
classifications. A similar shift from fibroblastic to cuboidal morphology is observed in R2-WT 
and R2-C278F between 2 to 4 days in culture. Therefore at confluence the stage of maturity 
cannot be distinguished amongst the three cell lines based on morphology as all cells are 
cuboidal. 
 
The key morphological differences lie at preconfluence: R2-C278F cells have the lowest 
percentage of fibroblastic cells (15%), compared to both MC3T3 and R2-WT (30%), indicating 
that R2-C278F cultures contain fewer immature cells, suggesting that the mutant cells are more 
mature. Interestingly, in R2-C278F cultures there is a significant increase in the proportion of 
bright round cells, which could be apoptotic cells or dividing cells as rounding of the cells are 
observed during both of these events. 
 
To summarise, R2-C278F cells are morphologically more differentiated than MC3T3 and R2-
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4.3.2  Osteoblast proliferation is significantly reduced in R2-C278F cells 
Fgfr2 expression has been positively correlated to cell proliferation in bone (Iseki et al., 1997; 
Iseki et al., 1999; Ratisoontorn et al., 2003). However FGFR2-C278F, like other constitutively 
active FGFR2 mutations may either increase or decrease osteoblast proliferation (Marie et al., 
2005). Therefore it is essential to characterise these cells properly for later comparison. 
 
At preconfluence, there are no differences in proliferation between MC3T3 and R2-WT cells, as 
shown by cell cycle analysis (Figure 4.4 and Figure 4.5). At confluence however, there are 
fewer R2-WT cells than in MC3T3, which may suggest that FGFR2-WT expression may lead to 
a marginal decrease in proliferation as the cells approach confluence (Figure 4.3). The level of 
apoptosis at both preconfluence and confluence between R2-WT and MC3T3 are not 
significantly different, suggesting that this difference in cell growth is not cell survival related 
(Figure 4.6). 
 
R2-C278F cells proliferate less than in MC3T3 and R2-WT cells, as shown by a lower 
percentage of cells in S-phase (Figure 4.4) and M-phase (Figure 4.5), which indicates a 
reduction in cells undergoing DNA synthesis and cell division. Moreover this is supported by 
the R2-C278F cell count at 4 days, which is lower than in both R2-WT and MC3T3 cells 
(Figure 4.3). An increased percentage of R2-C278F cells in G0/G1 phase compared to MC3T3, 
indicates a larger percentage of cells in growth arrest. There is also a significantly larger 
percentage of R2-C278F cells in G2/M phase than in both controls. As the percentage of cells in 
M-phase was very small (approximately 2% in all three cell lines), this suggested that most cells 
in G2/M phase were in G2 phase, inferring that the percentage of R2-C278F cells at G2 phase 
was higher than in controls.  
 
These findings indicate that compared to MC3T3, normal FGFR2-WT does not significantly 
affect proliferation at preconfluence, but FGFR2-C278F significantly reduces cell proliferation, 
with more cells arrested at both the G0/G1 and at the G2 check point than in MC3T3 and R2-
WT controls. It is possible that the increased percentage of G2 phase cells may relate to the 
increase in the percentage of bright round cells found in the previous section. Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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4.3.3  FGFR2-C782F increases apoptosis and metabolic requirements 
Expression of constitutively active mutations of FGFR2 (FGFR2-C432Y) have been shown to 
significantly increase apoptosis in immature osteoblast clones (OB1) of newborn mice 
(Mansukhani et al., 2000). Increased apoptosis is also observed in a human model carrying the 
FGFR2-C342Y mutation (Marie et al., 2005). In this study, the level of apoptosis was 
significantly increased in R2-C278F cells compared to MC3T3 and R2-WT cells, indicating that 
FGFR2-C278F also leads to a small increase in apoptosis (Figure 4.6). 
 
When the cell medium is not changed for 7 days, cell death is significantly greater in R2-C278F 
cells compared to both MC3T3 and R2-WT cells (Figure 4.7), suggesting that R2-C278F have a 
reduced ability to survive compared to the controls cell lines. As there were a higher number of 
MC3T3 cells in culture with a total number of apoptotic cells, this may suggest that the main 
limiting factor for R2-C278F survival may not be the medium nutrient content, but perhaps an 
increase in a metabolic waste. Increased metabolic waste has been indicated by a study showing 
that MC3T3 transfected with FGFR2-C278F acidify their medium to a greater extent than the 
controls after 5-7 days of culture (Hatch et al., 2006). 
 
Apoptosis may be induced in MC3T3 by serum starvation (Wang et al., 2008). Floating cells 
were observed in MC3T3 18 hours after serum deprivation, supporting the Wang report, 
suggesting that serum components are essential for MC3T3 cell survival (Figure 4.8). R2-WT 
cells had a group of floating cells of a similar size suggesting that apoptosis was also induced in 
these cells. Many more floating cells were present in R2-C278F cells under the same conditions, 
compared to MC3T3 and R2-WT cultures, suggesting that R2-C278F have a higher dependency 
on serum for survival than both MC3T3 and R2-WT cells. FGF2 may rescue human osteoblasts 
from serum induced apoptosis for up to 50 hours before the percentage apoptosis becomes the 
same as untreated controls, but longer term FGF2 treatment results in increased apoptosis 
(Debiais et al., 2004). This 18 hour analysis indicates that FGFR2-WT signalling does not 
protect against apoptosis and actually may increase with aberrant FGFR2-C278F signalling. 
These findings indicate that FGF2 may not increase cell survival via FGFR2 signalling, but 
perhaps the other FGFRs, such as FGFR1IIIc, FGFR3IIIc and FGFR4. 
 
Gapdh is an important molecule in metabolism with involvement in glycolysis, cell cycling, and 
apoptosis (Sirover, 1997). Although Gapdh is considered as a stable housekeeping gene and 
used as an internal control for analyses such as RT-PCR, its expression levels may vary with 
growth factor treatment and cellular transformation events such as epithelial-mesenchyme Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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transition (EMT) and neoplasia (Elberg et al., 2006; Gong et al., 1996). Gapdh is discussed in 
this section as there is reason to exclude the changes observed in Gapdh to cell proliferation. 
 
Gapdh expression can be a function of proliferation (Meyer-Siegler et al., 1992). High Gapdh 
expression is found in cells that are at mid to late stage S-phase of cell cycling, whereas it is low 
in cells that are arrested in early S-phase and G2 phase (Mansur et al., 1993). R2-C278F cells 
have lower Gapdh expression, a decreased proportion in cells in S-phase and an increased 
proportion in G2 phase than MC3T3 and R2-WT controls. However, Gapdh expression is still 
lower in R2-C278F cells than in R2-WT cells and MC3T3 at confluence. An initial study (M-
phase by FACS analysis) at confluence suggested that the level of proliferation may actually be 
higher in R2-C278F cells, compared to MC3T3, R2-WT and R2-C278F (Appendix Figure 8.2). 
This suggests low Gapdh expression is not linked to the low proliferation in R2-C278F cells. 
 
Gapdh overexpression in fibroblasts increases apoptosis and sensistivity to apoptotic agents 
(Dastoor and Dreyer, 2001). The Nitric Oxide (NO) induced NO-GAPDH-Siah death casade is 
positively mediated by GAPDH (Hara and Snyder, 2006). However R2-C278F cells express 
lower levels of Gapdh, suggesting that their increased apoptosis and sensitivity to apoptosis is 
not via NO-GAPDH-Siah1 (Figure 4.9 A). Caspase independent cell death (CICD) is a type of 
Programmed Cell Death (PCD) that occurs alongside caspase dependent cell death in many cells 
including maturing osteoblasts (Broker et al., 2005). In HeLa cells undergoing CICD following 
Mitochondrial Outer Membrane Permeabilization (MOMP), Gapdh overexpression inhibits 
apoptosis by increasing glycolysis and autophagy (Colell et al., 2007). Low Gapdh expression 
in R2-C278F suggests that increased apoptosis in these cells could correlate with a CICD 
mechanism. An initial analysis of Gapdh protein expression indicates that it may be lower in 
R2-C278F cells compared to MC3T3 and R2-WT cells (Appendix Figure 8.4), supporting a 
basis to investigate CICD in R2-C278F cells. 
  
Akt1 mediates osteogenesis, Runx2 dependent differentiation and inhibits apoptosis (Kawamura 
et al., 2007). There was a significant decrease in Akt1 expression in R2-C278F cells compared 
to MC3T3 at 2 days in culture, indicating that increased apoptosis may be associated with lower 
Akt1 expression (Figure 4.9 B). However the Akt1 expression alone may not be the main driving 
factor behind the higher rate of apoptosis, as there was no significant difference in Akt1 between 
all three cell lines at 4 days in culture, when the level of apoptosis was still higher in R2-C278F 
cells (Figure 4.6 B). Alternatively the decrease in Akt1 expression could be a compensatory 
mechanism to reduce differentiation in R2-C278F cells, as overexpression of Akt1 positively 
induces differentiation in osteoblasts (Raucci et al., 2008). To confirm this suggestion, Akt1 
protein expression and activation should be analysed. Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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4.3.4  FGFR2-C278F increases osteoblast differentiation 
The Ferretti lab suggested that differentiation may be increased in R2-C278F, based on 
increased Col1 protein expression in these cells at preconfluence (unpublished), increased 
Osteocalcin expression at postconfluence and increased mineralisation (Santos-Ruiz et al., 
2007). Runx2 is a master transcription factor for osteogenic cell differentiation by transcription 
of other markers of differentiation such as Col1, Alp, Opn and Oc (Ducy et al., 1997; Harada et 
al., 1999; Karsenty et al., 1999). Any change in the level of Runx2 would confirm an alteration 
in the progression of osteoblast differentiation. Neither the Runx2 gene expression or protein 
expression level or localisation were different in the R2-C278F cells compared to the MC3T3 
cells, indicating that enhanced differentiation in R2-C278F cells suggested by morphology   
expression  is not via Runx2 (Figure 4.10, Figure 4.11 and Figure 4.12A). 
 
Twist is a negative regulator of osteoblast differentiation, which inhibits Runx2 transactivation, 
thereby inhibiting Runx2 induced differentiation (Bialek et al., 2004). Twist is expressed in 
osteoprogenitors and lost in mature osteoblasts (Rice et al., 2000). If R2-C278F cells were more 
differentiated, it would be expected that Twist expression would be lower than in MC3T3 and 
R2-WT cells. This was not the case, indicating that differentiation is not altered in R2-C278F 
cells with respect to Twist expresssion. 
 
Osteopontin (Opn) is expressed in preosteoblasts and increases in expression as they 
differentiate into mature osteoblasts (Aubin, 2001). It also inhibits bone mineralisation (Boskey 
et al., 2002). Furthermore Opn is a negative regulator of differentiation and has been shown to 
negatively regulate bone sialoprotein (Bsp) and osteocalcin (Oc) expression (Huang et al., 
2004). In MC3T3 and R2-WT2 cells, Opn expression appeared to increase from as cells reached 
confluence supporting the morphological observations that differentiation had occurred. 
However Opn in R2-C278F cultures did not appear to change upon reaching confluence, even 
though cells were morphologically cuboidal indicating an abnormality in differentiation (Figure 
4.12 C). As Opn negatively regulates late stage differentiation, it can be interpreted that Opn 
expression that is lower in R2-C278F cells compared to the controls (Figure 4.12 C) may 
contribute to enhanced differentiation in the mutant cells. However it was necessary to analyse 
Bsp and Oc expression to confirm these effects, as an alternative explanation for this finding 
could be that R2-C278F cells are less differentiated therefore have lower Opn expression.  
 
BSP is a late differentiation marker which has been found to be restricted to differentiated 
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Bsp expression at 4 days in culture compared to E13.5 mouse head, where Bsp expression was 
found (Appendix Figure 8.5). Bsp is expressed in differentiated rat osteoblasts that are actively 
forming mineralized bone (Chen et al., 1992). It is possible in this model; bone mineralisation is 
required before Bsp expression can be observed. 
 
Oc is a late differentiation marker and restricted to differentiated osteoblasts (Mark et al., 1988; 
Yoon et al., 1987; Stein et al., 1990). Oc expression was higher in R2-C278F cells, based on 
Gapdh as an endogenous control (Santos-Ruiz et al., 2007). However in this chapter Gapdh 
expression was found to be reduced in R2-C278F cells, which would have altered the relative 
measurement of Oc. Therefore for this study the endogenous control, 18S was used instead. As 
suspected, R2-C278F cells have a higher Oc expression, confirming that the mutant cells have 
an enhanced level of differentiation (Figure 4.13). Interestingly the level of Oc expression was 
even higher in R2-WT cells than in R2-C278F, suggesting that these cells are also more 
differentiated than in MC3T3 at 4 days in culture. This also indicates that other factors related to 
FGFR2 signalling in addition to Opn are also regulating Oc expression. 
 
4.3.5  Comparisons of the current findings to current literature 
R2-C278F cell proliferation is decreased, apoptosis increased, differentiation increased and the 
metabolic requirements increased. There are similarities and differences in osteoblast behaviour 
between studies of craniosynostosis (Marie et al., 2005). The main similarities are that apoptosis 
has increased in all studies published, including this study. It is suggested that increased 
osteoblast apoptosis is due to compensation for either excessive proliferation or accelerated 
differentiation (Lemonnier et al., 2001; Mansukhani et al., 2000; Marie et al., 2005). There are 
two distinct osteoblast characteristics between models of LICA FGFR2: either proliferation 
increases and differentiation decreases, or proliferation decreases and differentiation increases.  
 
These two patterns have been explained by differentiation occurring secondary to proliferation, 
therefore increased proliferation results in decreased differentiation and vice versa (Mansukhani 
et al., 2000; Marie et al., 2005). However, this does not explain why proliferation is different 
between studies. There are many possible factors. Firstly, the gene mutations may not be the 
same and cause different effects in the osteoblasts. There is also the issue with transient and 
stable transfections used to create the animal models; transient transfections may have higher 
levels of gene expression if the analysis is carried out before the sample cells can divide or the 
may have very low expression if they are allowed to divide several times before analysis. Stable 
transfections often have a low and stable level of expression; however the site of integration 
may affect assessibility to transcription factor binding or disrupt expression of other genes. Chapter 4 Characterising MC3T3, FGFR2-WT and R2-C278F cells 
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Genetic and environmental background may also contribute, such as the actual mutation and the 
animal used for modelling (Marie et al., 2005). 
 
Point mutations in FGFR2 such as positions C278F, C342A and C342Y lead to receptor 
dimerisation and activation (Mangasarian et al., 1997; Robertson et al., 1998). As these 
mutations disrupt the same 278-342 disulphide bond, it is possible that the same or similar 
mechanism of constitutive ligand independent activation exists and therefore the same 
pathology would follow. This is supported by the observations that both Crouzon and Pfeiffer 
syndromes have been found not only with these mutations but also C342R, C342S and C342W 
(Ornitz and Marie, 2002). 
 
In this review mouse, chicken and human models will be compared with the assumption LICA 
FGFR2 mutations have the same mechanism(s) of action. Fgfr2 positively regulates osteoblast 
proliferation (Eswarakumar et al., 2002; Iseki et al., 1999; Ratisoontorn et al., 2003). The 
FGFR2-C342Y mouse craniosynostotic phenotype is rescued by blocking or attenuating the 
FGFR2-C342Y signalling (Eswarakumar et al., 2006; Perlyn et al., 2006). Therefore aberrant 
FGFR2 signalling can be hypothesised to produces either a strong positive signal (increased 
proliferation and decreased differentiation) or a negative feedback (reduced proliferation and 
increased differentiation). 
 
The pattern of osteoblast behaviour is dependent on the stage of development. In chick 
embryonic day 13 osteogenic cells, FGFR2-C278F increases proliferation and decreases 
differentiation, indicated by decreased Col1 and Alp expression, increased Opn expression, and 
decreased mineralisation (Ratisoontorn et al., 2003). FGFR2-C342Y expression also increases 
proliferation in immature murine coronal osteoblasts at E14.5 but not in more mature osteoblast 
cultures at P1, where a decrease in proliferation is postulated (Eswarakumar et al., 2004). In that 
report, osteoblasts at E18.5 also showed an increase in cell growth with an increased Opn 
expression, which may be an indication of decreased differentiation. Immature osteoblasts 
isolated from newborn mice calvarial (OB1) showed a mild increase in proliferation and 
decrease in differentiation as shown by low Alp expression (Mansukhani et al., 2000). In a three 
month old craniosynostosis patient with the FGFR2-C342R mutation there was reduced 
osteoblast proliferation, an increased ALP expression and decreased Opn expression, which 
may suggest increased differentiation (Fragale et al., 1999). Together these reports suggest that 
LICA FGFR2 increases osteogenic cell proliferation at an embryonic stage and at some point 
postnatally may decrease proliferation and increase differentiation. 
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Therefore a working hypothesis is that LICA FGFR2 increases proliferation in embryonic 
osteoblasts and decreases proliferation in postnatal osteoblasts. As mentioned, FGFR2-C278F 
mutation in chick embryonic osteoblasts show increased proliferation and decreased 
differentiation, which is consistent with the hypothesis. R2-C278F cell proliferation is decreased 
and differentiation increased, which also fits the hypothesis, as the MC3T3 background is 
derived from postnatal newborn mouse calvaria (Sudo et al., 1983). However there is a 
discrepancy between these findings and that of the OB1 clones from Mansukhani (Mansukhani 
et al., 2000). It has been suggested that osteoblast response to Fgf signalling may depend on the 
stage of maturation. In less mature osteoblasts proliferation increases and differentiation 
decreases with Fgf2 treatment, whereas in mature osteoblasts proliferation is not affected and 
differentiation increases (Debiais et al., 1998). Similarly in the Mansukhani report, in immature 
OB1 cells there was a great increase in proliferation following Fgf treatment, whereas the more 
mature OB4 cells responded to Fgf treatment with a small increase in proliferation (Mansukhani 
et al., 2000). The Ferretti lab has studied cell growth in all three cell lines with respect to Fgf2 
and Fgf18 treatment, which resulted in a small increase in cell growth in all three cell lines in 
low serum conditions. This indicates that MC3T3 in this model resembles mature OB4 cells 
more, which may suggest that the response to Fgf may contribute to the mutant cell phenotype 
as R2-C278F cells are already more differentiated than MC3T3. 
 
Reduced proliferation in R2-C278F cells does not follow from earlier FGFR2-C278F expression 
during embryogenesis, as FGFR2-C278F was stably transfected at a postnatal stage. Therefore 
the main difference between the two in craniosynostotic phenotypes could be a result of 
differing responses to FGFR2 signalling, intrinsic to the age or maturation stage of the 
osteoblast. The mechanism(s) underlying this switch in cellular responses to LICA FGFR2 for 
now are unknown. It is speculated that increased positive FGFR2 signalling will be found in 
embryonic and immature early postnatal osteoblasts, whereas increased negative feedback on 
FGFR2 is found in postnatal and more mature cells, such as those in human patients (Fragale et 
al., 1999). Further investigation of FGF’s downstream pathways may help uncover this/these 
mechanisms in both embryonic and postnatal cells. A review of the phenotypes are given in 
Table 4.1. 
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Stage Embryo  Embryo 
(E18.5) 
Postnatal Postnatal  3  month 
Osteoblast 
source 






Type  In-vitro In-vivo  In-vitro  In-vitro  In-vitro 
Mutation C278F  C342Y  C342Y  C278F  C342R 
FGFR M  M  M  H  H 
Proliferation  ↑  ↑  ↑  ↓*  ↓ 
Apoptosis       ↑*   
Differentiation  ↓  ↓  ↓  ↑*  ↑ 
RUNX2   ↑   =   
ALP  ↓    ↓  ↑  ↑ 
COL  ↓     ↑   
TWIST      =   
OPN  ↑  ↑    ↓*  ↓ 
OC =  =    ↑*   
Mineralisation  ↓ (Alizarin R)    ↓ (von kossa)  ↑ (Alizarin R)  ↓ 
H = Human FGFR2, M = Mouse FGFR2, bold arrow* = investigated in this thesis. 
 
References: 
1: Ratisoontorn et al., 2003, 2: Eswarakumar et al., 2004, 3: Mansukhani et al., 2000, 4: Santos-Ruiz et 
al., 2007, 5: Fragale et al., 1999 
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4.4 Conclusion 
R2-C278F cells have a reduced proliferation, increased differentiation and apoptosis and higher 
metabolic requirements for survival. Proliferation is reduced in R2-C278F cells compared to 
R2-WT and MC3T3 cells at preconfluence. Increased differentiation in R2-C278F cells is 
indicated by a lower proportion of cells with a fibroblastic morphology at pre-confluence and 
both a low Opn expression and a high Oc expression at confluence. Twist1 and Runx2 gene 
expression is not significantly affected in R2-C278F cells; however this does not exclude 
functional changes to the protein that might affect the cell phenotype. R2-C278F cells show 
increased apoptosis both at preconfluence and confluence. The FGFR2 mutant cells also have an 
increased dependency on serum for survival and low Gapdh expression, which is speculated to 
be a result of increased caspase independent cell death (CICD). Increased apoptosis is also 
speculated to be a result of compensation for enhanced osteoblast differentiation. 
 
The stage of development appears to be crucial in determining the phenotype of ligand 
independent constitutively active (LICA) FGFR2 craniosynostotic osteoblasts. The FGFR2 
mutant osteoblasts at the embryonic stage show increased proliferation and decreased 
differentiation, whereas most of the models at the postnatal stage including the current R2-
C278F model are consistent with decreased proliferation and increased differentiation. It is 
hypothesised that during embryogenesis LICA FGFR2 mutations display a true “gain-of-
function” demonstrated by the proliferative phenotype. In contrast postnatal LICA FGFR R2-
C278F cell phenotype may result from a negative feedback on FGFR2 signalling on 
proliferation and that increased differentiation is a secondary effect leading to craniosynostosis. 
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Chapter 5  FGF signalling in R2-C278F cells 
5.1 Introduction 
The most fascinating property of the FGFR2-C278F mutation is its ability to dimerise and 
signal without FGF (Mangasarian et al., 1997), previously termed as ligand independent 
constitutively activated (LICA) FGFR2. This property in NIH3T3 fibroblasts is observed in a 
number of FGFR2 point mutations including W290G, T341P, C342A and C342Y (Robertson et 
al., 1998). All of these mutations dimerise FGFR2 by disulphide bridging at position 278 or 
342, suggesting that these different point mutations may share the same mechanism of aberrant 
FGF signalling that leads to craniosynostosis. As suggested in chapter 4, there is a pattern to 
how osteoblast cell behaviour is altered by LICA FGFR2 depending on whether they are 
embryonic or postnatal, supporting the hypothesis that these mutations share a similar disease 
mechanism. 
 
FGFR2-C278F initiates signalling in MC3T3 cells via FRS and PLC-γ, and due to incomplete 
glycosylation this receptor has increased degradation (Hatch et al., 2006). Craniosynostosis in 
mice expressing FGFR2-C342Y may be rescued by either attenuating the TK domain of this 
mutant receptor or simply inhibiting FGFR TK activation (Eswarakumar et al., 2006). This 
suggests that the aberrant FGFR2 signalling, rather than the effects of receptor degradation 
alone, is responsible for inducing a craniosynostotic phenotype. The FGF signalling pathway is 
complex, because of the large numbers of ligands, receptors and intracellular binding sites for 
FGF, FGFR and FGF-FGFR signal initiation involved. Moreover there is direct (protein level) 
and indirect (transcriptional) feedback signalling on FGF. The Fgf ligands essential for normal 
bone formation and Fgfr2 activation are more likely to be involved in craniosynostosis, as bone 
formation is affected. FGFR2 signalling is mediated by downstream pathways such as the 
Mitogen Activated Protein Kinase (MAPK) - Extracellular Related Kinase (ERK) 1/2 pathway 
and the Protein Kinase C (PKC) pathway. Both pathways affect proliferation and differentiation 
in osteoblasts and may be relevant to the aberrant signalling of FGFR2-C278F, given the R2-
C278F cell phenotype. Normal FGFR2 may positively regulate osteoblast proliferation (Iseki et 
al., 1999), yet FGFR2-C278F expression in MC3T3 reduces proliferation and increases 
differentiation, suggestive of some effects of negative feedback (Chapter 4). 
 
The aim of this chapter was to find alterations within the FGFR signalling pathway in R2-
C278F cells and relate these to their cell phenotype. 
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5.2 Results 
5.2.1  Fgf1, -2, -18 and Fgfr2IIIc expression in osteoblasts 
Fgf1, -2 and -18 are important in both bone formation and Fgfr2 activation as they affect 
osteoblast proliferation and differentiation. Their expression levels were analysed by PCR in 
case they were linked to the proliferation and differentiation defects of R2-C278F cells. The 
main Fgfr2 isoform expressed in osteoblasts and essential for normal bone development is 
Fgfr2IIIc (Eswarakumar et al., 2002; Orr-Urtreger et al., 1993). The endogenous Fgfr2IIIc gene 
expression was analysed. The samples for all three cell lines were cultured for 2 or 4 days, with 
a change of culture medium at 2 days for the 4 day samples.  Fgf1, -2 and Fgfr2IIIc were 
analysed by RT-PCR, using Gapdh as an endogenous control. SYBR green real time PCR was 
used to further analyse Fgfr2IIIc with 18S as an endogenous control. Fgf18 expression was 
analysed by real time PCR. 
 
The conditions for measuring Fgf1 and -2 were optimized. Fgf1 expression was present in 
mouse head E13.5 (Figure 5.1 A). However Fgf1 expression was undetectable in MC3T3, R2-
WT and R2-C278F cells at both 2 and 4 days in culture (Figure 5.1 B and C). Although Fgf2 
was expressed in E13.5 mouse head (Figure 5.2 A), it was undetectable in all three cell lines at 2 
and 4 days in culture (Figure 5.2 A and B). The expression level of both genes was later 
analysed using real time PCR, which revealed a low expression level for each cell line at 2 and 
4 days (Chapter 6). Fgfr2IIIc was present in all three cell lines (Figure 5.2 A and B). 
Densitometry of Fgfr2IIIc normalised to Gapdh showed no significant differences between all 
three cell lines at 2 days and at 4 days, but a trend towards increased expression was observed in 
R2-C278F cells (Figure 5.2 C). Fgfr2IIIc was further analysed at 2 days in culture using SYBR 
green real time PCR with 18S. This revealed that the expression level of Fgfr2IIIc had increased 
in R2-C278F cells, relative to MC3T3 (Figure 5.3 A). Interestingly, the Fgfr2IIIc expression 
had also increased in R2-WT cells, compared to MC3T3. At 4 days in culture, the levels of 
Fgfr2IIIc were not significantly different among the three cell lines (Figure 5.3 B). Fgf18 was 
expressed in all three cell lines at 2 and 4 days in culture (Figure 5.4). At 2 days in culture, there 
were no significant differences in the expression level of Fgf18 amongst all three cell lines. At 4 
days in culture, Fgf18 expression in both R2-WT and R2-C278F cells was significantly higher 
compared to the MC3T3 cells. The Fgf18 expression in R2-WT cells was also higher than in 
R2-C278F cells. Chapter 5 FGF signalling in R2-C278F cells 
 




Figure 5.1 Fgf1 gene expression analysis by RT-PCR in MC3T3, R2-WT and R2-C278F cells 
MC3T3, R2-WT and R2-C278F cells were cultured for 2 or 4 days before gene expression analysis by 
RT-PCR. Fgf1 and Gapdh PCR products of RT-PCR were analysed at 2 and 4 days in culture using gel 
electrophoresis. A: The Fgf1 transcript is detectable in E13.5 mouse head (387 bp).  B: Although Gapdh 
(492 bp) is clearly visible in all three cell lines at 2 days in culture, Fgf1 is undetectable in MC3T3 and 
R2-WT; it is barely detectable in R2-C278F cells. C: Gapdh is present at 4 days in culture, however Fgf1 
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Figure 5.2 Fgf2 and Fgfr2 expression in MC3T3, R2-WT and R2-C278F cells by RT-PCR 
Fgf2, Fgfr2IIIc and Gapdh expressions were analysed in MC3T3, R2-WT and R2-C278F cells at 2 and 4 
days in culture. A: Fgf2 amplification product of size 429 is detectable in E13.5 mouse head. B: Fgf2 is 
not detectable in any of the three cell lines at 2 days in culture, however Fgfr2IIIc (315 bp) and Gapdh 
(492 bp) are present. C: At 4 days in culture, Fgf2 is not detectable, but both Fgfr2IIIc and Gapdh are 
present. D: Densitometry of Fgfr2IIIc expression in MC3T3, R2-WT and R2-C278F cells, normalised the 
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Figure 5.3 Analysis of Fgfr2IIIc expression by SYBR Green real time PCR at 2 and 4 days culture 
Cells were grown for 2 and 4 days in culture for Fgfr2IIIc expression studies. For each cell line the 
expression levels were normalised to that of the MC3T3 controls. A: Compared to MC3T3, the level of 
Fgfr2IIIc is higher in R2-C278F and R2-WT cells at 2 days. Fgfr2IIIc expression is also higher in R2-WT 
cells, compared to MC3T3 at 2 days. B: At 4 days in culture, there are no differences in the Fgfr2IIIc 
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Figure 5.4 Real time PCR analysis of Fgf18 expression in MC3T3, R2-WT and R2-C278F cells 
MC3T3, R2-WT and R2-C278F cells were cultured for 2 or 4 days. The level of Fgf18 expression was 
normalised to 18S. This  was  then normalised to an E13.5 mouse head calibrator to give a Relative 
Quantification (RQ) value. Fgf18 expression levels are not significantly different between cell lines at 2 
days in culture. However at 4 days, the level of Fgf18 expression in R2-C278F cells is significantly 
higher than in MC3T3 cells. In R2-WT cells, Fgf18 is significantly higher than both MC3T3 and R2-
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5.2.2  Erk1 protein levels increase relative to Erk2 in R2-C278F cells 
MAPK Erk1/2 is a downstream pathway essential for Fgf induced proliferation and 
differentiation in osteoblasts (Lai et al., 2001; Spector et al., 2005). To assess this pathway for 
changes during the proliferative phase in culture, Erk1/2 protein expression was measured at 2 
days in culture using FACS analysis. This revealed that the total Erk1/2 protein expression was 
significantly higher in R2-C278F cells than in both MC3T3 and R2-WT cells (Figure 5.5 A). To 
make an assessment of Erk1/2 activation, cells were fixed and the level of phospho-Erk (pErk) 
analysed by FACS. No significant differences were found in pErk1/2 between the cell lines 
(Figure 5.5 B). 
 
Erk1 and Erk2 protein expression was assessed in 2 and 4 day cultures by Western blotting and 
semi-quantified using Alpha tubulin. This showed no significant differences between the total 
level of Erk1/2 in each cell line, but a high variability between experiments was observed 
(Appendix Figure 8.9). The raw Alpha tubulin levels were carefully compared, using equal 
protein loading. This revealed that the level of Alpha tubulin was significantly higher in R2-
C278F cells compared to MC3T3 and R2-WT cells (Appendix Figure 8.9). The level of Alpha 
tubulin was also higher in R2-WT cells compared to MC3T3. To reduce the variability and 
compare the relative expression of Erk1 and Erk2, Erk1 was normalised to Erk2 to give a ratio 
between Erk1 and Erk2 protein expression, hereafter defined as the Erk1/Erk2 ratio. In R2-
C278F cells the Erk1/Erk2 ratio was higher than in MC3T3 at 2 days, at 0.61, 0.62 and 0.83, for 
MC3T3, R2-WT and R2-C278F respectively (Figure 5.6 A). At 4 days in culture the Erk1/Erk2 
ratio was still higher in R2-C278F with values of 0.83, 0.86 and 1.21, for MC3T3, R2-WT and 
R2-C278F respectively (Figure 5.6 B). There were no significant differences in the Erk1/Erk2 
ratio between MC3T3 and R2-WT cells at either 2 or 4 days in culture. 
 
Phosphorylation of Erk1/2 was analysed using Western blotting. The pErk1 band intensity was 
normalised to that of pErk2 to give the ratio of activation hereafter termed the pErk1/pErk2 
ratio. Cells were incubated for 10 minutes with the Protein Kinase C (PKC) activator phorbol 
12-myristate 13-acetate (PMA) before protein analysis in order to activate pErk1 and pErk2. 
PMA appeared to induce a small increase in pErk1/pErk2 activation in MC3T3 and R2-WT at 2 
days in culture, as shown by an increase in the pErk1 band intensity, but not in R2-C278F cells 
(Figure 5.7 A). Without activation, the pErk1/pErk2 ratios in untreated MC3T3, R2-WT and 
R2-C278F cells were approximately 0.4, 0.4 and 0.75, respectively (Figure 5.7 B). However 
there were not enough control samples for a proper statistical analysis to confirm that these 
ratios were different. Amongst the PMA treated groups, no significant differences were found in 
the pErk1/pErk2 ratio (Figure 5.7 B). At 4 days in culture the ratio of untreated R2-C278F was Chapter 5 FGF signalling in R2-C278F cells 
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significantly higher than in untreated MC3T3 and R2-WT (Figure 5.8 B). The PMA treatment 
did not significantly change the Erk1/Erk2 ratio between untreated and treated cells of the same 
cell line. No significant differences in ratios were found when the treated R2-C278F samples 
were compared to the treated MC3T3 and R2-WT samples. Interestingly, the ratio of treated R2-
WT remained significantly lower than the untreated R2-C278F. Chapter 5 FGF signalling in R2-C278F cells 
 




Figure 5.5 Erk1/2 and pErk1/2 in MC3T3, R2-WT and R2-C278F cells analysed by FACS 
MC3T3, R2-WT and R2-C278F cells were growth for 2 days in culture prior to FACS analysis. The 
average Erk1/2 and pErk1/2 fluorescence for each experiment was normalised to the value of the MC3T3 
control in order to analyse all the data together. A: The level of Erk1/2 in R2-C278F cells is significantly 
higher than in R2-WT and MC3T3 cells by approximately 1.5 fold. B: No significant differences are 
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Figure 5.6 Western blot analysis of Erk1/2 expression in MC3T3, R2-WT and R2-C278F cells 
A: Erk1/2 was detected in cells cultured for 2 or 4 days. α-Tubulin was used as a loading control B: 
Erk1/Erk2 ratio at 2 and 4 days in culture. The areas of Erk1 and Erk2 bands were measured by 
densitometry and the area of Erk1 divided by Erk2 to obtain the ratio shown in the graphs. Erk1/Erk2 
ratios are similar between MC3T3 and R2-WT cells, but significantly higher in R2-C278F than in the 
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Figure 5.7 Phospho-Erk expression ratios with PMA treatment in cells at 2 days in culture 
A: Western blotting of MC3T3, R2-WT and R2-C278F cells cultured for 2 days and treated with 50 
ng/ml of PMA 10 minutes prior to protein extraction. B: Densitometry analysis of pErk expression 
detected by western blot of pErk1/pErk2 in cells treated in (A). No significant differences were found 
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Figure 5.8  pErk expression ratios of PMA treated cells at 4 days in culture 
A: Western blotting of MC3T3, R2-WT and R2-C278F cells cultured for 4 days and treated with 50 
ng/ml of PMA 10 minutes prior to protein extraction. B: Densitometry of pErk1/pErk2 in cells treated in 
(A). Between the untreated groups, there is no significant difference in the pErk1/pErk2 ratio between 
MC3T3 and R2-WT cells, however in R2-C278F cells the Erk1/Erk2 ratio is significantly higher than in 
both controls. The ratio of pErk1/pErk2 between the untreated and PMA treatment groups of each 
respective cell line are not significantly different. The pErk1/pErk2 ratio is significantly higher in control 
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5.2.3 The  effect  of  FGF signalling manipulation on cell growth 
Blocking of FGFR2-C342Y signalling in mice has been shown to rescue suture obliteration 
normally found in craniosynostosis (Eswarakumar et al., 2006). As FGFR2-C278F is thought to 
constitutively signal (Hatch et al., 2006), it was hypothesised that there may be oversignalling of 
FGF. FGFR signalling was assessed with respect to proliferation with FGFR TK inhibitor 
SU5402 and measuring cell growth. FGF signals are transduced by downstream pathways such 
as Pkc and Erk1/2, which are both involved in osteoblast proliferation (Ghayor et al., 2005; Lai 
et al., 2001), therefore these pathways were assessed in a similar manner. MC3T3, R2-WT and 
R2-C278F cells were seeded in 96 well plates before treating the cells with reagents as 
described below. Cell proliferation (in terms of the number of cells) was inferred by the scale of 
optical density values, analysed from the methylene blue assay (Details in methods section 
3.1.6). 
 
Initial FGFR inhibition with SU5402 from 5 to 10 µM revealed that cell growth inhibition in all 
three cell lines was greater with a higher dose (Appendix Figure 8.12). SU5402 (5µM) was used 
in 10 and 1% FBS containing medium every 24 hours for 3 days. This resulted in decrease in 
cell proliferation in all three cell lines in both 10 and 1% serum (Figure 5.9 A and B). In 10% 
FBS cell culture medium, the percentage cell proliferation in SU5402 treated MC3T3, R2-WT 
and R2-C278F compared to their controls was 81, 69 and 52%, respectively.  
 
For inhibition of Erk1/2, the MEK1/2 inhibitor U0126 was added to the cells in 10% FBS 
containing medium every 24 hours and cell growth analysed at 1, 2 or 3 days. No significant 
changes in cell growth were observed after 1 day in culture (Figure 5.10 A). By 2 days in 
culture MC3T3, R2-WT and R2-C278F cells displayed a decrease in cell proliferation of 34, 29 
and 46% respectively (Figure 5.10 B). Decreased cell proliferation was also observed in MC3T3 
(35%), R2-WT (40%) and R2-C278F (58%) cells (Figure 5.10 C). 
 
Effective inhibition of Pkc activation was not easily attainable, as most inhibitors of Pkc can 
only bind to one or a few of the many Pkc isoforms. Thus, to further study the role of Pkc with 
respect to cell growth, the approach taken was to activate Pkc every 24 hours using PMA for 3 
days in 1% FBS containing culture medium. PMA cotreated with U0126 was carried out to 
investigate any possible relationship between Pkc and Erk1/2 pathways. These experiments 
revealed that both PMA and U0126 treatments can reduce cell growth in MC3T3 cells (Figure 
5.11 A). The cell growth was lower with a combination of PMA-U1026 than both untreated and 
PMA treated groups but this was not significantly different to U0126 alone. In R2-WT cells, 
treatment with PMA did not have any significant effect on cell growth (Figure 5.11 B). R2-WT Chapter 5 FGF signalling in R2-C278F cells 
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cell growth decreased with U0126 treatment and with the PMA-U0126 combination treatment, 
however no significant differences were found between these treatment groups. Following PMA 
treatment, cell growth increased in R2-C278F cells. U0126 treatment and the PMA U0126 
combination treatment significantly reduced cell growth compared to controls, however 
between these two treatment groups no significant differences were found (Figure 5.11 C). 
 
The effect of PMA was also tested in the presence of 10% FBS. At 3 days in culture with 10% 
serum, PMA did not significantly alter cell growth in MC3T3 and R2-WT cells, whereas it 
decreased cell growth in R2-C278F cells (Figure 5.12). Chapter 5 FGF signalling in R2-C278F cells 
 




Figure 5.9 Cell growth analysis by Methylene blue assay of SU5402 treated cells after 3 days 
MC3T3, R2-WT and R2-C278F cells treated with fresh medium containing 5 µM of SU5402 every 24 
hours for 3 days. Cell growth was indicated by the magnitude of the optical density in the Methylene blue 
assay. A: In 10% serum, SU5402 treatment causes a significant decrease in cell growth compared to the 
untreated controls in all three cell lines (n = 16, *p < 0.05). B: In 1% serum there is also a significant 
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Figure 5.10 Cell growth assessed by Methylene Blue assay in U0126 treated cells  
MC3T3, R2-WT and R2-C278F Cells were cultured and treated with 20µM of U0126 for 1, 2 and 3 days 
in 10% FBS containing culture medium prior to analysis. A: At 1 day, no significant differences in cell 
growth were found with U0126 treatment. B: By 2 days, U0126 treatment decreases cell growth in 
MC3T3, R2-WT and R2-C278F compared to the untreated controls. C: At 3 days, cell growth is also 
significantly decreased in U0126 treated MC3T3, R2-WT and R2-C278F cells compared to the controls 
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Figure 5.11 Effects of PMA and U0126 on cell growth in MC3T2, R2-WT and R2-C278F cells 
Cells were cultured with 1% FBS containing culture medium and treated with 50 ng/ml of PMA and 20 
µM U0126 every 24 hours for 3 days. A: PMA treatment reduces cell growth in MC3T3. With U0126 
treatment cell growth is reduced to a greater extent. U0126 treated cells do not show any significant 
differences compared with cells treated with both PMA and U0126. B: PMA treatment does not alter cell 
growth in R2-WT cells. U0126 and a combination of U0126 and PMA treatment induce a comparable 
decrease in cell growth. C: In R2-C278F cells, PMA increases cell growth. U0126 or U0126 and PMA 
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Figure 5.12 Cell growth in MC3T3, R2-WT and R2-C278F cells with PMA in 10% FBS medium 
Cells were seeded for 3 hours and treated every 24 hours with PMA in 10% FBS containing culture 
medium and grown for 3 days. Cell growth was analysed with the methylene blue assay. Treatment with 
PMA does not significantly affect cell growth in MC3T3 and R2-WT cells, but in R2-C278F cells there is 
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5.2.4  Morphology of MC3T3, R2-WT and R2-C278F cells treated with 
SU5402 and PMA 
The effect of SU5402 and PMA on cell morphology was examined in order to gain some 
information on the differentiation state of the cells. The cells were seeded and cultured in cell 
culture medium containing 1% FBS for three days, with a change of culture medium every 24 
hours. 
 
SU5402-treated MC3T3 cells appeared to have an increased number of processes per cell, 
compared to their untreated controls (Figure 5.13 A and B). Most control cells had one large 
process extending to a neighbouring cell, whereas with SU5402 treatment, many cells had a 
extended several thinner processes towards neighbouring cells. The PMA-treated MC3T3 cells 
were nearly all cuboidal in appearance as compared to the untreated group (Figure 5.13 A and 
C). 
 
There was some difference in the morphology of SU5402-treated R2-WT cells in that there 
were more cells with a larger number of processes, but not as obviously as in MC3T3 cultures 
(Figure 5.14 A and B). There appeared to be a slight increase in the proportion of cuboidal cells 
in the PMA treated R2-WT cells and their distribution and arrangement appeared to be similar 
to the untreated controls (Figure 5.14 A and C). 
 
SU5402 treatment visibly reduced the number of cells in R2-C278F cultures. The morphology 
appeared unchanged; however there were visibly fewer cells. Cells treated with PMA appeared 
to contain a higher proportion of cuboidal cells than controls (Figure 5.15 A and B). 
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Figure 5.13 Phase contrast images of MC3T3 cells treated with SU5402 or PMA for 3 days 
Cells were treated with PMA (10 ng/ml) or SU5402 (5 µM) in cell medium with 1% FBS every 24 hours 
for 3 days in culture before imaging at 5x magnification. A, C and E:  Untreated, SU5402-treated and 
PMA-treated cells respectively.  B, D and F: The 4x enlargement of A, C and E respectively. SU5402-
treated cells (D) have shorter and finer processes than the controls (arrows) (B). PMA treated cells (F) 
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Figure 5.14 Phase contrast images of R2-WT cells treated with SU5402 or PMA for 3 days 
Cells were treated with PMA (10 ng/ml) or SU5402 (5 µM) in cell medium with 1% FBS every 24 hours 
for 3 days in culture before imaging at 5x magnification. A, C and E: Untreated, SU5402-treated and 
PMA-treated cells respectively.  B, D and F: 4x enlargement of A, C and E respectively. Compared to the 
controls (B), SU5402-treated cells appear to have more processes. Cell morphology in PMA-treated cells 
(F) are slightly more cuboidal than the untreated controls (B), but they still maintain a similar distribution 
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Figure 5.15 Phase contrast images of R2-C278F cells treated with SU5402 or PMA for 3 days 
Cells were treated with PMA (10 ng/ml) or SU5402 (5 µM) in cell medium with 1% FBS every 24 hours 
for 3 days in culture before imaging at 5x magnification. A, C and E: Untreated, SU5402 treated and 
PMA treated cells respectively.  B,  D and F: 4x enlargement of A, C and E respectively. SU5402 
treatment (D) results in a visible decrease in the cell density than in controls (B). More rounded cells are 
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5.3 Discussion 
5.3.1 FGFR2-C278F  alters  Fgf18 and FGFR2IIIc expression 
Fgf1, -2 and -18 are the main Fgfs involved in bone formation that also bind to endogenous 
Fgfr2IIIc, therefore the expression of these ligands and the receptor would be useful indications 
of endogenous changes in response to aberrant signalling from FGFR2-C278F. 
 
Fgf1 and -2 expressions were undetectable in all three cell lines by RT-PCR (Figure 5.1 and 
Figure 5.2). A real time PCR analysis performed later in Chapter 6 revealed a low level of gene 
expression, which suggests that although Fgf1 and -2 are involved in bone development, they do 
not play a main role producing the R2-C278F phenotype shown in Chapter 4. 
 
Fgf18 is expressed in all three cell lines, suggesting that it has a significant role in FGF 
signalling in osteoblasts in culture. Fgf18 is important for osteoblast proliferation and 
differentiation (Ohbayashi et al., 2002). Neither FGFR2-WT nor FGFR2-C278F expression in 
MC3T3 significantly affects Fgf18 expression at preconfluence, suggesting Fgf18 expression 
per se is not related to the low proliferation in R2-C278F cells (Figure 5.4). Fgf18 expression is 
upregulated by FGFR2-WT and FGFR2-C278F at confluence, indicating that Fgf18 may play a 
role in the late stage of differentiation of R2-WT and R2-C278F cells. It has been shown that 
Fgf18 can drive differentiation by Osteopontin (Opn) and Osteocalcin (Oc) expression (Liu et 
al., 2002). As Fgf18 expression is higher in R2-WT cells than R2-C278F cells, this suggests the 
ligand’s expression is finely controlled by FGFR2 signalling. 
 
Fgfr2IIIc expression decreases in differentiating osteoblasts (Iseki et al., 1999). From these 
reports it was expected that in R2-C278F cells Fgfr2IIIc expression would be lower due to 
expression of FGFR2-C278F and increased differentiation as shown in Chapter 4. In this study, 
the level of Fgfr2IIIc expression increases in both R2-WT and R2-C278F cells at 2 days in 
culture (Figure 5.3 A), suggesting that FGFR2 signalling may positively regulate itself. At 
confluence, there is no difference in Fgfr2IIIc expression amongst all three cell lines (Figure 5.3 
B), indicates that FGFR2 signalling is not the main factor controlling Fgfr2IIIc expression at the 
stage in culture. Fgfr2IIIc may be downregulated in differentiating osteoblasts following 
exogenous Fgf2, which is also known to activate other FGFRs (Iseki et al., 1999; Mathy et al., 
2003). 
 
Together, these data suggest that Fgf signalling in R2-C278F cells is altered via increased 
Fgfr2IIIc expression at preconfluence and increased Fgf18 at confluence. As temporally the 
expressions do not coincide, both ligand and receptor may have different roles. Chapter 5 FGF signalling in R2-C278F cells 
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5.3.2 FGFR and Erk1/2 signalling with regard to proliferation is 
reduced in R2-C278F cells 
SU5402 was initially considered as an FGFR1 specific TK blocker, however other studies have 
provided evidence that it actually blocks the TK domains of FGFR1-3 (Mohammadi et al., 
1997; Paterson et al., 2004; Bernard-Pierrot et al., 2004; Zhang et al., 2007). As discussed in 
Chapter 1, FGFR2 is the main isoform associated with osteoblast proliferation (Iseki et al., 
1999; Ratisoontorn et al., 2003). Treatment with SU5402 reduced proliferation in MC3T3 and 
R2-WT cells, indicating that FGFR signalling is mitogenic (Figure 5.9). Furthermore, the level 
of cell growth decreases to a greater degree by SU5402 treatment in R2-C278F cells, than in 
both MC3T3 and R2-WT cells (Figure 5.9). This suggests that R2-C278F cells have a lower 
level of FGFR2 signalling than MC3T3 and R2-WT, given that FGFR2 signalling is normally 
proliferative. 
 
The reduced FGFR2 signalling suggested above may be mediated by Erk1/2, as it is 
downstream of FGF and plays a positive role with respect to osteoblast proliferation (Lai et al., 
2001; Kapur et al., 2003) Erk1/2 inhbition with U0126 resulted in a greater percentage 
reduction in R2-C278F cell growth compared to controls (Figure 5.10), suggesting that Erk1/2 
signalling is also lower in the mutant cells. 
 
5.3.3  The effect of SU5402 on osteoblast morphology 
SU5402 reduced the number of large processes in MC3T3 and R2-WT cells and increased the 
number of small processes (Figure 5.13 B and D, Figure 5.14 B and D). R2-C278F do not have 
the cell morphology described in SU5402 treated MC3T3 and R2-WT cells, indicating that the 
effect of FGFR2-C278F on morphology is not directly equivalent to a lower level of FGFR 
signalling. In fact SU5402 had a similar effect in R2-C278F cells, although less apparent 
(Figure 5.15 B and D). It is possible that signalling from other FGFR isoforms may contribute 
to process formation and size in osteoblasts. FGFR signalling affects the number of processes in 
other cell types, for exmple in dorsal marginal zone (DMZ) cells during gastrulation where there 
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5.3.4  Pkc induced cell growth in R2-C278F cells is Erk1/2 dependent 
The PKC pathway can mediate cell proliferation and differentiation. PKC activation by Phorbol 
12-myristate 13-acetate (PMA) has been suggested to increase proliferation in MC3T3 cells 
(Kozawa et al., 1989). DMSO induced PKC activation may induce differentiation in MC3T3 
cells (Cheung et al., 2006). 
 
Interestingly cell growth after PMA treatment in 1% FBS culture medium decreases in MC3T3, 
has no significant effect in R2-WT cells and increases in R2-C278F cells. This indicates that 
Pkc signalling is different in each of the three cell lines. A possible reason for the differences in 
proliferative effect between the literature and this study could be the duration of PKC 
stimulation and the type of analysis. Cell growth was measured after 2 days in this study, 
whereas DNA synthesis analysis was performed at 22 and 24 hours, respectively (Kozawa et al., 
1989; Villa et al., 2003). PMA induced cell growth in R2-C278F cells is blocked by Erk1/2 
inhibition, indicating the effect is dependent on Erk1/2 signalling (Figure 5.11), which is 
consistent with another report showing that PKC induced cell proliferation is Erk1/2 dependent 
in MC3T3 (Ghayor et al., 2005). In 10% serum conditions, PMA had no effect on cell growth in 
MC3T3 and R2-WT cells, whereas in R2-C278F cells it decreased. This suggests that the 
effects of Pkc on proliferation are modulated by serum components. 
 
5.3.5 The  effect  of  PMA on cell morphology 
The PMA treatment induced an almost ubiquitous change to cuboidal morphology in MC3T3 
cultures, which may also indicate a strong induction to differentiation (Figure 5.13 B and F).  In 
R2-WT cells there was also a change to cuboidal morphology, although in to a lesser degree, 
which may indicate that the FGFR2 signalling may block or interfere with the differentiation 
signals by PKC. Interestingly R2-C278F cells have an appearance similar to those in PMA 
treated MC3T3 and Pkc treatment of R2-C278F cells slightly increases the amount of cuboidal 
cells. It is possible that R2-C278F cells have increased stimulation via Pkc, which could be 
investigated. This data supports the suggestion in the last section, that there is a difference in the 
PKC signalling between MC3T3, R2-WT and R2-C278F. PMA induces differentiation by 
activation of Osteocalcin in human osteoblast-like cells (Opperman et al., 1997), which might 
provide a clue to why osteoblasts appear to be more differentiated in morphology. Further 
investigation of PKC induction of differentiation markers such as osteocalcin may yield more 
information regarding the way in which PKC may have changed osteoblast behaviour. 
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5.3.6  Erk1/2 expression and activation is affected in R2-C278F cells 
Erk1/2 activation is essential for osteoblast cell growth and differentiation (Lai et al., 2001), 
both of which are altered in R2-C278F cells, but how Erk1/2 performs both functions is less 
clear. Erk1/2 signalling with respect to proliferation depends on the relative amount of the Erk1 
compared to the Erk2 isoforms (Pouyssegur and Lenormand, 2003; Vantaggiato et al., 2006). In 
addition, the timing of Erk1/2 signalling such as short term, sustained and oscillating, may all 
lead to different phenotypical outcome (Nakayama et al., 2008). The effects may also be cell 
type specific, for example late and sustained Erk1/2 activation induces fibroblast proliferation, 
whereas sustained Erk1/2 activation causes growth arrest and differentiation in PC12 
pheochromocytomas cells (Chambard et al., 2007). Other factors such as cross talk of Erk1/2 
with Akt may also contribute, but investigation of this idea is beyond the scope of this thesis 
(Raucci et al., 2008). 
 
The level of Erk1/2 protein is higher in R2-C278F cells than in MCT3 and R2-WT cells (Figure 
5.5 A), however FACS analysis of pErk1/2 in fixed osteoblasts did not show any significant 
differences in Erk1/2 activation. This suggests that the basal level of Erk1/2 activation is not 
limited by the Erk1/2 protein expression in all three cell lines (Figure 5.5 B). One research 
group has suggested that MAPK activation levels do not differ between the constitutively active 
FGFR mutants and controls, because of a rapid turnover of the pErk1/2, making protein 
activation assessments more difficult (Mansukhani et al., 2000). 
 
The total increase in Erk1/2 and in Erk1 expression relative to Erk2 in R2-C278F cells is very 
interesting and consistent with the change in cell behaviour. In different cellular structures of 
the brain,  different ratios of Erk1 to Erk2 naturally occur, implicating different and specific 
types of Erk1/2 signalling, that are as yet undefined (Ortiz et al., 1995). Although Erk1 and 
Erk2 are part of the same signalling pathway, they have distinct roles with respect to 
proliferation (Fremin et al., 2007; Pouyssegur and Lenormand, 2003; Vantaggiato et al., 2006). 
Erk2 is vital for proliferation in MC3T3 osteoblasts, NIH3T3 fibroblasts, and hepatocytes 
(Fremin et al., 2007; Lai et al., 2001; Vantaggiato et al., 2006). Erk1 is not responsible for 
proliferation in hepatocytes and only weakly induces proliferation in NIH3T3 fibroblasts with a 
lack of Erk2 (Fremin et al., 2007; Lefloch et al., 2008). In NIH3T3 fibroblasts, Erk1 
overexpression experiments have indicated that either normal or kinase inactive Erk1 
competitively inhibits Erk2 activation by Ras (Lai et al., 2001). Moreover shRNA silencing of 
Erk1 increased NIH3T3 cell proliferation, highlighting an inhibitory role of Erk1 upon Erk2 
proliferation (Vantaggiato et al., 2006). Collectively these data suggest that Erk2 is essential for 
proliferation, whereas Erk1 does not play a major role in proliferation, but inhibits Erk2 by Chapter 5 FGF signalling in R2-C278F cells 
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competing with Erk2 for activation. The increase in Erk1 relative to Erk2 appears to correlate 
with the observed effects on fibroblasts and hepatocytes in the literature, and it is possible that 
Erk1 competes with Erk2 for activation, resulting in a defect in R2-C278F cells proliferation, 
due to lowering the level of Erk2 activation for a given upstream stimulus. Interestingly, the 
Erk1/Erk2 ratio is still higher in R2-C278F cells at confluence compared to MC3T3 and R2-WT 
cells, suggesting that this Erk1/Erk2 ratio may also have an involvement in cell differentiation. 
To date, Erk1/2 inhibition with a dominant negative Erk1 has blocked osteoblast differentiation, 
indicating that Erk1 and/or Erk2 is required for osteoblast differentiation (Lai et al., 2001).  
 
Stoichiometric analysis of Erk1/2 has shown that the ratio of Erk1/Erk2 correlates with the ratio 
pErk1/pErk2 (Lefloch et al., 2008). In this study, the analysis of ratios by Western blotting was 
not stoichiometric, as the value of the ratios could be affected by the differences in binding 
affinity of the anti-Erk1/2 and anti-pErk1/2 antibodies to Erk1 and Erk2. If in this model a 
stoichiometric relationship exists, a raised Erk1/Erk2 ratio in R2-C278F cells would also result 
in a raised pErk1/pErk2 ratio in R2-C278F compared to both controls. Although a statistical test 
could not be applied, the pErk1/pErk2 ratios in untreated cells at 2 days in culture appeared to 
be higher in R2-C278F cells than in MC3T3 and R2-WT cells (Figure 5.7). In untreated cells at 
4 days in culture, the pErk1/pErk2 ratio was significantly higher compared to MC3T3 and R2-
WT (and Figure 5.8). 
 
In summary, an important effect of the FGFR2-C278F mutation in MC3T3 is that Erk1/2 
signalling is altered. The increase in Erk1/Erk2 ratio leads to an increased pErk1/pErk2 ratio, 
which correlates with a shift toward growth arrest as less Erk2 will be activated for a given level 
of stimulation. As Erk1/2 positively regulates osteoblast differentiation, it is possible that Erk1 
is the isoform that induces differentiation. 
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5.4 Conclusions 
It has been confirmed that FGF signalling is altered in R2-C278F cells. There is a raised 
Fgfr2IIIc gene expression in R2-C278F cells at preconfluence, which may compensate for 
impaired Fgfr2 signalling, as indicated by FGFR inhibition with SU5402. Furthermore there is a 
reduction Erk1/2 signalling (as suggested by Erk1/2 inhibition with U0126) and an increased 
Erk1/Erk2 ratio. These effects are indicated to contribute to decreased cell proliferation. 
 
At confluence, FGF signalling is altered in R2-C278F cells by an increase in Fgf18 expression.  
Fgf18 may be associated with increased differentiation, because it can induce Osteocalcin (Oc) 
expression, which is raised in R2-C278F cells. At this stage in culture the Erk1/Erk2 ratio is 
increased and Pkc signalling is also altered. Pkc signalling in R2-C278F cells is speculated to be 
increased, because in human SG12 osteoblasts Pkc activation with PMA induces Osteocalcin 
expression (Boguslawski et al., 2000), which was raised in R2-C278F cells (as shown in 
Chapter 4) and that Pkc activation by PMA induces a shift from fibroblastic morphology 
observed in MC3T3 cells to the more cuboidal morphology of R2-C278F cells. 
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Chapter 6  TGFbeta signalling in R2-C278F cells 
6.1 Introduction 
The TGFbetas are important in both bone and suture formation and maturation (Lee et al., 2006; 
Opperman et al., 1997; Opperman et al., 2000; Opperman et al., 2002a; Opperman et al., 
2002b). Addition of TGFbeta in-vivo induces rapid closure of skull defects (Beck et al., 1991), 
however TGFbeta mutations have not been reported to result in craniosynostosis except for one 
case of a patient with TβRI-D400G (Loeys et al., 2005). Studies of calvarial cultures indicate 
that the addition of TGFbeta3 into sutures may inhibit or delay suture fusion, whereas addition 
of TGFbeta2 into the same region may accelerate suture fusion (Opperman et al., 2000). It has 
been suggested that TGFbeta plays a secondary role in sutural morphogenesis and is part of a 
complex multiple regulated mechanism (Cabiling et al., 2007). Together, these reports suggest 
that TGFbetas may contribute, but are not essential to suture maintenance and fusion. TGFbeta 
signalling via TβRII is essential for frontal bone and the caudal region of the skull (Hosokawa et 
al., 2007; Sasaki et al., 2006). Interestingly CNC cell proliferation induced by TGFbeta 
signalling is mediated by FGF signalling. 
 
In bone development, the TGFbetas regulate bone formation and resorption by influencing 
osteoblast and osteoclast development respectively (Filvaroff et al., 1999). In osteoblasts, the 
TGFbetas are involved in proliferation, differentiation. For example TGFbeta1 increases early 
proliferation and inhibits late stage differentiation and mineralisation (Alliston et al., 2001; 
Centrella et al., 1994). TGFbeta2 and -3 may also increase pre-osteoblast proliferation (Bosetti 
et al., 2007; Centrella et al., 1994; Opperman et al., 2000). Though TGFbetas are well known to 
signal via the SMAD downstream pathways (Miyazawa et al., 2002), they also activate MAPK 
and PKC pathways (Ghayor et al., 2005; Lee et al., 2002; Sowa et al., 2002). One of the 
complex mechanisms in osteoblasts are the interactions between TGFbeta and FGF, such as 
FGF induced TGFbeta1 expression (Noda and Vogel, 1989). FGFR2-C278F signalling, 
suggested in Chapter 5, alters FGF signalling, therefore FGF-TGFbeta interactions may also be 
altered in R2-C278F cells. As FGF and TGFbeta signalling can converge along MAPK and 
PKC downstream pathways, investigation of their interactions may be performed using 
TGFbeta treatment and inhibition with respect to cell proliferation and differentiation. 
 
The first aim of this chapter is to find whether FGF-TGFbeta interactions are altered by the 
FGFR2-C278F mutation. The second aim is to identify where these interactions occur using 
TGFbeta treatment and inhibition on R2-C278F cells.   Chapter 6 TGFbeta signalling 
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6.2 Results 
6.2.1  TGFbeta expression in MC3T3, R2-WT and R2-C278F cells 
To make an assessment of the level of TGFbeta signalling, expression of the Tgfbeta1, -2 and -3 
transcript was analysed at 2 and 4 days in culture using real time PCR. TGFbetas, like BMPs 
signal via the SMAD pathway (Miyazawa et al., 2002). In general, TGFbeta is known to signal 
via SMAD2 and -3, whereas BMPs activate SMAD1, -5 and -8; however TGFbeta has also been 
known to signal via SMAD1 and -5. Therefore, Smad1 and -2 expressions were measured by 
real time PCR in order to investigate the downstream pathways of Tgfbeta and Bmp. 
 
Tgfbeta1 expression was significantly lower in R2-C278F cells than in MC3T3 and R2-WT 
cells at both 2 and 4 days in culture (Figure 6.1 A). There were no significant differences in 
Tgfbeta1 expression between MC3T3 and R2-WT cells. Tgfbeta2 levels appeared to be low 
compared to the E13.5 mouse head, but was present in all three cell lines and no significant 
differences in expression were found amongst the three cell lines at 2 or 4 days in culture 
(Figure 6.1 B). Tgfbeta3 expression was significantly lower in R2-C278F cells compared to 
MC3T3 and R2-WT cells at 2 and 4 days in culture (Figure 6.1 C). In R2-WT cells the 
TGFbeta3 expression was also significantly lower than in MC3T3 cells. 
 
No significant differences in Smad1 expression were found between the three cell lines at 2 
days. (Figure 6.2 A). At 4 days, the pattern of Smad1 expression in all three cell lines was 
similar to that at 2 days, with no significant differences to report. 
 
Smad2 expression at 2 days was not significantly different between MC3T3 and R2-C278F 
cells, but in R2-WT cells Smad2 expression was higher than in R2-C278F cells (Figure 6.2 B). 
At 4 days, no significant difference in Smad2 expression was found between the three cell lines. 
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Figure 6.1 Real time PCR analysis of Tgfbeta1, -2 & -3 in MC3T3, R2-WT and R2-C278F cells 
Cells were cultured for 2 and 4 days before relative quantification (RQ) of Tgfbeta expressions. A: 
Compared to MC3T3 and R2-WT cells, Tgfbeta1 expression is significantly lower in R2-C278F cells at 2 
and 4 days in culture. B: Tgfbeta2 expression is not significant different between the three cell lines at 2 
or 4 days. C: Tgfbeta3 expression is lower in R2-C278F cells at 2 and 4 days than in both controls. At 4 
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Figure 6.2 Real time PCR analysis of Smad1 & -2 in MC3T3, R2-WT and R2-C278F cells 
Cells were grown for 2 and 4 days in culture before relative quantification (RQ) of gene expression by 
real time PCR. A: No significant differences in Smad1 expression were found between MC3T3, R2-WT 
and R2-C278F cells at 2 and 4 days in culture (n = 3). B: At 2 days, MC3T3 and R2-C278F cells do not 
show any significant differences in Smad2 expression, however in R2-WT cells the level of Smad2 
expression is significantly higher compared to R2-C278F cells. At 4 days there are no significant 
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6.2.2 Effects  of  exogenous  TGFbeta1 on cell morphology 
Of the TGFbetas in osteoblasts, TGFbeta1 was used as a candiate treatment in this chapter, due 
to its reported mitogenic effects and also its inhibition of late differentiation. MC3T3, R2-WT 
and R2-C278F cells were grown in T25 flasks were treated with 1, 10 and 20 ng/ml of 
recombinant human TGFbeta1 every 24 hours for 2 or 4 days in culture, before capturing phase 
contrast images. As TGFbeta1 was suspended in 1 mg/ml BSA in 4mM HCl, this was used as a 
BSA control for the effects of the solvent. 
 
In MC3T3 cells at 2 days there were no morphological differences between untreated and BSA 
control cultures in MC3T3 cells (Figure 6.3 A and B). All levels of TGFbeta1 treatment led to 
an increased number of bright round cells, which did not appear to be dose dependent (Figure 
6.3 C, D and E). No other morphological differences were found between the treated and 
untreated MC3T3 cells. Untreated and BSA controls in R2-WT cultures were similar in 
morphology at 2 days (Figure 6.4 A and B). No morphological changes were observed with any 
of the TGFbeta1 treatments compared to the controls (Figure 6.4 A, B, C, D and E). In R2-
C278F cultures at 2 days, untreated and BSA controls were morphologically similar (Figure 6.5 
B). No noticeable differences were found between TGFbeta1 treated R2-C278F cells and their 
controls (Figure 6.5 A, B, C, D and E). 
 
At 4 days in MC3T3 cells, both the untreated and BSA control cultures reached confluence and 
did not appear to be different to each other (Figure 6.6 A and B). Similarly, all TGFbeta1 
treated cultures reached confluence and interestingly there was an increase in the number of 
bright apoptotic figures, which appear like bright round cells, but without a dark centre (Figure 
6.6 C, D and E). Under the microscope, the number of apoptotic figures did not appear to be 
correlated with the dose. In R2-WT cells no differences were observed between the untreated 
and the BSA control cultures, which were both confluent at 4 days (Figure 6.7 A and B). 
TGFbeta1 treated R2-WT cells also reached confluence and interestingly the morphology was 
markedly different, as demonstrated by the presence of many cells of thin elongated cells 
arranged in striae (Figure 6.7 A, B, C , D, and E). All three concentrations of TGFbeta1 
treatment affected cell morphology in the same fashion. In R2-C278F cells, the untreated and 
BSA controls were almost 100% confluent at 4 days and there were no differences in 
morphology between the two groups (Figure 6.8 A and B). The TGFbeta1 treated R2-C278F 
cells were also near confluence, but there was a great increase in the number of bright round 
cells figures and an increase in the number of spaces between the cells (C, D and E). Both cell 
density and number of bright round cells did not appear to depend on the dose of TGFbeta1 
used.   Chapter 6 TGFbeta signalling 
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Figure 6.3 Phase contrast microscopy of TGFbeta1 treated MC3T3 cells at 2 days in culture 
Cells were treated TGFbeta1 every 24 hours for 2 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. Treatment with TGFbeta1 may increase the 
number of round bright cells (black arrows), (n = 3, bar = 50 µm). 
A  Untreated B BSA control
C  1 ng/ml  D 10 ng/ml 
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Figure 6.4 Phase contrast microscopy of TGFbeta1 treated R2-WT cells at 2 days in culture 
Cells were treated TGFbeta1 every 24 hours for 2 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. Cell morphology is the same in the controls 
(A and B) as compared to TGFbeta1 treated samples (C-E), (n = 3, bar = 50 µm). 
A  Untreated B BSA control
C  1 ng/ml  D 10 ng/ml 
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Figure 6.5 Phase contrast microscopy of TGFbeta1 treated R2-C278F cells at 2 days in culture 
Cells were treated TGFbeta1 every 24 hours for 2 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. Control cell morphology (A and B) are the 
same as with TGFbeta1 treatment (C-E), (n = 3, bar = 50 µm).  
A  Untreated B BSA control
C  1 ng/ml  D 10 ng/ml 
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Figure 6.6 Phase contrast microscopy of TGFbeta1 treated MC3T3 cells at 4 days in culture 
Cells were treated TGFbeta1 every 24 hours for 4 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. More bright apoptotic figures (black 
arrows) are found in TGFbeta1 treated cells (C-E) than in controls (A and B). (n = 3, bar = 50 µm). 
A  Untreated B BSA control
C  1 ng/ml  D 10 ng/ml 
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Figure 6.7 Phase contrast microscopy of TGFbeta1 treated R2-WT cells at 4 days in culture 
Cells were treated TGFbeta1 every 24 hours for 4 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. Treated cells (C, D and E) are more aligned 
(black arrows) compared to untreated controls (A and B), (n = 3, bar = 50 µm). 
A  Untreated B BSA control
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Figure 6.8 Phase contrast microscopy of TGFbeta1 treated R2-C278F cells at 4 days in culture 
Cells were treated TGFbeta1 every 24 hours for 4 days. A and B: Untreated and BSA control. C, D, and 
E: Treated with TGFbeta1 at 1, 10 and 20 ng/ml respectively. TGFbeta1 treated cells (C-E) have many 
apoptotic figures (black arrows), than in the controls (A and B), (n = 3, bar = 50 µm). 
A  Untreated B BSA control
C  1 ng/ml  D 10 ng/ml 
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6.2.3  The effect of TGFbeta1 and U0126 on cell morphology 
To assess whether the morphological changes previously observed with TGFbeta1 were 
dependent on the Erk1/2 pathway, U0126 was used to inhibit Erk1/2 when cells were treated 
with TGFbeta1. MC3T3, R2-WT and R2-C278F cells were cultured in 96 well plates and 
treated with 10 ng/ml of TGFbeta1 and 10 µM of U0126 in 1 % serum. The treatment was given 
every 24 hours for 3 days.  Images were then taken in phase contrast. 
 
MC3T3 cell morphology did not change with TGFbeta1 at 3 days (Figure 6.9 A and B). Erk1/2 
inhibition with U0126 treatment led to visibly fewer cells and a decrease in cells with 
fibroblastic morphology (Figure 6.9 C). The cell morphology in the TGFbeta1 and U0126 
combined treatment group was indistinguishable from the U0126 treated group (Figure 6.9 D). 
 
In R2-WT cells, there was no obvious change in morphology with TGFbeta1 treatment at 3 days 
(Figure 6.10 A and B). With U0126 treatment there were visibly fewer cells and the cell 
morphology was less fibroblastic and more cuboidal (Figure 6.10 C). The same effects were 
observed with the TGFbeta1-U0126 combined treatment (Figure 6.10 D). 
 
The morphology of R2-C278F cells at 3 days did not appear to change with TGFbeta1 treatment 
(Figure 6.11 A and B). With U0126 treatment, the cell morphology was less fibroblastic than in 
the untreated control (Figure 6.11 C). Interestingly with both TGFbeta1 and U0126 treatments 
there were more cells with a rounded morphology than in the U0126 treated group (Figure 6.11 
D).   Chapter 6 TGFbeta signalling 
  




Figure 6.9 Phase contrast images of MC3T3 cells treated with TGFbeta1 and U0126 in 1% serum 
Untreated cells (A) and TGFbeta1 treated cells (B) have a similar morphology. U0126 treatment (C) 
markedly reduces the number of cells, particularly fibroblastic cells. The number of cells and their 
morphology in the TGFbeta1 + U0126 treatment group (D) is similar to (C) the U0126 treatment group (n 
= 3, bar = 50 µm). 
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Figure 6.10 Phase contrast images of R2-WT cells treated with TGFbeta1 and U0126 
Untreated (A) and TGFbeta1 treated cells (B) were similar in morphology. U0126 treatment (C) led to a 
visible loss of cells, especially cells with fibroblastic morphology. The combination of TGFbeta1 and 
U0126 treatment (D) also led to a reduction in the number of cells, particularly fibroblastic-like cells (n = 
3, bar = 50 µm). 
 
 
Untreated  TGFbeta1 10ng/ml 
U0126 20µM  TGFbeta1 + U0126 
A B
C  D  Chapter 6 TGFbeta signalling 
  
  165 
 
 
Figure 6.11 Phase contrast microscopy of R2-C278F cells treated with TGFbeta1 and U0126 
Morphology of TGFbeta1 treated cells are less fibroblastic (B) compared to the untreated controls (A). 
U0126 treatment (C) reduces the number of fibroblastic cells and the number of cellular processes. The 
effect of TGFbeta1 and U0126 treatment (D) induces a greater loss of fibroblastic cells (n = 3, bar = 50 
µm). 
Untreated  TGFbeta1 10ng/ml 
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6.2.4 Effects  of  exogenous TGFbeta1 on Fgf expression 
Fgf1,  -2 and -18 expressions were analysed in MC3T3, R2-WT and R2-C278F cells to 
investigate whether TGFbeta1 interacts with FGF signalling by altering expression of these 
ligands. Three hours after seeding, cells were treated with 10 ng/ml of TGFbeta1 every 24 hours 
for either 2 days or 4 days in culture. 
 
Analysis by Real Time RT-PCR at 2 days revealed that Fgf1 was barely detectable particularly 
in the R2-WT and R2-C278F cells, with a high cycle threshold (CT) value (35 cycles) and in 
some cases it was undetectable (Figure 6.12 A). When untreated groups were compared, the 
level of Fgf1 was significantly higher in R2-WT cells than in MC3T3 and R2-C278F cells. 
Treatment with TGFbeta1 did not statistically change the expression of Fgf1. 
 
At 2 days, Fgf2 expression was also very low in all three cell lines and there was no significant 
change in Fgf2 expression with TGFbeta treatment (Figure 6.12 B). The levels of Fgf2 were not 
significantly different between cell lines. 
 
A significant increase in Fgf18 expression was found at 2 days in MC3T3 and R2-C278F cells 
after TGFbeta1 treatment, but not in R2-WT cells (Figure 6.13 A). At 4 days, after TGFbeta1 
treatment, Fgf18 expression also increased in MC3T3, but not in R2-WT or R2-C278F cells 




   Chapter 6 TGFbeta signalling 
  
  167 
 
 
Figure 6.12 Real time PCR analysis of Fgf1 and -2 expressions in TGFbeta1 treated cells 
Cells were grown for 2 days in culture with 10 ng/ml of TGFbeta1 before relative quantification (RQ) of 
gene expression by real time PCR. A: Fgf1 is expressed at very low levels in all three cell lines and 
Tgfbeta1 treatment in each cell line does not induce any significant changes compared to their respective 
untreated controls. The level of Fgf1 in untreated R2-WT cells is significantly higher than in both 
untreated MC3T3 and R2-C278F cells. B: Fgf2 is barely detectable in all three cell lines. No significant 
differences in Fgf2 expression were found between cell lines. TGFbeta1 treatment did not alter Fgf2 
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Figure 6.13 Real time PCR analysis Fgf18 with TGFbeta1 treatment 
MC3T3, R2-WT and R2-C278F cells were treated with 10 ng/ml of TGFbeta1 every 24 hours for 2 or 4 
days. For each cell line the expression levels were normalised to the untreated controls. A: At 2 days in 
culture, TGFbeta treatment significantly increases Fgf18 in MC3T3 and R2-C278F, but not in R2-WT 
cells. B: Fgf18 is also increased in MC3T3 with treatment at 4 days in culture. No significant changes are 
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6.2.5 Effects  of  Exogenous TGFbeta1 on cell growth 
Tgfbeta1 may induce proliferation in osteoblast cells (Reyes-Botella et al., 2002). As low 
TGFbeta1 expression was found in R2-C278F, exogenous TGFbeta1 was used to determine 
whether the R2-C278F cell proliferation could be increased. Cells were seeded onto a 96 well 
plate and treated with 10 ng/ml of TGFbeta1 in 10% FBS every 24 hours for 1, 2 and 3 days 
before cell growth analysis using the methylene blue assay. Untreated controls were cultured in 
normal cell culture medium with 1  mg/ml BSA in 4 mM HCl, the solution for TGFbeta1 
suspension. This experiment was repeated with 10 ng/ml of TGFbeta1 treatment in cell culture 
medium containing 1 % FBS, after seeding in 10 % FBS for 3 hours. 
 
After 1 day, TGFbeta treatment induced significantly more cell growth in MC3T3, whereas in 
R2-WT and R2-C278F cells there was no significant increase in cell growth (Figure 6.14 A). By 
2 days, cell growth significantly increased in both MC3T3 and R2-WT with TGFbeta treatment, 
but there was no change in R2-C278F cells (Figure 6.14 B). In MC3T3 and R2-WT at 3 days 
there was still a significant increase in cell growth, however no change was found in R2-C278F 
cells. 
 
In 1% serum after 1 day of TGFbeta treatment, no significant increase in cell growth was 
observed in any of the three cell lines (Figure 6.15 A). By 2 days, TGFbeta1 treatment resulted 
in significantly increased cell growth in MC3T3, R2-WT and R2-C278F cells (Figure 6.15 B). 
At 3 days in culture, all three cell lines showed a significant increase in cell growth when treated 
with TGFbeta1 (Figure 6.15 C). 
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Figure 6.14 Methylene blue analysis of TGFbeta1 treated MC3T3, R2-WT and R2-C278F cells 
Cells were cultured in 10% FBS containing serum and treated with 10 ng/ml TGFbeta1 every 24 hours for 
1, 2 or 3 days. By 1 day (A) there is a significant increase in cell growth in MC3T3 after TGFbeta 
treatment, but not in R2-WT and R2-C278F cells. By 2 and 3 days (B and C), the treated groups in both 
MC3T3 and R2-WT cells showed increased cell growth, whereas there was no difference between treated 
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Figure 6.15 Methylene blue analysis of TGFbeta1 treated cells in 1% FBS 
MC3T3, R2-WT and R2-C278F cells were treated with 10 ng/ml TGFbeta1  in 1% FBS containing 
culture medium every 24 hours for 1, 2 or 3 days. By 1 day (A), TGFbeta does not significantly affect cell 
growth in any of the three cell lines. At 2 and 3 days (B and C), cell growth is significantly increased with 
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6.2.6  The effect of TGFbeta1, U0126 and SB431542 on cell growth 
TGFbeta1 was used in conjunction with Erk1/2 inhibitor U0126 on MC3T3, R2-WT and R2-
C278F cells to determine whether cell growth induced by TGFbeta1 is dependent on Erk1/2. To 
investigate the the level of TGFbeta signalling resulting in cell growth, TβRI activation was 
inhibited with SB431542. The cells were treated after seeding every 24 hours for 3 days as 
described in Section 3.1.6. Treatment with TGFbeta and U0126 were performed in 1 % serum 
for 3 days. 
 
In all cells TGFbeta1 treatment significantly increased cell growth, whereas with U0126 
treatment cell growth decreased (Figure 6.16). The cell growth after TGFbeta1 and U0126 
combined was not significantly different to U0126 alone, in MC3T3 and R2-WT cells. In R2-
C278F cells, TGFbeta1 and U0126 treated cells had a significantly higher level of cell growth 
than the group treated with U0126 alone. 
 
Treatment of MC3T3 with SB431542 in 10 % FBS had no effect on cell growth at 1 µM in 
MC3T3 and R2-WT cells, but decreased cell growth maximally in R2-C278F cells, as higher 
doses did not further inhibit R2-C278F cell growth (Figure 6.17). In contrast, increasing the 
dose to 10 µM led to a further decrease in cell growth in MC3T3 and R2-WT cells and further 
still in MC3T3 treated with 20 µM. 
 
At 1% serum conditions, there was a dose dependent decrease in cell growth from 1, 10 to 20 
µM in MC3T3 (Figure 6.18 A). 1 µM in R2-WT cells also reduced cell growth and this was 
further reduced with 20 µM (Figure 6.18 B). In R2-C278F cells there was a significant decrease 
in cell growth with 1 µM, but 10 and 20 µM did not lead to a further decrease in cell growth 
beyond that of the 1 µM dose (Figure 6.18 C). 
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Figure 6.16 Methylene Blue analysis of cell growth in TGFbeta1 and U0126 treated cells in 1% FBS 
Cells were cultured with TGFbeta1 (10 ng/ml) and U0126 (20 uM) for three days before analysis. A, B 
and C: Treatment TGFbeta1 increases cell growth in all three cell lines. For each cell line, the cell growth 
in the U0126 treated groups are significantly lower, compared to both untreated and TGFbeta1-treated 
groups. Cell growth in the combined treatments of TGFbeta1 and U0126 are not significantly different 
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Figure 6.17 Methylene blue analysis of cell growth in SB431542 treated cells in 10% FBS 
Cells were treated with SB431542 at 1, 10 and 20 µM for three days before analysis. A: The decrease in 
MC3T3 cell growth is dose dependent. B: In R2-WT cells, 10 µM is sufficient to reduce cell growth, but 
20 µM has no further effect. C: 1 µM is sufficient to reduce cell growth significantly in R2-C278F cells 
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Figure 6.18 Cell growth with TGFbeta receptor inhibitor SB431542 in 1% FBS 
Cells were treated with SB431542 at 1, 10 and 20 µM for three days before analysis. A: Cell growth 
decreases in MC3T3 at all concentrations used. B: In R2-WT cells, 1 µM decreases cell growth and a 
further decrease is observed with 20 µM. C: 1 µM already induces maximal cell growth inhibition in R2-





























































































C   Chapter 6 TGFbeta signalling 
  
  176 
 
6.2.7 Effects  of  exogenous  TGFbeta1 on differentiation 
TGFbeta may inhibit late stage differentiation in osteoblasts by control of Runx2 and Opn 
expression (Noda et al., 1988; Viereck et al., 2002). Therefore the expression of Runx2 and Opn 
was analysed in MC3T3, R2-WT, R2-C278F cells following TGFbeta1 treatment. Cells were 
treated with 10 ng/ml of TGFbeta1 treatment every 24 hours for 2 and 4 days. 
 
After 2 days of TGFbeta1 treatment, all three cell lines showed a significant increase in Runx2 
expression (Figure 6.19 A). At 4 days, TGFbeta1 treated MC3T3 and R2-WT cells showed 
significantly increased Runx2 expression compared to their untreated controls, whereas in R2-
C278F, Runx2 decreased with TGFbeta1 treatment (Figure 6.19 B). 
 
Opn expression significantly decreased in TGFbeta1-treated MC3T3 cells at 2 days, while in 
R2-WT cells Opn significantly increased with treatment; in R2-C278F cells TGFbeta did not 
significantly change the level of Opn (Figure 6.20 A). At 4 days both MC3T3 and R2-WT cells 
responded to TGFbeta1 treatment by significantly increasing Opn expression; however in R2-
C278F cells there was no significant difference in Opn expression (Figure 6.20 B). 
   Chapter 6 TGFbeta signalling 
  
  177 
 
 
Figure 6.19 Real time PCR analysis of Runx2 expression in MC3T3, R2-WT and R2-C278F cells 
Cells were treated with 10 ng/ml of TGFbeta1 for 2 and 4 days in culture before relative quantification 
(RQ) of gene expression by real time PCR. For each cell line the expression levels were normalised to the 
untreated controls. A: TGFbeta1 treatment significantly increases Runx2 levels in MC3T3, R2-WT and 
R2-C278F cells at 2 days compared to their respective controls. B:  Runx2 expression increases in 
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Figure 6.20 Real time PCR analysis of Opn expression in MC3T3, R2-WT and R2-C278F cells 
Cells were treated with 10 ng/ml of TGFbeta1 for 2 and 4 days in culture before relative quantification 
(RQ) of gene expression by real time PCR. A: Opn decreases in MC3T3, increases in R2-WT and does 
not significantly change in R2-C278F cells at 2 days in culture. B: At 4 days, TGFbeta1 treatment 
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6.2.8  The effect of TGFbeta1 on Smad2 expression 
Given that FGFR signalling may have had some effect on Smad2 expression, its expression was 
analysed following TGFbeta1 treatment. Cells were treated with 10 ng/ml of TGFbeta1 
treatment every 24 hours for 2 or 4 days. 
 
TGFbeta treatment did not significantly affect Smad2 expression in any of the three cell lines at 
2 days (Figure 6.21 A). At 4 days, Smad2 expression increased in both MC3T3 and R2-WT 
cells with TGFbeta1 treatment, whereas in R2-C278F cells TGFbeta1 treatment decreased 
Smad2 expression (Figure 6.21 B).   Chapter 6 TGFbeta signalling 
  




Figure 6.21 Real time PCR analysis of Smad2 levels in MC3T3, FGFR2-WT and R2-C278F cells. 
Cells were seeded for 3 hours then treated with 10 ng/ml of TGFbeta1 for 2 and 4 days in culture before 
relative quantification (RQ) of gene expression by real time PCR. The gene expression for each cell line 
was normalised to the untreated control. A:  Smad2 expression does not change significantly after 
TGFbeta treatment in all three cell lines at 2 days. B: TGFbeta1 treatment after 4 days significantly 
increases Smad2 expression in MC3T3 and R2-WT cells, but it significantly decreases it in R2-C278F 
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6.2.9 The  affect  of  TGFbeta1 treatment on Gapdh expression 
As reported in Chapter 4, Gapdh gene expression was reduced in R2-C278F cells (Figure 4.9 A) 
and it was suggested that this change could be related to an altered metabolism with an 
increased dependency on serum for cell survival. To investigate whether the low expression of 
Gapdh could be corrected by exogenous TGFbeta1 MC3T3, R2-WT and R2-C278F cells were 
treated with 10 ng/ml of TGFbeta1 for 2 to 4 days in culture. 
 
At 2 days, treatment with TGFbeta1 did not significantly change Gapdh expression in MC3T3, 
R2-WT and R2-C278F cells (Figure 6.22 A). By 4 days in culture, treatment with TGFbeta1 did 
not significantly affect Gapdh expression MC3T3 or R2-WT cells; however Gapdh significant 
decreased in R2-C278F cells (Figure 6.22).   Chapter 6 TGFbeta signalling 
  




Figure 6.22 Real time PCR analysis of Gapdh expression in MC3T3, FGFR2-WT and C278F cells. 
Cells were treated with 10ng/ml of TGFbeta1 for 2 and 4 days in culture before relative quantification 
(RQ) of gene expression by real time PCR. The gene expression for each cell line was normalised to the 
untreated control.  A: TGFBeta1 increases expression in R2-WT at 2 day. B: At 4 days, Gapdh expression 
does not significantly change with TGFBeta1 treatment in MC3T3 and R2-WT cells, however in R2-











CTRL Treated CTRL Treated CTRL Treated
MC3T3 R2-WT R2-C278F





















CTRL Treated CTRL Treated CTRL Treated
MC3T3 R2-WT R2-C278F














*   Chapter 6 TGFbeta signalling 
  
  183 
 
6.3 Discussion 
6.3.1 FGFR2-C278F downregulates TGFbeta1 and -3 expression 
The main objective in this chapter is to identify whether FGFR2-C278F changes TGFbeta 
signalling. FGF2 treatment for 48 hours increases the steady state expression levels of Tgfbeta1 
in MC3T3-E1, rat and human osteosarcoma cells, (Noda and Vogel, 1989). In this study at 
preconfluence,  Tgfbeta1 and -3 expressions are reduced in R2-C278F cells, compared to 
MC3T3 and R2-WT controls (Figure 6.1 A), confirming that Tgfbeta signalling is altered by 
FGFR2-C278F. Interestingly FGF2 and FGFR2-C278F have different transcriptional control of 
Tgfbeta signalling. 
 
At 4 days in culture, in R2-WT cells, the level of Tgfbeta3 was also lower than MC3T3, but 
higher than R2-C278F. This suggests that the FGF-TGFbeta3 interaction is abnormally altered 
in R2-C278F cells, but in a more profound manner than in R2-WT cells. TGFbeta3 expression 
is also reduced in osteoblasts following 24 hours of FGF2 treatment (Mathy et al., 2003). As the 
FGF2 and FGFR2-WT upregulate Tgfbeta3, it is possible that FGF2 signalling acts via FGFR2. 
Tgfbeta2 expression is not altered by FGFR-C278F (Figure 6.1 B), indicating that Tgfbeta2 
signalling may not be altered by FGFR2-C278F signalling at the gene expression level. 
 
Smad2 was significantly higher in R2-WT cells compared to R2-C278F, but not significantly 
different to MC3T3 (Figure 6.2 B), indicating that it is unlikely that FGFR2-WT or FGFR2-
C278F has a significant effect on Smad2 expression levels. 
 
Underexpression of TGFbeta1 and -3 proteins and the overexpression of TGFbeta2 protein 
found in the perisutural regions of fused sutures is associated with craniosynostosis in rabbits 
(Poisson et al., 2004). It is possible that the low Tgfbeta1 and -3 may precede the suture 
obliteration event and that Tgfbeta2 expression, although not significant in R2-C278F cells, 
could be involved later during suture obliteration. In summary, FGFR2-C278F expression 
reduces TGFbeta1 and -3, which may contribute to low R2-C278F proliferation as these ligands 
induce osteoblast proliferation (Opperman et al., 2000; Reyes-Botella et al., 2002). 
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6.3.2 TGFbeta  signalling  is  lower in R2-C278F cells 
TGFbetas are mitogens, particularly in less mature osteoblasts (Centrella et al., 1994). In 10 % 
serum conditions, inhibition of TβRI with 10 µM of SB431542 decreased cell growth in all 
three cell lines (Figure 6.17), confirming that TGFbeta positively regulates proliferation in this 
model. Interestingly a smaller dose of SB431542 (1 µM) reduced cell growth only in R2-C278F 
cells (Figure 6.17), indicating that TGFbeta signalling is reduced in these mutant cells compared 
to MC3T3 and R2-WT controls. In contrast to MC3T3 and R2-WT cells, increasing the dose of 
SB431542 did not further reduce R2-C278F cell growth, providing more evidence that 
TGFbeta1 signalling is lower in the mutant cells. In 1 % serum conditions, cell growth 
decreased in all cell lines with 1 µM SB431542 (Figure 6.18), suggesting that serum 
concentration positively affects the level of TGFbeta signalling, at least in MC3T3 and R2-WT 
cells. Increasing the dose to 20 µM produced a further decrease in cell growth in MC3T3 and 
R2-WT cells, but this was already maximal in R2-C278F cells as no further decrease was 
observed, indicating that in 1 % serum, the level of TGFbeta signalling is still the lowest in R2-
C278F cells. It is possible that serum also positively affects the level of TGFbeta signalling in 
R2-C278F cells, but the current study does not provide enough evidence for this effect. 
 
In summary, FGFR2-C278F reduces the level of TGFbeta signalling in R2-278F cells, 
regardless of serum conditions. 
 
6.3.3  TGFbeta1 induced cell growth impaired in R2-C278F cells and 
dependent on Erk1/2 
Increased proliferation in MC3T3 with TGFbeta1 treatment has been observed in subconfluent 
rat osteoblast cell cultures when treated with 0.15 to 15 ng/ml of TGFbeta1 (Centrella et al., 
1987). Likewise, TGFbeta1 induces cell growth in MC3T3 and R2-WT cells in 10% serum 
conditions in this model. However there is no significant effect on R2-C278F cells, suggesting 
that the effect of TGFbeta1 is impaired by FGFR2-C278F. 
 
In 1% serum conditions, TGFbeta1 treatment increases cell growth in all three cell lines (Figure 
6.15), indicating that the effect of TGFbeta1 is modulated by serum conditions. Under these 
conditions, TGFbeta1 induced cell growth is dependent on Erk1/2 signalling in all three cell 
lines as TGFbeta1 could not rescue the inhibition of proliferation induced by Erk1/2 inhibitor 
U0126 (Figure 6.16). 
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6.3.4  TGFbeta1 does not alter MC3T3 cell morphology 
In R2-C278F cell cultures, the proportion of fibroblastic cells is lower than in both MC3T3 and 
R2-WT cells, as shown in Chapter 4. In osteoblasts, TGFbeta1 may inhibit late stage 
differentiation (Alliston et al., 2001).  If differentiation is inhibited by TGFbeta1, it is 
conceivable that the proportion of fibroblastic cells could be increased. 
 
At preconfluence (2 days in culture), TGFbeta1 treatment does not change MC3T3, R2-WT nor 
R2-C278F cell morphology, indicating that it does not alter morphology in proliferating 
osteoblasts nor rescue R2-C278F cells from their differentiated phenotype. 
 
Compared to MC3T3, TGFbeta1 treated R2-C278F cultures at confluence (4 days in culture) 
displayed a greater number of bright apoptotic figures, clearly indicating that the reduced 
TGFbeta1 expression is not related to the R2-C278F cell phenotype normally found at this stage 
of culture. Interestingly it indicates that FGFR2-C278F signalling in R2-C278F cells increases 
sensitivity to TGFbeta1 induced apoptosis, as a small increase in the number of bright apoptotic 
figures, suggesting increased apoptosis in MC3T3 (Figure 6.6). It is possible that this may be an 
effect of TGFbeta1 to inhibit differentiation by inducing apoptosis at confluence. However in 
osteoblasts grown in DMEM with differentiation medium (L-ascorbic acid 2-phosphate), 
TGFbeta1 does not have any effect on osteoblast apoptosis (Cabiling et al., 2007), indicating 
that the above effects may also be depend on culture medium conditions. In R2-WT cells, 
TGFbeta1 induces an elongated morphology where cells are arranged in striae along the 
confluent monolayer (Figure 6.7), which may suggest that TGFbeta alters R2-WT 
differentiation with regard to morphology. This osteoblast elongation effect by TGFbeta1 has 
been observed in MC3T3 seeded onto bone slices, where it was suggested to be mediated by a 
MAPK p38 dependent mechanism (Karsdal et al., 2001). It is possible that the culture 
conditions in this study do not permit MC3T3 to change morphology in response to TGFbeta1, 
whereas in bone slices there is a permissive environment, perhaps mediated by FGFR2 in the 
surrounding tissue.  
 
Overall, the reduced Tgfbeta1 does not affect preconfluent cell morphology, but greatly 
increases the number apoptotic figures in R2-C278F cells and alters R2-WT morphology, 
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6.3.5  Erk1/2 inhibition alters osteoblast morphology 
In 1% FBS, TGFbeta1 did not alter the morphology of MC3T3 and R2-WT cells except for R2-
C278F where it appeared to increase the number of cells with cuboidal morphology. This 
further indicates that in R2-C278F cells TGFbeta1 cannot restore osteoblast morphology to that 
of MC3T3. Erk1/2 inhibition using U0126 treatment resulted in a loss of fibroblastic cells in 
MC3T3, R2-WT and R2-C278F cultures, which may suggest that differentiation is increased. 
However Erk1/2 inhibition with Erk1DN suppresses differentiation in MC3T3 (Lai et al., 2001), 
and the morphology of MC3T3 cells expressing Erk1DN also appears similar to the U0126 
treated cells of this study. Another report has shown that Erk1/2 has been reported positively 
affect differentiation (Raucci et al., 2008). This may indicate that the cuboidal morphology 
resulting from Erk1/2 inhibition with U0126 treatment causes a decrease in differentiation. To 
confirm this interpretation, differentiation markers should be analysed in cells with U0126 
treatment. 
 
Following U0126 treatment MC3T3 (Figure 6.9) morphology was similar to U0126 treated R2-
WT (Figure 6.10). The morphology of U0126 treated cells was similar to the TGFbeta1 and 
U0126 combined treatment in all three cell lines, suggesting that TGFbeta1 does not 
compensate for the morphological changes by U0126. 
 
6.3.6 FGFR2-C278F impairs upregulation of Fgf18 by TGFbeta1 at 
confluence 
This study shows that Fgf18 expression is affected by exogenous TGFbeta1, but not Fgf1 and -2 
at preconfluence (Figure 6.12). It is likely that the effect of exogenous TGFbeta1 at 
preconfluence on Fgf18 expression is mediated by FGFR2-WT as TGFbeta1 induced Fgf18 was 
only observed in MC3T3 and R2-C278F cells at 2 days (Figure 6.13). In metatarsal bone, Fgf18 
expression also increases with TGFbeta1 treatment (Mukherjee et al., 2005). 
 
Interestingly in R2-WT cells Fgf1 expression is significantly higher than in MC3T3 and R2-
C278F cells, suggesting that FGFR2-WT mediates Fgf1 expression levels, but this effect is not 
associated with the R2-C278F cell phenotype. 
 
At confluence, TGFbeta1 still induces Fgf18 expression in MC3T3, but not in R2-WT and R2-
C278F cells, suggesting that at confluence both FGFR2-WT and FGFR2-C278F expressions 
block the effects of TGFbeta1 on Fgf18 expression.   Chapter 6 TGFbeta signalling 
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6.3.7  FGFR2-C278F impairs differentiation marker responses to 
TGFbeta1 
TGFbeta1 treatment significantly increases Runx2 expression all 3 cell lines at preconfluence 
(Figure 6.19 A), which suggests that it may enhance early differentiation. Runx2 expression has 
also been reported to increase as immature osteoblasts differentiate and mature (Aubin, 2001). 
TGFBeta1 induces Runx2 at confluence in MC3T3 and R2-WT cells; an effect also observed in 
mature osteoblasts (Viereck et al., 2002). However Runx2 is decreased in R2-C278F cells at 
confluence (Figure 6.19 B). TGFbeta1 can decrease Runx2 expression in rat osteosarcoma cells 
and also downregulate Oc (Alliston et al., 2001). R2-C278F cells may respond like 
osteosarcoma cells, however to confirm this Oc expression should be measured in R2-C278F 
cells following TGFbeta1 treatment. The results would indicate whether TGFbeta1 can affect 
late stage differentiation in R2-C278F cells. 
 
At preconfluence TGFbeta1 treatment in MC3T3 cells decreases Opn expression, which may 
suggest that differentiation is induced. Opn expression also decreases after 48 hours of 
TGFbeta1 treatment in MC3T3 in differentiation medium (beta-glycerophosphate and ascorbic 
acid) (Pungchanchaikul, 2008). This was not expected as TGFbeta1 has been reported to 
increase Opn expression in osteoblasts (Cabiling et al., 2007; Noda, 1989). FGFR2-WT may 
interact with TGFbeta as TGFbeta1 is induced Opn expression in R2-WT cells (Figure 6.20 A). 
FGFR2-C278F appears to block any change in Opn expression following TGFbeta1 treatment, 
suggesting that FGF and TGFbeta signalling interact to control Opn expression. 
 
At confluence Opn expression increases in MC3T3 and R2-WT cells after TGFbeta1 treatment, 
which is consistent with reports of increased Opn expression following TGFbeta1 treatment in 
mature osteoblasts (Noda et al., 1988; Sodek et al., 1995). FGFR2-C278F impairs TGFbeta1 
induced Opn expression (Figure 6.20 B). The changes in Opn expression do not correlate with 
the changes in Runx2 expression, which may reflect the findings that TGFbeta may affect Opn 
expression independently of Runx2 (Bae et al., 2007). 
 
Together at preconfluence, the increased Runx2 and decreased Opn expression in MC3T3 
induced by TGFbeta1 suggests that differentiation is increased following TGFbeta1 treatment. 
The increase in both Runx2 and Opn in R2-WT suggests that early differentiation is increased 
and late differentiation is inhibited. In R2-C278F cells, the increase in Runx2 and no change to 
Opn expression suggests that early differentiation is increased. At confluence in both MC3T3 
and R2-WT, when both Runx2 and Opn are increased, this suggests that late stage 
differentiation is inhibited. The decrease in Runx2 and no change in Opn in R2-C278F cells   Chapter 6 TGFbeta signalling 
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suggest that differentiation is affected, but requires an analysis of Oc expression to clarify 
whether differentiation is enhanced or inhibited. 
 
6.3.8 FGFR2-C278F  impairs TGFbeta1 induced Smad2 expression at 
confluence 
TGFbeta1 did not significantly change Smad2 expression in any of the three cell lines at 
preconfluence, which suggests that TGFbeta1 induced proliferation is not associated with 
alteration of Smad2 expression. At confluence, TGFbeta1 treatment induced Smad2 expression 
in both MC3T3 and R2-WT cells, whereas in R2-C278F cells its expression decreased (Figure 
6.21 B). This suggests that TGFbeta1 plays a role in controlling Smad2 expression in mature 
osteoblasts, which may feed back into the level of TGFbeta signalling. It is possible that at 
confluence, Smad2 may be associated with osteoblast differentiation occurring at this stage in 
culture and that FGFR2-C278F may act downstream of TGFbeta1 induced Smad2 expression. 
In mature osteoblasts, overexpression of Smad2 decreases Runx2 expression and Oc expression 
(Li et al., 1998). This pattern does not correlate to the increased Smad2 and Runx2 found in 
MC3T3 and R2-WT cells in this model, which suggests that TGFbeta1 does not control Runx2 
expression via Smad2 expression per se. 
 
6.3.9 TGFbeta1  downregulates Gapdh expression in R2-C278F cells at 
confluence 
TGFbeta1 treatment does not significantly alter Gapdh expression in all three cell lines at 
preconfluence, suggesting that Gapdh expression is not involved in TGFbeta1-induced 
proliferation and effects on differentiation R2-C278F cells (Figure 6.22 A). FGFR2-C278F 
interacts with TGFbeta by causing R2-C278F cells to reduce Gapdh expression in response to 
TGFbeta1 at confluence (Figure 6.22), which may be associated to an increase of bright 
apoptotic figures at confluence observed from the previous morphological studies under the 
same experimental conditionss. As suggested in Chapter 4, a caspase independent cell death 
(CICD) mechanism may be responsible for these observations, which should be further 
investigated.   Chapter 6 TGFbeta signalling 
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6.4 Conclusions 
This study confirms that Tgfbeta signalling is altered in R2-C278F cells and has revealed a 
number of interactions with FGFR2-C278F and TGFbeta1 signalling. Firstly, FGFR2-C278F 
reduces the level of TGFbeta1 signalling as shown by inhibition of TGFbeta with SB431542. It 
also decreases TGFbeta1 and -3 gene expression. FGFR2-C278F blocks TGFbeta1 induced 
osteoblast proliferation in R2-C278F cells 10% serum conditions. At confluence, FGFR2-
C278F expression may alter the downstream signalling of TGFbeta1 by downregulation Smad2 
expression, instead the normal upregulation of Smad2 observed in MC3T3 and R2-WT cells. 
Rescue of R2-C278F cell growth with TGFbeta1 treatment is limited to 1% serum conditions 
and this is dependent on Erk1/2 signalling. 
 
The FGFR2-C278F abnormally interacts with exogenous TGFbeta1 to alter Fgf18 signalling, as 
it inhibits TGFbeta1 induced Fgf18 expression at confluence. FGFR2-C278F impairs the effect 
of TGFbeta1 on osteoblast differentiation, particularly at confluence by reversing the normal 
upregulation of Runx2 expression observed in MC3T3 and R2-WT cells and blocking TGFbeta1 
induced Opn expression. FGFR2-C278F interacts with exogenous TGFbeta1 to lower Gapdh 
expression, which may be associated with increased apoptosis as suggested by morphological 
observations of TGFbeta1 treated R2-C278F cells at confluence. 
 
In summary, FGFR2-C278F alters FGF-TGFbeta interactions in MC3T3 by both lowering the 
level of TGFbeta signalling and impairing its downstream cellular responses. It also interferes 
with the effect of TGFbeta1 on cell differentiation. 
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Chapter 7  Final Discussion 
The aim of this thesis was to determine how FGF signalling was impaired in craniosynostotic 
osteoblasts and investigate whether TGFbeta signalling was also affected, using an in-vitro 
model of MC3T3-E1 cells, which expressed human FGFR2-C278F. In this model, a number of 
alterations were found in both FGF signalling, and interactions with TGFbeta were successfully 
identified. Here I discuss in detail the relationships between these alterations and the 
craniosynostotic R2-C278F cell phenotype. I will also propose mechanisms to link FGF and 
TGFbeta signalling to proliferation phenotype of R2-C278F cells to be tested in further studies 
into Ligand Independent Constitutively Active (LICA) FGFR2. 
 
7.1 R2-C278F cells show lower proliferation and increased 
differentiation and apoptosis 
R2-C278F cells have a reduced proliferation rate, a higher level of differentiation and an 
increased level of apoptosis (Chapter 4). This phenotype is similar to that reported in a number 
of human models (Marie et al., 2005), suggesting that results from this model may reflect the 
defects and mechanisms that exist in human osteoblasts of patients with FGFR2-related 
craniosynostosis. It is likely that the changes to proliferation and differentiation are the main 
factors influencing the craniosynostotic phenotype, as the changes observed in apoptosis in this 
thesis are relatively small. It may be hypothesised from this data and the literature concerning 
LICA FGFR2 craniosynostosis, that embryonic osteoblast proliferation is increased and 
differentiation decreased until birth. Afterwards, osteoblast proliferation decreases and 
differentiation increases (Table 7.1). 
 
Table 7.1 Hypothesised effects of LICA FGFR2 mutations on osteoblast behaviour 












1: Ratisoontorn et al., 2003 and Eswarakumar et al., 2004 
2: Ratisoontorn et al., 2003  
3: Lemonnier et al., 2001, Mansukhani et al., 2000 and Marie et al., 2005 
4: This study and Fragale et al., 1999 
5,6: This study and Marie et al., 2005   Chapter 7 Final Discussion 
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7.2 This  model  in-vitro can be compared to bone fronts in-vivo 
Fgf2 is normally present in bone and adjacent to the site of suture fusion, but not in bone fronts 
of presumptive and patent sutures (Opperman, 2000). Other tissues, such as dura express Fgf2 
(Li et al., 2007) and Fgf1 embryonically (Ogle et al., 2004), suggesting that bone fronts receive 
Fgf1 and -2 from their neighbouring tissues. The low level of Fgf2 expression in MC3T3, R2-
C278F and R2-WT cultures indicates that they may mimic osteogenic cells of the bone front 
before suture fusion. As the expression levels of Fgf1 and -2 were normal in R2-C278F cells 
compared to controls; these ligands did not appear to contribute to the mutated phenotype, 
although it did not exclude a signalling role for the two ligands in-vivo. 
 
Proliferation of osteoprogenitors is essential for bone growth (Lana-Elola et al., 2007), which 
occurs adjacent to the bone front. The decreased proliferation in R2-C278F cells and in other 
craniosynostotic osteoblasts reviewed postnatally (Table 7.1) may explain why bone repair and 
regrowth is limited in LICA FGFR2 mutated osteoblasts, following the craniofacial surgery for 
craniosynostosis. 
 
7.3  FGFR signalling is decreased in R2-C278F cells 
Work in this thesis has provided evidence that Fgf signalling was downregulated in R2-C278F 
cells, as shown by the data regarding cell proliferation before and after inhibition of Fgfr 
signalling. The key point to note is that Fgfr2 positively regulates osteoblast proliferation 
(Eswarakumar et al., 2002; Iseki et al., 1999; Ratisoontorn et al., 2003). Fgfr inhibition in R2-
C278F produced the greatest reduction in cell growth among the three cell lines (MC3T3, R2-
WT and R2-C278F), suggesting that Fgfr signalling was reduced in the mutant cells. 
 
It is clear that although FGFR2-C278F is a LICA-FGFR2, constitutive activation does not result 
in an increased osteoblast growth. Of the four FGFR isoforms, only FGFR2IIIc is reported as 
essential for inducing osteoblast proliferation (Chapter 1, Section 1.3.3). Together this data 
suggests that there is a decrease in Fgfr2 signalling in R2-C278F cells, resulting in reduced cell 
proliferation (Figure 7.1). 
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Figure 7.1 FGFR2 signalling and proliferation defects in R2-C278F cells 
A: Fgfr2-Erk1/2 signalling pathway resulting in proliferation. B: FGFR2-C278F reduces the level of 
Fgfr2-Erk1/2 signalling, which results in a reduction of proliferation in R2-C278F cells. 
 
7.4  Fgf18 may be involved in R2-C278F cell differentiation 
Although Fgf18 may induce proliferation  in osteoblasts (Ohbayashi et al., 2002), in R2-C278F 
cells appears to correlate to enhanced differentiation rather than proliferation, because the 
expression in R2-C278F cells is similar to MC3T3 at preconfluence, but higher than MC3T3 at 
confluence (Chapter 5). Furthermore, studies in our laboratory have shown that the addition of 
exogenous Fgf18 does not significantly increase cell growth in MC3T3, R2-WT or R2-C278F 
cells in 10% serum conditions (unpublished data). Functionally, Fgf18 treatment may influence 
osteoblast differentiation by increasing the gene expression of differentiation markers 
Osteopontin ( Opn) and Osteocalcin ( Oc) (Liu et al., 2002). A similar relationship between 
Fgf18 and Oc is found in R2-WT and R2-C278F cells, as Fgf18 and Oc expression was raised 
compared to MC3T3 at confluence (Chapters 4 and 5). These findings indicate a positive 
association between Fgf18 and Oc expression in R2-WT and R2-C278F cells. This relationship 
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both R2-WT and R2-C278F cells. Interestingly the expression of Oc is greater in R2-WT cells 
than in both MC3T3 and R2-C278F cells at confluence. It is possible that Oc expression may 
also be linked to an increased Fgf1 expression found in R2-WT cells compared to MC3T3 and 





Figure 7.2 Hypothesised effects of FGFR2-C278F on Fgf18 and differentiation 
A: Fgf18 induces Oc expression by increasing osteoblast differentiation (Ohbayashi et al., 2002). B: 
FGFR2-C278F expression results in increased expression of Fgf18, which is known to upregulate Oc 
expression and hence enhance differentiation in R2-C278F cells. 
 
In contrast to Oc at confluence, there is no clear relationship between Fgf18 and Opn expression 
in R2-WT and R2-C278F cells. Opn expression was not higher in R2-WT compared to MC3T3 
cells, whereas in R2-C278F cells Opn was actually lower than in MC3T3 and R2-WT cells. 
Fgf18 therefore is not the main factor modulating Opn expression in this model. Although Oc 
expression is increased in R2-WT and R2-C278F cells, the differences in Opn expression 
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7.5  Changes in Erk1/2 may underlie defective FGFR signalling 
in R2-C278F cells 
Two important changes in Erk1/2 signalling have been identified: an increased Erk1/Erk2 ratio 
and a decreased level of Erk1/2 signalling as shown in Chapter 5, which were suggested to 
cause impaired R2-C278F cell proliferation (Figure 7.3). 
 
 
Figure 7.3 Proposed mechanism leading to reduced proliferation signalling in R2-C278F cells 
A: FGFR2 increases osteoblast proliferation via activation of Erk2. B: FGFR2 signalling is reduced and 
Erk1/2 signalling is directed towards the Erk1 part of the pathway by increasing the Erk1/Erk2 ratio, 
reducing the level of proliferation in R2-C278F cells. 
 
As Erk1 and Erk2 compete for activation by MEK1/2, the increased Erk1/Erk2 ratio may reduce 
the activation of Erk2, the key Erk isoform mediating growth factor induced proliferation 
(Fremin et al., 2007; Vantaggiato et al., 2006). The level of Erk1/2 signalling is essential for 
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7.6 Changes in Erk1/Erk2 ratio correlate with cell cycle 
changes in R2-C278F cells 
In the cell cycle, Erk1/2 facilitates G1 transition to S phase (Wu et al., 2006), and from G2/M to 
G0/G1 phase (Roberts et al., 2006). In NIH3T3 fibroblasts, Erk1 and Erk2 are strongly 
phosphorylated in G1 phase, but only Erk2 is strongly phosphorylated in G2 and M Phase 
(Suzuki et al., 2002b). These reports suggest that both Erk1 and Erk2 facilitate G1 to S phase 
transition, but Erk2 predominantly facilitates transition from G2/M to G0/G1 phase. The 
relative expression of Erk2 has been shown to decrease compared to Erk1 in R2-C278F cells, 
which correlates with a higher proportion of cells in G2 phase. It is possible that the relatively 
low Erk2 activation results in slower progression of cells from the G2 phase into G1. 
 
7.7  Pkc signalling is altered in R2-C278F cells 
Pkc signalling is altered in R2-C278F cells compared to MC3T3 and R2-WT cells, but the level 
of signalling and the relationship to the R2-C278F cell phenotype is unclear as the effects of 
Pkc stimulation differ depending on the serum concentration. For example, I have shown that 
Pkc activation with PMA in 10% serum decreases cell growth in R2-C278F cells, but not in 
control cells. In 1% serum, cell growth increases in R2-C278F, does not change in R2-WT and 
decreases in MC3T3 cells. Pkc is known to affect proliferation and differentiation (Sabatini et 
al., 1996; Boguslawski et al., 2000), therefore the altered Pkc signalling may play a role in both 
proliferation and differentiation in R2-C278F cells. Aperts FGFR mutations constitutively 
activate PKC-α, which in turn increases apoptosis (Lemonnier et al., 2001). It is possible that 
Pkc also induces apoptosis in R2-C278F cells, however the same changes in Pkc activation 
should be confirmed, as FGFR signalling by loss of ligand specificity in Aperts is not equivalent 
to constitutively active FGFR2. 
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7.8  FGF-TGFbeta interactions and their relevance to R2-C278F 
cell phenotype 
As concluded in Chapter 6, FGFR2-C278F altered FGF-TGFbeta interactions in MC3T3 by 
lowering the level of TGFbeta signalling and impairing its downstream cellular responses. It 
also suggested that overstimulation by FGF2 could not be directly compared to LICA FGFR 
signalling due to the differences in Tgfbeta1 expression, which was upregulated by FGF2 (Noda 
and Vogel, 1989)  and down regulated by FGFR2-C278F (Chapter 6). Although similarities 
exist in that FGF2 may induce craniosynostosis (Crane et al., 2005), the mechanisms underlying 
the craniosynostoses are likely to differ. 
 
7.8.1  Proliferation is regulated by FGF-TGFbeta signalling interactions 
through a convergent pathway 
TGFbeta1 may induce proliferation in immature osteoblasts in serum, without differentiation 
medium (Bosetti et al., 2007; Centrella et al., 1994; Chung et al., 1999; Janssens et al., 2005; 
Reyes-Botella et al., 2002). As similar conditions have been used in this thesis, the low 
TGFbeta1 expression found in R2-C278F cells may reflect a reduction in TGFbeta-induced 
proliferation. 
 
The combination of reduced FGF and TGFbeta signalling found in R2-C278F cells may explain 
the low proliferation observed in Chapter 4. Osteoblasts in-vivo are able to receive TGFbeta1 
released from surrounding bone tissue (Janssens et al., 2005), whereas osteoblasts in-vitro rely 
on endogenous TGFbeta production alone. However exogenous TGFbeta1 could not stimulate 
cell growth in R2-C278F cells; cell growth was only inducible in MC3T3 and R2-WT cells. 
This suggests that R2-C278F osteoblasts in-vivo would not be able to respond correctly to 
signals from bone and other tissues such as the dura in which TGFbeta is strongly expressed 
(Mehrara et al., 1999). Our laboratory has also experimented on the three cell lines using 
exogenous Fgf2 and -18, which in 10% serum conditions did not have any significant effects on 
cell growth, but in 1% led to a small increase in cell growth (data unpublished). This suggests 
that at 10 % serum conditions, that Fgf signalling may be maximally stimulated with respect to 
the proliferative effects. 
 
As TGFbeta induced signalling with regard to proliferation is mediated by Erk1/2 (Ghayor et 
al., 2005), the abrogation of TGFbeta1 induced proliferation in R2-C278F cells in 10% serum   Chapter 7 Final Discussion 
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may be related to the increased Erk1/Erk2 ratio, which may potentially limit proliferative 
responses to growth factors. Interestingly, at 1% serum conditions TGFbeta1 increased cell 
growth in R2-C278F cells (Chapter 6). FCS-induced proliferation is dependent on Erk1/2 
signalling (Suzuki et al., 2002a), suggesting that serum induces proliferation by activating the 
Erk1/2 pathway. In 1% serum conditions, the small amount of serum may reduce the level of 
Erk1/2 activation, resulting in a lower proliferation. When Erk2 activation was severely limited, 
Erk1 has been shown to increase proliferation in osteoblasts (Lefloch et al., 2008). It is likely 
that in 1 % serum Erk2 is also limited; therefore Erk1 may stimulate proliferation, which would 
be consistent with increased cell growth in R2-C278F cells, following Erk1/2 stimulation by 
TGFbeta. An alternative explanation could be that under these conditions, even a small amount 
of Erk2 activation could result in R2-C278F reaching their maximal proliferation rate. 
 
7.8.2  Decreased FGF and TGFbeta signalling may increase 
differentiation 
FGFR2 is required for proliferation, but it is not necessary for osteoblast differentiation (Yu et 
al., 2003), suggesting that increased differentiation in R2-C278F cells may not be a direct effect 
of the FGFR2-C278F signalling. R2-C278F cells were suggested to be more differentiated, 
based on cuboidal cell morphology at preconfluence, which was supported by observations that 
Col1 was increased compared to both controls (Santos-Ruiz et al., 2007). Low Opn expression 
and high Oc expression at confluence further suggested that R2-C278F cells were more 
differentiated than MC3T3 cells. It appears that the expression of FGFR2-C278F blocks 
TGFbeta1-induced Opn expression that is normally observed in MC3T3 (Chapter 6), indicating 
that FGF signalling mediates the effect of TGFbeta on osteoblast differentiation. 
 
Downstream of FGF and TGFbeta, Erk1/2 activation increases Opn protein expression in 
MC3T3 (Kono et al., 2006). Opn expression is also increased by inorganic phosphate via 
Erk1/2, Pkc and proteosome activity (Beck, Jr. and Knecht, 2003). Assuming that TGFbeta1 
utilises the same downstream pathways it is possible that the changes to Erk1/2 or Pkc 
signalling may facilitate the inhibition of TGFbeta1-induced Opn by FGFR2-C278F (Section 
7.2.1). The relationship was hypothesised with TGFbeta and Erk1/2 (Figure 7.4), but not for Pkc 
as it has not yet been determined whether Pkc signalling is increased or decreased. 
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Figure 7.4 Hypothesised connection between FGF-TGFbeta-Erk1/2 signalling and differentiation 
A:  TGFbeta1 is present in cells with normal FGFR2 and FGFR2-WT signalling, which via Erk1/2 
activation induces Opn expression and inhibits differentiation. B: Downregulation of TGFbeta1 by 
FGFR2-C278F and decreased FGFR signalling may decrease Erk1/2 activation, resulting in lower Opn 
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7.8.3  FGF-TGFbeta-Smad and differentiation 
As mentioned above, the mutation in FGFR may alter the downstream pathways of Erk1/2 and 
Pkc, which are shared with TGFbeta signalling. Furthermore, the mutation also affects TGFbeta 
signalling via Smad. In Chapter 6, TGFbeta1 treatment in R2-C278F cells decreased Smad2 
expression in R2-C278F cells, but increased Smad2 in both MC3T3 and R2-WT cells. As 
Smad2 interacts with Runx2 (Selvamurugan et al., 2004), R2-C278F cell differentiation may 
have been affected. It was indicated In Chapter 6 that FGFR2-C278F did not affect Smad1 
expression. An intial analysis of Smad1 expression after TGFbeta1 treatment at confluence 
showed that Smad1 expression was induced in MC3T3 and R2-WT cells, but had no effect on 
R2-C278F cells (Figure 8.6). As Smad1 may increase Opn expression (Yang et al., 2000), the 
defect in TGFbeta-induced Smad1 may have prevented TGFbeta1-induced Opn expression in 
R2-C278F cells (Chapter 6). However this does not explain the reduced Opn expression in R2-
C278F cells at confluence (Chapter 4), as there was no difference in Smad1 expression between 
all three cell lines (Chapter 6). It is possible that the reduced level of TGFbeta signalling 
(indicated in Chapter 6) may lower Smad1 activation by TGFbeta, which would limit Smad1 
induced Opn expression. FGFR2-C278F may therefore have a role in preventing TGFbeta from 
inhibiting late stage differentiation in R2-C278F cells by lowering Smad1 activation via 
reducing TGFbeta signalling. Assessment of the Smad1 activation level at confluence by 
TGFbeta stimulation is required to confirm this interpretation.   Chapter 7 Final Discussion 
  




Figure 7.5 Hypothesised pathway of FGFR2-C278F-TGFbeta-Smad1 and differentiation 
A: TGFbeta1 activates Smad1 (Miyazawa et al., 2002). Smad1 induces Opn expression and inhibits 
differentiation (Yang et al., 2000). B: Reduced expression of TGFbeta1 in R2-C278F cells may result in 
decreased Smad1 activation, and consequently lower Opn expression. 
 
 
7.8.4  Metabolism and apoptosis 
The work in this thesis has suggested that increased apoptosis in R2-C278F cells may be 
functionally related to a low Gapdh expression (Chapter 4) by a caspase independent cell death 
(CICD) mechanism. Low Gapdh levels may also affect metabolism in R2-C278F cells, as 
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relationship between FGF, Gapdh and cell survival is shown in Figure 7.6. The addition of 
TGFbeta1 to R2-C278F cells (Chapter 6) greatly increased the number of bright apoptotic 
figures and decreased Gapdh at confluence compared to both MC3T3 and R2-WT cells, 
suggesting that FGFR2-C278F may play a positive role with TGFbeta in mature osteoblast 
apoptosis. However the lack of TGFbeta signalling in R2-C278F cells (Chapter 6) did not result 




Figure 7.6 Hypothesised changes leading to increased apoptosis in R2-C278F cells 
A: Gapdh protects cells from CICD dependent apotosis by increasing glycolysis and autophagy (Collell 
2007).  B: Loss of Gapdh caused by FGFR2-C278F cells may reduce the level of glycolysis and 
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7.9 Conclusions 
The results in this thesis support a working hypothesis that FGFR-C278F increases osteoblast 
proliferation and decreases differentiation during embryonic development, whereas postnatally 
osteoblast proliferation is decreased and differentiation increased, which concurs with the 
current literature findings. Regarding apoptosis, the expression of FGFR2-C278F lowers the 
level of Gapdh, which may limit glycolysis and contribute metabolic requirements of R2-C278F 
cells. The lack of Gapdh may be associated with increased apoptosis via caspase independent 
cell death (CICD). 
 
In the postnatal stage model used in this thesis, ligand independent constitutively active receptor 
mutations such as FGFR2-C278F are thought to result in a gain-of-function in signalling; 
however the phenotype of osteoblasts does not reflect the direct consequence of increased 
FGFR2 signalling. Instead, R2-C278F cells show decreased proliferation, a result that implies a 
negative feedback on FGFR2 signalling in craniosynostotic osteoblasts. 
 
FGFR2-C278F alters FGF and TGFbeta signalling in R2-C278F cells. Three mechanisms have 
been suggested to impair cell proliferation. The first is a decrease in the overall level of Fgfr / 
FGFR2 signalling. The second is a decrease in the level of TGFbeta signalling. The third is an 
increased Erk1/Erk2 ratio, diverting the downstream signalling away from Erk2. The combined 
changes are shown in the pathway, presented in Figure 7.7. In addition to lowering the level of 
TGFbeta signalling, FGFR2-C278F expression also appears to block the proliferative response 
of osteoblasts following TGFbeta1 treatment. 
 
Differentiation is increased in R2-C278F cells and changes in Fgf and Tgfbeta signalling may 
be involved, however the exact role is not as clear as with proliferation. It is possible that the 
increased differentiation in R2-C278F cells is associated with decreased Erk1/2 signalling and 
increased Fgf18 signalling. Mechanisms of enhanced differentiation may include Fgf18 
induction of Oc expression, and impairment Opn expression following low Erk1/2 activation. It 
is also possible that low TGFbeta signalling may contribute to low Opn expression via low 
levels of Smad1 activation. Control of differentiation by FGF and TGFbeta may converge on 
Opn expression (Figure 7.8). 
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Figure 7.7 Proposed regulation of ERK pathway and its relationship to the proliferation defects in 
R2-C278F cells 
A: In MC3T3 and R2-WT cells, the mitogenic signal most strongly activates the ERK2, favouring a 
proliferative response rather than growth arrest. B: In R2-C278F cells, there is a reduction in FGFR2 
signalling, limiting the proliferative stimulation of the ERK1/2 pathway. There is also an increased 
ERK1/ERK2 ratio, which causes a shift in the ERK activation to ERK1, thereby resulting in a smaller 
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Figure 7.8 Hypothetical scheme of FGF and TGFbeta controlled differentiation via Opn expression 
A: FGF activates Erk1/2; TGFbeta activates Erk1/2 and Smad1 signalling. Erk1/2 and Smad1 both 
upregulate Opn gene expression, which inhibits osteoblast differentiation. B: In R2-C278F cells the level 
of FGF and TGFbeta signalling is lower, which reduces Erk1/2 and Smad1 activation, thus reducing Opn 
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7.10 Further work 
From the findings in this thesis, three main hypotheses have been created: One concerns the 
mechanisms of R2-C278F cell death and survival (Figure 7.6); another suggests a relationship 
between Fgf18 and osteoblast differentiation (Figure 7.2) and the third regarding the interaction 
between Fgf and Tgfbeta on osteoblast differentiation. The immediate future work will be to 
prove or disprove these hypotheses stated earlier in this chapter.  
 
It is hypothesised that a low Gapdh expression is responsible for reduced R2-C278F cell 
survival, via a low level of glycolysis secondary to Gapdh (Figure 7.6). The level of glycolysis 
may be assessed by measuring the levels of ATP, which if low would support this hypothesis. 
Alternatively, Gapdh could be overexpressed in the R2-C278F mutant to observe for rescue of 
cell death. Caspase inhibitors may be used to determine whether cell death in R2-C278F cells 
occurs via a caspase independent mechanism. 
 
Analysis of Oc expression in MC3T3, R2-WT and R2-C278F cells following exogenous FGF18 
treatment would test the hypothesis that raised Fgf18 expression found in R2-C278F cells 
positively regulates Oc expression, enhancing osteoblast differentiation (Figure 7.2). 
 
For assessing the action of FGF and TGFbeta on Opn regulated differentiation, Erk1/2 should 
be inhibited with U0126 and Opn expression measured at confluence. If Erk1/2 inhibition 
reduces Opn expression, it would support the hypothesis that the reduction in Fgfr and Tgfbeta 
signalling leads to a reduced Erk1/2 signalling, which is responsible for regulating Opn 
expression (Figure 7.8). For TGFbeta and Smad1, it is necessary to confirm whether exogenous 
TGFbeta1 increases Smad1 activity in cells at confluence (as Opn expression was shown to 
increase in MC3T3 and R2-WT cells). If confirmed, the level of endogenous Smad1 activity 
should be determined. If Smad1 activity is low in R2-C278F cells, then this would support the 
hypothesis in Figure 7.8. 
 
There are also several areas to investigate, which are discussed below. 
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7.10.1 The role of Erk1 in osteoblast differentiation 
This study has correlated Erk2 with proliferation and implied that Erk1 may inhibit Erk2-
induced proliferation and was involved in differentiation. To confirm these two suggestions, 
Erk1 could be overexpressed in MC3T3 cells and analysed for both proliferation and 
differentiation markers. Interestingly, alterations of the ratio between pERK1 and pERK2 are 
currently being researched and even patented (US 20070082366) for diagnosing pathological 
conditions such as Alzheimers disease (http://www.freshpatents.com/Alzheimer-s-disease-
specific-alterations-of-the-erk1-erk2-phosphorylation-ratio-dt20070412ptan20070082366.php). 
Should modification of the Erk1/Erk2 prove useful in rescue of proliferation in craniosynostotic 
osteoblasts, this ratio could be of use in assessing the effectiveness of treatments. Alternatively 
in the future if osteoblast proliferation and differentiation are closely correlated to the Erk1/Erk2 
ratio, this could be used as a simpler test to reflect the severity of disease or the prognosis to 
surgical or medical treatments. 
 
To understand the mechanisms behind the change in Erk1/Erk2 ratio, it would be useful to 
investigate whether FGFR2 signalling can control Erk expression directly. This would also 
indicate that FGF signalling can modulate proliferative responses to other growth factors that 
signal via Erk1/2. One way of testing this would be to treat MC3T3, R2-WT and R2-C278F 
with cycloheximide to reduce the basal levels of Erk1 and Erk2 mRNA, followed by FGF2 
treatment to observe whether the Erk expression is higher in treated cells compared to untreated 
cells. If Erk1 or Erk2 expression is upregulated, it will suggest that the ratio of Erk1 and Erk2 
expression is directly regulated by FGF signalling. 
 
7.10.2 Control of ERK ratios by FGF signalling 
Explanations for the raised Erk1/Erk2 ratio in R2-C278F cells may lie in the stability of Erk 
protein or differences in gene expression. Both Erk1 and Erk2 are very similar in structure and 
sequence, however the 5’ promoter sequences are notably different, indicating that there are 
different transcriptional controls for the Erk isoforms (Sugiura et al., 1997). The Erk2 promoter 
may be activated by NF-Y or Sp3 (Sugiura and Takishima, 2000). GC boxes are known targets 
of the Sp family of transcription factors, wheras CCAAT boxes are commonly targests of NF-Y 
transcription factors. Erk1 contains GC boxes in the promoter domain, whereas Erk2 contains 
both GC boxes and a CCAAT box, suggesting that Erk1 is targeted by Sp3, but not NF-Y 
(Sugiura and Takishima, 2000). FGF activates an Sp1-like transcription factor Spr2, thus it is 
possible that FGF signalling plays a role in the differential regulation of Erks as activation of 
Sp-like transcription factors has been reported to be downstream of FGF (Zhao et al., 2003). It   Chapter 7 Final Discussion 
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is possible that FGFR2 signals activate a member of the Sp family or similar proteins to change 
the Erk ratio. These molecules should be candidates for further investigation. 
 
7.10.3 Investigating TGFbeta signalling  
Both FGF and TGFbeta1 activate Erk1/2, however given that both produce different levels of 
cell growth, they are likely to activate this pathway in a different manner, such as signal 
intensity, time-course and cross talk between the downstream pathways. In this thesis, low 
TGFbeta signalling was suggested on the basis that SB431542 at low dose inhibited TβRI 
activation. It is also possible that low TβRI or TβRII expression could give a low and saturated 
TGFbeta signalling, assuming the ligand was in excess. The expression level of both receptors 
and the endogenous level of TGFbeta1 and -3 protein will need to be assessed in order to 
exclude for this effect. 
 
7.10.4 Control of Fgf18 expression 
In R2-C278F exogenous TGFbeta1 can increase Fgf18 expression; however the low level of 
Tgfbeta1 expression in these cells suggests that TGFbeta1 indirectly causes the increase in 
Fgf18 expression observed at 2 days in culture. The underlying mechanisms for Fgf18 
regulation by FGFR2 signalling were not investigated in this thesis, but in the brain Fgf8b has 
been shown to  positively regulate Fgf18 expression (Liu et al., 2003). Interestingly, Fgf18 
expression has been linked to FGF signalling in conjunction with Wnt signalling (Reinhold and 
Naski, 2007). Further study of the state of Wnt signalling may be necessary to determine how 
FGFR2 can control Fgf18 expression. 
 
7.10.5 Control of Gapdh expression by Fgf 
It is not clear whether Gapdh is a direct target of FGF signalling as changes in Gapdh 
expression may be secondary to other effects such as hypoxia (Lu et al., 2002). To determine 
this, protein synthesis could be inhibited using cyclohexamide and measuring Gapdh gene 
expression in response to FGF stimulation. Increased Gapdh expression would indicate this 
gene to be a direct target for FGF signalling. 
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7.10.6 Negative feedback of FGF signalling in R2-C278F cells 
As mentioned in Chapter 4, there is decreased proliferation in R2-C278F cells instead of 
increased, implying a negative feedback response, supported in chapter 5 by observing a 
decreased level of mitogenic FGFR signalling and changes to Fgfr2IIIc expression. 
 
However there are many other established negative feedback pathways associated with FGFR 
signalling, which may also be overactive in R2-C278F cells. The FGFR2 signalling expected 
from FGFR2-C278F may induce many feedback responses from the FGFR signalling pathway. 
Some ideas include the inhibitors Spred and Sprouty, which are transcriptionally activated upon 
FGF induced Erk1/2 activation (Yang et al., 2006). However the current literature suggests that 
the action of Spreds and Sproutys are at the level of Ras and Raf, not the receptor, therefore it is 
unlikely that a reduced level of FGFR signalling is wholly due to these inhibitors. Sef on the 
other hand, has been shown to inhibit FGFR tyrosine phosphorylation (Eblaghie et al., 2003; 
Kovalenko et al., 2003). It is interesting that the Erk1/2 expression levels had increased, but its 
level of signalling had not been shown to increase in R2-C278F cells. Activated Erk1/2 can 
negatively regulate further Erk1/2 activation by binding to FRS2 (Wu et al., 2003). It is possible 
that the level of pErk1/2 bound FRS may be involved with the observed negative feedback 
effect. It is not known whether there is also a difference the effectiveness of pErk1 and pErk2 in 
binding FRS to inhibit FGFR activation, which may be of interest for future studies due to the 
change in pErk1/pErk2 ratio reported in this thesis. These possiblities are laid out in Figure 7.9. 
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Figure 7.9 Possible negative feedback mechanisms for FGFR signalling 
PYST1/MKP3, SEF, SPRED and SPROUTY are transcriptionally upregulated following FGFR MAPK 
signalling and inhibit FGFR and the ERK1/2 pathway as indicated in red. The activated form of ERK1/2 
binds and inhibits FRS2 from further activating the ERK1/2 pathway. Adapted from Eblaghie 2003, Wu 
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7.11 Implications for patient treatment 
 
Patient treatment may be divided into avoidance, prevention or reduction of the impact of 
craniosynostosis and post-surgical therapies. 
 
Genetic counselling and preimplantation genetic diagnosis (PGD) with in-vitro fertilization 
(IVF) may be useful to avoid selection of affected embryos for couples with familial 
craniosynostoses, for example in Crouzon syndrome (Abou-Sleiman et al., 2002). 
 
Although prenatal screening is a possible diagnostic tool, prenatal intrauterine treatment is both 
invasive and complicated with risks to both mother and foetus. Limiting the impacts of 
craniosynostosis may be an option if the suture fusion occurs after birth. Mouse studies have 
shown that treating sutures with reagents such as cytokines (e.g. TGFbeta) or antibodies to 
cytokines may help to block or delay suture fusion (Opperman et al., 1999; Eswarakumar et al., 
2006; Wan et al., 2008). 
 
Another area of treatment is post surgical. It has been shown that in osteoblasts with Apert or 
Crouzon syndrome craniosynostosis that cell proliferation is reduced (Fragale et al., 1999). 
Following craniotomies, it may be useful to increase osteoblast proliferation for faster healing 
and repair for which growth factors and other reagents may be used. 
 
The work in this thesis have suggested that in osteoblasts carrying LICA FGFR mutations such 
as FGFR2-C278F, TGFbeta treatments may not be as effective as in normal osteoblasts because 
the aberrant FGFR signalling that impairs normal cellular responses to TGFbeta. This indicates 
that the role of TGFbeta may be limited in the delay of suture fusion and post-surgical treatment 
strategies. Furthermore the increased Erk1/Erk2 ratio observed in osteoblasts with FGFR2-
C278F may have a role in affecting the proliferative responses to growth factors. It is possible 
that decreasing this ratio, for example by Erk1 siRNA may improve cellular responses to growth 
factor treatment such as TGFbeta and subsequently increase osteoblast proliferation. The 
findings in this thesis may therefore contribute to finding appropriate biological treatments of 
sutures pre- and post-surgery. 
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Figure 8.1 Immunocytochemistry staining of Phosphorylated Histone 3 
The pH3 antibody supplied was tested and confirmed to bind in MC3T3. A: Hoescht counterstain for cell 
nuclei. B: Positive pH3 staining using Alexa 488 conjugated antibodies. C: Merged image demonstrating 
the distinction between M-phase and non-M-phase cells. 
A 
B 
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Figure 8.2 FACS M-phase analysis of MC3T3, R2-WT and R2-C278F cells at 4 days in culture 









































Figure 8.3 Photographs of cells at 6 days in culture without a change of culture medium.  












Figure 8.4 Gapdh protein expression at 4 days in culture 
An initial study of Gapdh protein expression was performed using western blotting and normalised with 
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Figure 8.5 Real time PCR analysis of Bsp in MC3T3, R2-WT and R2-C278F cells at 4 DIC 
A: Bsp expression amplification is found in Mouse Head at E13.5, but not in MC3T3, R2-WT and R2-
C278F cells. B: The cDNA viability was confirmed using the endogenous control 18S. cDNA was 
present in all samples. 
A 
B 
Mouse Head Bsp 
18S for Mouse head & 
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Figure 8.6 Real time PCR of Smad1 expression in MC3T3, R2-WT and R2-C278F cells 
Cells were seeded for 3 hours then treated with 1, 10 and 20, ng/ml of TGFbeta1 for 2 and 4 days in 
culture before relative quantification (RQ) of gene expression by real time PCR. A: Smad1 increases in 
FGFR2-WT with TGFBeta1 treatment at 2 DIC, but not MC3T3 and R2-C278F cells B: TGFbeta1 
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Figure 8.7 Western blot of TGFbeta1 treated MC3T3, R2-WT and R2-C278F cells  
Western blot of TGFbeta1 treated MC3T3, R2-WT and R2-C278F cells at 2 days in culture. Cells were 
treated with TGFbeta1 for 10 minutes prior to Western blot analysis. Activation was seen in MC3T3, in 
R2-WT cells this was the opposite and in R2-C278F activation was not detected (n = 1). 
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Figure 8.8 Analysis of Erk1/2 expression in MC3T3, R2-WT and R2-C278F cells by WB 

































































































































Figure 8.9 Semi-quantification of Alpha Tubulin in MC3T3, R2-WT and R2-C278F by WB 
Alpha Tubulin was analysed at 2 days in culture by Western blotting. The band intensities alpha tubulin 
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Figure 8.10 Optimization of Fgf1 and -2 RT-PCR products 
PCR products of Fgf1 and Fgf2 were present in Mouse Head cDNA. It was confirmed that the optimal 
number of cycles was 35 cycles and the optimal concentration was 2 mM of Magnesium Chloride.  Appendix 
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Figure 8.11 Cells treated with PMA for 2 days in culture 
Cells were seeded for three hours before treating with PMA in titration range from 0.1 ng/ml to 500ng/ml 
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Figure 8.12 Treatment of cells with SU5402 at 10% serum 
Cell growth in MC3T3, R2-WT and R2-C278F cells decrease with SU5402 treatment with a dose 





































































































Figure 8.13 Treatment of cells with SU5402 at 1% serum 
Cell growth in MC3T3, R2-WT and R2-C278F cells decrease with SU5402 treatment with a dose 




































































































Figure 8.14 FACS analysis of pH3 in PMA treated MC3T3, R2-WT and R2-C278F cells 
Cells were seeded for 3 hours and treated with PMA every 24 hours for 2 days in culture in 10% FBS 
containing cell medium. Treatment with PMA did not significantly change the percentage pH3 in MC3T3 
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